
<html lang="en"     class="pb-page"  data-request-id="d24d2580-6f91-48df-8709-566f00d3e05e"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.1c00712;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2021.64.issue-14"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery of the Next-Generation Pan-TRK Kinase Inhibitors for the Treatment of Cancer" /></meta><meta name="dc.Creator" content="Zongliang  Liu" /></meta><meta name="dc.Creator" content="Pengfei  Yu" /></meta><meta name="dc.Creator" content="Lin  Dong" /></meta><meta name="dc.Creator" content="Wenyan  Wang" /></meta><meta name="dc.Creator" content="Sijin  Duan" /></meta><meta name="dc.Creator" content="Bingsi  Wang" /></meta><meta name="dc.Creator" content="Xiaoyan  Gong" /></meta><meta name="dc.Creator" content="Liang  Ye" /></meta><meta name="dc.Creator" content="Hongbo  Wang" /></meta><meta name="dc.Creator" content="Jingwei  Tian" /></meta><meta name="dc.Description" content="The neurotrophic receptor tyrosine kinase (NTRK) genes including NTRK1, NTRK2, and NTRK3 encode the tropomyosin receptor kinase (Trk) proteins TrkA, TrkB, and TrkC, respectively. So far, two TRK in..." /></meta><meta name="Description" content="The neurotrophic receptor tyrosine kinase (NTRK) genes including NTRK1, NTRK2, and NTRK3 encode the tropomyosin receptor kinase (Trk) proteins TrkA, TrkB, and TrkC, respectively. So far, two TRK in..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="July 13, 2021" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.1c00712" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Â© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00712" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.1c00712" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00712" /></link>
        
    
    

<title>Discovery of the Next-Generation Pan-TRK Kinase Inhibitors for the Treatment of Cancer | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.1c00712" /></meta><meta property="og:title" content="Discovery of the Next-Generation Pan-TRK Kinase Inhibitors for the Treatment of Cancer" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00712/20210716/images/large/jm1c00712_0009.jpeg" /></meta><meta property="og:description" content="The neurotrophic receptor tyrosine kinase (NTRK) genes including NTRK1, NTRK2, and NTRK3 encode the tropomyosin receptor kinase (Trk) proteins TrkA, TrkB, and TrkC, respectively. So far, two TRK inhibitors, larotrectinib sulfate (LOXO-101 sulfate) and entrectinib (NMS-E628, RXDX-101), have been approved for clinical use in 2018 and 2019, respectively. To overcome acquired resistance, next-generation Trk inhibitors such as selitrectinib (LOXO-195) and repotrectinib (TPX-0005) have been developed and exhibit effectiveness to induce remission in patients with larotrectinib treatment failure. Herein, we report the identification and optimization of a series of macrocyclic compounds as potent pan-Trk (WT and MT) inhibitors that exhibited excellent physiochemical properties and good oral pharmacokinetics. Compound 10 was identified via optimization from the aspects of chemistry and pharmacokinetic properties, which showed good activity against wild and mutant TrkA/TrkC in in vitro and in vivo studies." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.1c00712"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00712">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.1c00712&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.1c00712&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.1c00712&amp;href=/doi/10.1021/acs.jmedchem.1c00712" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 14</span><span class="cit-fg-pageRange">, 10286-10296</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/14" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.1c00690" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.1c00708" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of the Next-Generation Pan-TRK Kinase Inhibitors for the Treatment of Cancer</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Zongliang Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zongliang Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, Yantai 264005, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zongliang++Liu">Zongliang Liu</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Pengfei Yu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Pengfei Yu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Clinical Medicine, Binzhou Medical College, Yantai 256603, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Pengfei++Yu">Pengfei Yu</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Lin Dong</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lin Dong</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Luye Pharma Group, Yantai 264005, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lin++Dong">Lin Dong</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Wenyan Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wenyan Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, Yantai 264005, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wenyan++Wang">Wenyan Wang</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Sijin Duan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sijin Duan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Luye Pharma Group, Yantai 264005, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sijin++Duan">Sijin Duan</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Bingsi Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Bingsi Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Luye Pharma Group, Yantai 264005, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Bingsi++Wang">Bingsi Wang</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Xiaoyan Gong</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xiaoyan Gong</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Luye Pharma Group, Yantai 264005, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xiaoyan++Gong">Xiaoyan Gong</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Liang Ye</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Liang Ye</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Clinical Medicine, Binzhou Medical College, Yantai 256603, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Liang++Ye">Liang Ye</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Hongbo Wang</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hongbo Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, Yantai 264005, China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#e28a8d8c85808d95838c859b96a2858f838b8ecc818d8f"><span class="__cf_email__" data-cfemail="a1c9cecfc6c3ced6c0cfc6d8d5e1c6ccc0c8cd8fc2cecc">[emailÂ protected]</span></a>. Phone: 86-535-6706060.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hongbo++Wang">Hongbo Wang</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0001-5055-4261" title="Orcid link">https://orcid.org/0000-0001-5055-4261</a></div></div></span></li><span class="comma-separator">,Â andÂ </span><li><span><span class="hlFld-ContribAuthor">Jingwei Tian</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jingwei Tian</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, Yantai 264005, China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#57233e36393d3e393020323e173b222e32793439"><span class="__cf_email__" data-cfemail="f18598909f9b989f96869498b19d848894df929f">[emailÂ protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jingwei++Tian">Jingwei Tian</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00712&amp;href=/doi/10.1021%2Facs.jmedchem.1c00712" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 14</span><span class="cit-pageRange">, 10286â10296</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">July 12, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>19 April 2021</li><li><span class="item_label"><b>Published</b> online</span>13 July 2021</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 22 July 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.1c00712" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00712</a></div><div class="article_header-article-copyright"><strong>Copyright Â© 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D10286%26pageCount%3D11%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DZongliang%2BLiu%252C%2BPengfei%2BYu%252C%2BLin%2BDong%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D64%26issueNum%3D14%26contentID%3Dacs.jmedchem.1c00712%26title%3DDiscovery%2Bof%2Bthe%2BNext-Generation%2BPan-TRK%2BKinase%2BInhibitors%2Bfor%2Bthe%2BTreatment%2Bof%2BCancer%26numPages%3D11%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D10296%26publicationDate%3DJuly%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.1c00712"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">590</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val">-</div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.1c00712" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of the Next-Generation Pan-TRK Kinase Inhibitors for the Treatment of Cancer&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Zongliang&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Pengfei&quot;,&quot;last_name&quot;:&quot;Yu&quot;},{&quot;first_name&quot;:&quot;Lin&quot;,&quot;last_name&quot;:&quot;Dong&quot;},{&quot;first_name&quot;:&quot;Wenyan&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Sijin&quot;,&quot;last_name&quot;:&quot;Duan&quot;},{&quot;first_name&quot;:&quot;Bingsi&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Xiaoyan&quot;,&quot;last_name&quot;:&quot;Gong&quot;},{&quot;first_name&quot;:&quot;Liang&quot;,&quot;last_name&quot;:&quot;Ye&quot;},{&quot;first_name&quot;:&quot;Hongbo&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Jingwei&quot;,&quot;last_name&quot;:&quot;Tian&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;07&quot;,&quot;day&quot;:&quot;13&quot;,&quot;issue&quot;:&quot;14&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;10286-10296&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.1c00712&quot;},&quot;abstract&quot;:&quot;The neurotrophic receptor tyrosine kinase (NTRK) genes including NTRK1, NTRK2, and NTRK3 encode the tropomyosin receptor kinase (Trk) proteins TrkA, TrkB, and TrkC, respectively. So far, two TRK inhibitors, larotrectinib sulfate (LOXO-101 sulfate) and entrectinib (NMS-E628, RXDX-101), have been approved for clinical use in 2018 and 2019, respectively. To overcome acquired resistance, next-generation Trk inhibitors such as selitrectinib (LOXO-195) and repotrectinib (TPX-0005) have been developed and exhibit effectiveness to induce remission in patients with larotrectinib treatment failure. Herein, we report the identification and optimization of a series of macrocyclic compounds as potent pan-Trk (WT and MT) inhibitors that exhibited excellent physiochemical properties and good oral pharmacokinetics. Compound 10 was identified via optimization from the aspects of chemistry and pharmacokinetic properties, which showed good activity against wild and mutant TrkA/TrkC in in vitro and in vivo studies.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00712&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00712" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00712&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00712" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00712&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00712" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00712&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00712&amp;href=/doi/10.1021/acs.jmedchem.1c00712" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.1c00712" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.1c00712" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00712&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.1c00712%26sid%3Dliteratum%253Aachs%26pmid%3D34253025%26genre%3Darticle%26aulast%3DLiu%26date%3D2021%26atitle%3DDiscovery%2Bof%2Bthe%2BNext-Generation%2BPan-TRK%2BKinase%2BInhibitors%2Bfor%2Bthe%2BTreatment%2Bof%2BCancer%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D14%26spage%3D10286%26epage%3D10296%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (3)</span><span class="article_header-suppInfo-arrow">Â»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=291651" title="Anions">Anions</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/14" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00712/20210716/images/medium/jm1c00712_0009.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00712/20210716/images/large/jm1c00712_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00712&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The neurotrophic receptor tyrosine kinase (NTRK) genes including NTRK1, NTRK2, and NTRK3 encode the tropomyosin receptor kinase (Trk) proteins TrkA, TrkB, and TrkC, respectively. So far, two TRK inhibitors, larotrectinib sulfate (LOXO-101 sulfate) and entrectinib (NMS-E628, RXDX-101), have been approved for clinical use in 2018 and 2019, respectively. To overcome acquired resistance, next-generation Trk inhibitors such as selitrectinib (LOXO-195) and repotrectinib (TPX-0005) have been developed and exhibit effectiveness to induce remission in patients with larotrectinib treatment failure. Herein, we report the identification and optimization of a series of macrocyclic compounds as potent pan-Trk (WT and MT) inhibitors that exhibited excellent physiochemical properties and good oral pharmacokinetics. Compound <b>10</b> was identified <i>via</i> optimization from the aspects of chemistry and pharmacokinetic properties, which showed good activity against wild and mutant TrkA/TrkC in <i>in vitro</i> and <i>in vivo</i> studies.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_16576" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_16576" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In order to improve the efficacy of anti-tumor drugs and reduce their side effects, cancer treatment is shifting toward precision oncology. As such, patients receive individualized therapy based on the prescreening of predictive biomarkers, such as oncogenic mutations, rather than using empiric chemotherapy. It was reported in 2007 that gene fusions account for 20% of human cancer morbidity.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> The neurotrophic receptor tyrosine kinase (NTRK) genes including NTRK1, NTRK2, and NTRK3 encode the tropomyosin receptor kinase (Trk) proteins TrkA, TrkB, and TrkC, respectively.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> NTRK rearrangements and fusion gene products have been observed in numerous tumor types.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> For example, NTRK fusions are found in about 50% of pediatric diffuse intrinsic pontine glioma and non-brainstem glioblastoma,<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> 16.7% of thyroid carcinoma,<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> 7.1% of pediatric gliomas,<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> 3.3% of lung cancers,<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> 2.5% of glioblastomas, and 2.2% of colorectal cancer.<a onclick="showRef(event, 'ref6 ref8'); return false;" href="javascript:void(0);" class="ref ref6 ref8">(6,8)</a></div><div class="NLM_p">The growing number of identified gene fusions involving the NTRK gene drew the interest of the scientific community to develop gene-specific anti-cancer drugs. So far, two TRK inhibitors, larotrectinib sulfate (LOXO-101 sulfate) and entrectinib (NMS-E628, RXDX-101), have been approved for clinical use in 2018 and 2019, respectively, and many are currently under clinical trials (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). Entrectinib is a potent, orally available, and central nervous system-active pan-Trk, ROS1, and ALK inhibitor. Entrectinib inhibits TrkA, TrkB, TrkC, ROS1, and ALK with IC<sub>50</sub> values of 1, 3, 5, 12, and 7 nM, respectively.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Larotrectinib is an adenosine triphosphate (ATP)-competitive orally active pan-Trk inhibitor, with IC<sub>50</sub> values of 2â20 nmol/L against cancer cells and between 5 and 11 nM against all three isoforms, and with 1000-fold or greater selectivity relative to other kinases.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> The first 55 patients with solid tumors with the confirmed NTRK gene fusion were enrolled in one of the three multicenter, open-label, single-arm clinical trials (NCT02122913, NCT02637687, and NCT02576431). Of all the enrolled patients with confirmatory response data available, the objective response rate was 76, with 12% complete response and 64% partial response (information from the drug label).</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00712/20210716/images/medium/jm1c00712_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00712/20210716/images/large/jm1c00712_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Trk inhibitors approved and in clinical trials.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00712/20210716/images/large/jm1c00712_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00712&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">One major limitation to maintain durable therapeutic efficacy for all kinase inhibitors is the acquired resistance. To overcome acquired resistance, next-generation Trk inhibitors such as selitrectinib (LOXO-195) and repotrectinib (TPX-0005) have been developed, which exhibited effectiveness to induce remission in patients with larotrectinib treatment failure (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).<a onclick="showRef(event, 'ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref11 ref12">(11,12)</a> LOXO-195 shows strong binding to the wild-type TrkA, TrkB, and TrkC kinase domains and has potent (IC<sub>50</sub> < 1 nM) inhibitory activity in kinase enzyme assays.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Importantly, LOXO-195 achieves low nanomolar inhibitory activity against TrkA<sup>G595R</sup>, TrkA<sup>G667C</sup>, TrkC<sup>G623R</sup>, and TrkC<sup>G696A</sup>, with IC<sub>50</sub> values being 2.0, 9.8, 2.3, and 2.5 nM, respectively, but showed little effect on 228 other different kinases. In an <i>in vitro</i> efficacy study, LOXO-195 demonstrated potent inhibition of cell proliferation in Trk fusion-containing KM12, CUTO-3, and MO-91 cell lines (IC<sub>50</sub> â¤ 5 nM).<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> TPX-0005 is a multi-kinase inhibitor which shows potent effects against ROS1 (IC<sub>50</sub> = 0.07 nM), Trk (IC<sub>50</sub> = 0.83/0.05/0.1 nM for TrkA/B/C), WT ALK (IC<sub>50</sub> = 1.01 nM), and JAK2 (IC<sub>50</sub> = 1.04 nM).<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Both LOXO-195 and TPX-0005 demonstrated significant efficacy in clinical trials in patients who were resistant to the first-generation Trk inhibitors.<a onclick="showRef(event, 'ref11 ref12 ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref11 ref12 ref13 ref14">(11â14)</a></div><div class="NLM_p last">In this study, we report the identification and optimization of a series of macrocyclic compounds as potent pan-Trk (WT and MT) inhibitors that exhibited excellent physiochemical properties and good oral pharmacokinetics.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81761" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81761" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Docking of LOXO-195 and TPX-0005 with TrkA</h3><div class="NLM_p">Currently, the cocrystal structures of LOXO-101 or LOXO-195 with Trk protein remain unknown. We docked LOXO-195 and TPX-0005 to explore their binding conformation with the TrkA protein by using Discovery Studio 2018 software (CDOCKER) and the existing eutectic complex (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4YNE">4YNE</a>).<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> From the docking test, we found that the binding modes of LOXO-195 and TPX-0005 with TrkC are nearly identical (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). The nitrogen atom on the pyrazole ring can form a hydrogen bond with Met592 in the hinge area. The fluorophenyl/fluoropyridine moiety that was well integrated into the hydrophobic pocket maintained a vertical conformation with the entire skeleton and had hydrophobic interactions with the surrounding Phe521, Leu657, Gly667, and Asp668. Simultaneously, the fluorine atom formed a key interaction force with Asn655. The oxygen atom on the amide formed a hydrogen bond with Met592 in the hinge region through the water molecule. There was a hydrophobic effect between the tetrahydropyrrole of LOXO-195 with the gatekeepers Phe589 and Phe521. The methyl group at the same position of TPX-0005 also had a hydrophobic effect with Phe521. The same hydrophobic interaction existed between the remaining methyl groups of LOXO-195 and TPX-0005 with P-loop Val524 and Gly517. The structures of the hinge region and the fluoropyridine/fluorobenzene region (marked in red) were relatively conservative, which plays a decisive role in the activity of Trk kinase. The tetrahydropyrrole region and the amide alkyl chain (marked in blue) were more flexible and there was chemical space for structural modification. Therefore, we mainly modified the blue area of the structure in order to obtain preclinical drug candidates with better activity and selectivity.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00712/20210716/images/medium/jm1c00712_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00712/20210716/images/large/jm1c00712_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Docking of LOXO-195 and TPX-0005 with TrkA.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00712/20210716/images/large/jm1c00712_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00712&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> StructureâActivity Relationship of TPX-0005</h3><div class="NLM_p">We first studied the structureâactivity relationship of TPX-0005. The amide group in TPX-0005 was replaced with a sulfonamide group (compound <b>1</b>, <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>), which led to the loss of its activity. Maintaining the chain length between the amide and fluorophenyl groups, the structure modification was carried out to obtain compounds <b>2</b>, <b>3</b>, <b>4</b>, <b>5</b>, and <b>6</b> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). Compounds <b>2</b> and <b>3</b> with imide and sulfonimide were unstable likely due to the increased ring tension. Changing the ether bond to an amide group (compound <b>4</b>) reduced the TrkA inhibitory activity by 300â400 times. When piperazine or piperidine was used for bonding, the TrkA inhibitory activity disappeared. This could be due to the fact that after the chain was replaced with a ring, the spatial conformation of the molecule was altered.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00712/20210716/images/medium/jm1c00712_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00712/20210716/images/large/jm1c00712_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Structureâactivity relationship of TPX-0005.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00712/20210716/images/large/jm1c00712_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00712&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Design of Compounds with One-Chiral Atom</h3><div class="NLM_p last">There are two chiral centers in LOXO-195 and TPX-0005, which posed great challenges for the synthesis and separation of such compounds. Compounds <b>7</b> and <b>8</b> were designed and synthesized, which contained only one chiral atom (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). Excitingly, both compounds had good inhibitory activity, particularly compound <b>8</b>, which showed a similar activity against wild TrkA/C with IC<sub>50</sub> ranging from 0.2 to 3.2 nM to LOXO-195 and TPX-0005.</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> <i>In Vitro</i> PD and PK Data of Compound <b>8</b></h3><div class="NLM_p">To determine the impact of TRK kinase resistance mutations on the activity of inhibitors, compound <b>8</b> was tested against purified kinase domains <i>in vitro</i>. Compound <b>8</b> achieved low nanomolar inhibitory activity against TrkA, TrkA<sup>G595R</sup>, TrkA<sup>G667C</sup>, TrkC, Alk, and Ros1, with IC<sub>50</sub> values being 3.2, 2.1, 0.7, 0.2, 18.5, and 0.2 nM, respectively (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). In an enzyme inhibition study, compound <b>8</b> also had good activity against mutant TrkA, especially its inhibitory activity against TrkA<sup>G667C</sup>, which was 10â100 times higher than those of LOXO-195 and TPX-0005. The anti-tumor activity of compound <b>8</b> was evaluated using Ba/F3 cells, and the IC<sub>50</sub> values were 0.2 and 5 nM in wild and mutant TrkA/C cells, respectively. In Ba/F3 cells with SLC34A2-Ros1 fusion, the activity of compound <b>8</b> was slightly lower (IC<sub>50</sub> value: 12.6 nM).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. PD Data of Compounds <b>8</b>, <b>9</b>, and <b>10</b><i>In Vitro</i></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="Â±" /></col><col align="char" char="Â±" /></col><col align="char" char="Â±" /></col><col align="char" char="Â±" /></col><col align="char" char="Â±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" align="center">Â </th><th class="rowsep1 colsep0" colspan="5" align="center" char="Â±">compound (IC<sub>50</sub> nM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" align="center" char="Â±">LOXO-195</th><th class="colsep0 rowsep0" align="center" char="Â±">TPX-0005</th><th class="colsep0 rowsep0" align="center" char="Â±"><b>8</b></th><th class="colsep0 rowsep0" align="center" char="Â±"><b>9</b></th><th class="colsep0 rowsep0" align="center" char="Â±"><b>10</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">enzymatic</td><td class="colsep0 rowsep0" align="left">TrkA</td><td class="colsep0 rowsep0" align="char" char="Â±">6.7Â Â±Â 0.5</td><td class="colsep0 rowsep0" align="char" char="Â±">2.5Â Â±Â 0.4</td><td class="colsep0 rowsep0" align="char" char="Â±">3.2Â Â±Â 0.6</td><td class="colsep0 rowsep0" align="char" char="Â±">4.9Â Â±Â 0.4</td><td class="colsep0 rowsep0" align="char" char="Â±">2.4Â Â±Â 0.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">TrkA<sup>G595R</sup></td><td class="colsep0 rowsep0" align="char" char="Â±">6.2Â Â±Â 0.5</td><td class="colsep0 rowsep0" align="char" char="Â±">1.4Â Â±Â 0.2</td><td class="colsep0 rowsep0" align="char" char="Â±">2.1Â Â±Â 0.4</td><td class="colsep0 rowsep0" align="char" char="Â±">9.4Â Â±Â 1.0</td><td class="colsep0 rowsep0" align="char" char="Â±">3.5Â Â±Â 0.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">TrkA<sup>G667C</sup></td><td class="colsep0 rowsep0" align="char" char="Â±">110.0Â Â±Â 10.1</td><td class="colsep0 rowsep0" align="char" char="Â±">8.7Â Â±Â 0.8</td><td class="colsep0 rowsep0" align="char" char="Â±">0.7Â Â±Â 0.1</td><td class="colsep0 rowsep0" align="char" char="Â±">1.7Â Â±Â 0.3</td><td class="colsep0 rowsep0" align="char" char="Â±">2.3Â Â±Â 0.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">TrkC</td><td class="colsep0 rowsep0" align="char" char="Â±">0.5Â Â±Â 0.1</td><td class="colsep0 rowsep0" align="char" char="Â±">0.01Â Â±Â 0.00</td><td class="colsep0 rowsep0" align="char" char="Â±">0.2Â Â±Â 0.0</td><td class="colsep0 rowsep0" align="char" char="Â±">0.2Â Â±Â 0.1</td><td class="colsep0 rowsep0" align="char" char="Â±">0.2Â Â±Â 0.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">ALK</td><td class="colsep0 rowsep0" align="char" char="Â±">274.0Â Â±Â 16.4</td><td class="colsep0 rowsep0" align="char" char="Â±">2.3Â Â±Â 0.4</td><td class="colsep0 rowsep0" align="char" char="Â±">18.5Â Â±Â 0.7</td><td class="colsep0 rowsep0" align="char" char="Â±">88.9Â Â±Â 12.5</td><td class="colsep0 rowsep0" align="char" char="Â±">182.0Â Â±Â 14.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Ros1</td><td class="colsep0 rowsep0" align="char" char="Â±">1.15Â Â±Â 0.07</td><td class="colsep0 rowsep0" align="char" char="Â±">0.17Â Â±Â 0.05</td><td class="colsep0 rowsep0" align="char" char="Â±">0.2Â Â±Â 0.1</td><td class="colsep0 rowsep0" align="char" char="Â±">1.2Â Â±Â 0.3</td><td class="colsep0 rowsep0" align="char" char="Â±">1.0Â Â±Â 0.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cellular</td><td class="colsep0 rowsep0" align="left">Ba/F3 TrkA</td><td class="colsep0 rowsep0" align="char" char="Â±">4.9Â Â±Â 0.3</td><td class="colsep0 rowsep0" align="char" char="Â±">1.8Â Â±Â 0.3</td><td class="colsep0 rowsep0" align="char" char="Â±">0.2Â Â±Â 0.0</td><td class="colsep0 rowsep0" align="char" char="Â±">0.6Â Â±Â 0.1</td><td class="colsep0 rowsep0" align="char" char="Â±">0.6Â Â±Â 0.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Ba/F3 TrkA<sup>G595R</sup></td><td class="colsep0 rowsep0" align="char" char="Â±">6.8Â Â±Â 0.7</td><td class="colsep0 rowsep0" align="char" char="Â±">8.0Â Â±Â 0.6</td><td class="colsep0 rowsep0" align="char" char="Â±">0.4Â Â±Â 0.0</td><td class="colsep0 rowsep0" align="char" char="Â±">Â </td><td class="colsep0 rowsep0" align="char" char="Â±">7.7Â Â±Â 0.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Ba/F3 TrkA<sup>F589L</sup></td><td class="colsep0 rowsep0" align="char" char="Â±">25.4Â Â±Â 4.5</td><td class="colsep0 rowsep0" align="char" char="Â±">0.7Â Â±Â 0.2</td><td class="colsep0 rowsep0" align="char" char="Â±">Â </td><td class="colsep0 rowsep0" align="char" char="Â±">Â </td><td class="colsep0 rowsep0" align="char" char="Â±">4.9Â Â±Â 0.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Ba/F3 TrkA<sup>G667A</sup></td><td class="colsep0 rowsep0" align="char" char="Â±">24.4Â Â±Â 2.5</td><td class="colsep0 rowsep0" align="char" char="Â±">Â </td><td class="colsep0 rowsep0" align="char" char="Â±">Â </td><td class="colsep0 rowsep0" align="char" char="Â±">Â </td><td class="colsep0 rowsep0" align="char" char="Â±">0.8Â Â±Â 0.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Ba/F3 TrkC<sup>G623R</sup></td><td class="colsep0 rowsep0" align="char" char="Â±">2.7Â Â±Â 0.5</td><td class="colsep0 rowsep0" align="char" char="Â±">4.8Â Â±Â 0.4</td><td class="colsep0 rowsep0" align="char" char="Â±">5.8Â Â±Â 0.3</td><td class="colsep0 rowsep0" align="char" char="Â±">Â </td><td class="colsep0 rowsep0" align="char" char="Â±">2.7Â Â±Â 0.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Ba/F3 SLC34A2-Ros1</td><td class="colsep0 rowsep0" align="char" char="Â±">36.7Â Â±Â 3.6</td><td class="colsep0 rowsep0" align="char" char="Â±">2.2Â Â±Â 0.4</td><td class="colsep0 rowsep0" align="char" char="Â±">12.6Â Â±Â 0.7</td><td class="colsep0 rowsep0" align="char" char="Â±">Â </td><td class="colsep0 rowsep0" align="char" char="Â±">2.3Â Â±Â 0.3</td></tr></tbody></table></div></div><div class="NLM_p">Due to its good kinase inhibitory activity and cellular pharmacodynamics, the pharmacokinetic evaluation of compound <b>8</b> was carried out <i>in vitro</i> (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Most of the pharmacokinetic parameters of compound <b>8</b> were similar to those of LOXO-195 or TPX-0005 except for MMS (mL/min/kg). From the perspective of MMS, compound <b>8</b> was metabolized faster in humans, rats, and dogs. The oxidation on the piperidine ring may be the reason for the faster metabolism of compound <b>8</b>. Based on this finding, the structural optimization was continued.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. PK Data of Compounds <b>8</b>, <b>9</b>, and <b>10</b><i>In Vitro</i></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" align="center">LOXO-195</th><th class="colsep0 rowsep0" align="center">TPX-0005</th><th class="colsep0 rowsep0" align="center"><b>8</b></th><th class="colsep0 rowsep0" align="center"><b>9</b></th><th class="colsep0 rowsep0" align="center"><b>10</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cLogÂ <i>P</i></td><td class="colsep0 rowsep0" align="left">1.86</td><td class="colsep0 rowsep0" align="left">2.96</td><td class="colsep0 rowsep0" align="left">1.97</td><td class="colsep0 rowsep0" align="left">0.57</td><td class="colsep0 rowsep0" align="left">0.58</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">LLE<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">6.3</td><td class="colsep0 rowsep0" align="left">5.6</td><td class="colsep0 rowsep0" align="left">6.5</td><td class="colsep0 rowsep0" align="left">7.7</td><td class="colsep0 rowsep0" align="left">8.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>P</i><sub>appAâB</sub> (10<sup>â6</sup>Â cm/s)/ER</td><td class="colsep0 rowsep0" align="left">8.4/4.1</td><td class="colsep0 rowsep0" align="left">0.9/45.3</td><td class="colsep0 rowsep0" align="left">16.3/1.4</td><td class="colsep0 rowsep0" align="left">3.9/9.5</td><td class="colsep0 rowsep0" align="left">12.0/2.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">KS<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a> (Î¼M)</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">65.8</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">192.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MMS (mL/min/kg) H/R/M/D<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">76/92/1351/38</td><td class="colsep0 rowsep0" align="left">29/49/982/21/</td><td class="colsep0 rowsep0" align="left">242/980/1010/268</td><td class="colsep0 rowsep0" align="left">43/29/342/74</td><td class="colsep0 rowsep0" align="left">17.7/28.8/1504/<10.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PPB (FuÂ %) H/R/M/D</td><td class="colsep0 rowsep0" align="left">34/3/2/20</td><td class="colsep0 rowsep0" align="left">5/6/5/9</td><td class="colsep0 rowsep0" align="left">2/2/2/3</td><td class="colsep0 rowsep0" align="left">36/30/28/34</td><td class="colsep0 rowsep0" align="left">16/12/11/21</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CYP (IC<sub>50</sub>, Î¼M):1A2/2C9/2C19/2D6/3A4</td><td class="colsep0 rowsep0" align="left">>50/>50/>50/>50/>50</td><td class="colsep0 rowsep0" align="left">>50/6.4/12.3/28.5/>50</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">>100/18.1/89.0/>100/>50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hERG (IC<sub>50</sub>, Î¼M)</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">6.7</td><td class="colsep0 rowsep0" align="left">13</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">LLE, ligand lipophilicity efficiency.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">KS, kinetic solubility.</p></div><div class="footnote" id="t2fn3"><sup><sup>c</sup></sup><p class="last">H/R/M/D, human/rat/mouse/dog.</p></div></div></div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> <i>In Vitro</i> PD and PK Data of Compounds <b>9</b> and <b>10</b></h3><div class="NLM_p">Substituting piperidine in compound <b>8</b> with piperazine gave compound <b>9</b> and replacing it with morpholine gave compound <b>10</b>. From the results of PD data <i>in vitro</i>, we can see that both compounds <b>9</b> and <b>10</b> maintained good inhibitory activity against WT and MT TrkA/TrkC, and IC<sub>50</sub> values were essentially the same as those of compound <b>8</b> (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). It is worth noting that the selectivity of compounds <b>9</b> and <b>10</b> to ALK was greatly improved, with IC<sub>50</sub> values of 88.9 and 182.0 nM, respectively, while the IC<sub>50</sub> value of compound <b>8</b> was 18.5 nM. This selectivity may be beneficial in reducing off-target side effects.</div><div class="NLM_p">The pharmacokinetic evaluation of compounds <b>9</b> and <b>10</b> was carried out <i>in vitro</i> (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). These results demonstrated that the drugability of compounds <b>9</b> and <b>10</b> was further improved compared to that of compound <b>8</b>. The ligand lipophilicity efficiencies (LLEs) of compounds <b>9</b> and <b>10</b> were 7.7 and 8.0, respectively, while the LLE of compound <b>8</b> was 6. The metabolic stability was greatly improved, and the MMS in humans, rats, and dogs were all less than 100 mL/min/Kg, which was not only superior to compound <b>8</b> but also better than LOXO-195 and TPX-0005. It was worth noting that the MMS values of these compounds in mice were significantly higher than those of other species, which may be caused by special metabolic enzymes. The inhibitory activity of compound <b>10</b> on the human ether-a-go-go-related gene (hERG) was much lower than that of compound <b>9</b>, with IC<sub>50</sub> values of 13 and 6.7 Î¼M, respectively. Therefore, compound <b>10</b> as a preclinical drug candidate continued to undergo efficacy and pharmacokinetic evaluation <i>in vivo</i> (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>).</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00712/20210716/images/medium/jm1c00712_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00712/20210716/images/large/jm1c00712_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Design of compounds with one-chiral atom.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00712/20210716/images/large/jm1c00712_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00712&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Kinase Assay Data of Compound <b>10</b></h3><div class="NLM_p">Kinase assays (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>) showed that compound <b>10</b> could inhibit the activities of TrkA, TrkB, and TRC with high selectivity at 0.5 Î¼M (kinase activity remaining, <10%) and slightly inhibit the activities of ALK and ROS1 (kinase activity remaining, 10â30%), and the inhibitory activities of other kinases were not significantly affected by compound <b>10</b>.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Kinase Assay Data of Compound <b>10</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">kinases</th><th class="colsep0 rowsep0" align="center" char=".">activity (%Â control)</th><th class="colsep0 rowsep0" align="center">kinases</th><th class="colsep0 rowsep0" align="center" char=".">activity (%Â control)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ALK</td><td class="colsep0 rowsep0" align="char" char=".">26</td><td class="colsep0 rowsep0" align="left">Met(M1268T)</td><td class="colsep0 rowsep0" align="char" char=".">86</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">A-Raf</td><td class="colsep0 rowsep0" align="char" char=".">103</td><td class="colsep0 rowsep0" align="left">Met(Y1248C)</td><td class="colsep0 rowsep0" align="char" char=".">85</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Blk</td><td class="colsep0 rowsep0" align="char" char=".">46</td><td class="colsep0 rowsep0" align="left">Met(Y1248D)</td><td class="colsep0 rowsep0" align="char" char=".">96</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BTK(R28H)</td><td class="colsep0 rowsep0" align="char" char=".">74</td><td class="colsep0 rowsep0" align="left">Met(Y1248H)</td><td class="colsep0 rowsep0" align="char" char=".">89</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">B-Raf</td><td class="colsep0 rowsep0" align="char" char=".">111</td><td class="colsep0 rowsep0" align="left">PDGFRÎ±</td><td class="colsep0 rowsep0" align="char" char=".">106</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">B-Raf(V599E)</td><td class="colsep0 rowsep0" align="char" char=".">87</td><td class="colsep0 rowsep0" align="left">PDGFRÎ±(D842V)</td><td class="colsep0 rowsep0" align="char" char=".">102</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cKit</td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="left">PDGFRÎ±(V561D)</td><td class="colsep0 rowsep0" align="char" char=".">103</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cKit(D816V)</td><td class="colsep0 rowsep0" align="char" char=".">101</td><td class="colsep0 rowsep0" align="left">Ret(h)</td><td class="colsep0 rowsep0" align="char" char=".">64</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cKit(D816H)</td><td class="colsep0 rowsep0" align="char" char=".">96</td><td class="colsep0 rowsep0" align="left">Ret(V804L)</td><td class="colsep0 rowsep0" align="char" char=".">59</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cKit(V560G)</td><td class="colsep0 rowsep0" align="char" char=".">109</td><td class="colsep0 rowsep0" align="left">Ret(V804M)</td><td class="colsep0 rowsep0" align="char" char=".">54</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cKit(V654A)</td><td class="colsep0 rowsep0" align="char" char=".">105</td><td class="colsep0 rowsep0" align="left">RIPK1</td><td class="colsep0 rowsep0" align="char" char=".">102</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">c-RAF</td><td class="colsep0 rowsep0" align="char" char=".">103</td><td class="colsep0 rowsep0" align="left">RIPK2</td><td class="colsep0 rowsep0" align="char" char=".">93</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EGFR</td><td class="colsep0 rowsep0" align="char" char=".">108</td><td class="colsep0 rowsep0" align="left">Ron</td><td class="colsep0 rowsep0" align="char" char=".">112</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EGFR(L858R)</td><td class="colsep0 rowsep0" align="char" char=".">91</td><td class="colsep0 rowsep0" align="left">Ros1</td><td class="colsep0 rowsep0" align="char" char=".">16</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EGFR(L861Q)</td><td class="colsep0 rowsep0" align="char" char=".">95</td><td class="colsep0 rowsep0" align="left">Src(1â530)</td><td class="colsep0 rowsep0" align="char" char=".">33</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EGFR(T790M)</td><td class="colsep0 rowsep0" align="char" char=".">105</td><td class="colsep0 rowsep0" align="left">Src(T341M)</td><td class="colsep0 rowsep0" align="char" char=".">55</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FAK</td><td class="colsep0 rowsep0" align="char" char=".">72</td><td class="colsep0 rowsep0" align="left">TrkA</td><td class="colsep0 rowsep0" align="char" char=".">2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FGFR1</td><td class="colsep0 rowsep0" align="char" char=".">92</td><td class="colsep0 rowsep0" align="left">TrkB</td><td class="colsep0 rowsep0" align="char" char=".">â1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FGFR2</td><td class="colsep0 rowsep0" align="char" char=".">93</td><td class="colsep0 rowsep0" align="left">TrkC</td><td class="colsep0 rowsep0" align="char" char=".">â3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FGFR3</td><td class="colsep0 rowsep0" align="char" char=".">96</td><td class="colsep0 rowsep0" align="left">JAK1</td><td class="colsep0 rowsep0" align="char" char=".">91</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FGFR4</td><td class="colsep0 rowsep0" align="char" char=".">114</td><td class="colsep0 rowsep0" align="left">JAK2</td><td class="colsep0 rowsep0" align="char" char=".">44</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Met</td><td class="colsep0 rowsep0" align="char" char=".">98</td><td class="colsep0 rowsep0" align="left">JAK3</td><td class="colsep0 rowsep0" align="char" char=".">94</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Met(D1246H)</td><td class="colsep0 rowsep0" align="char" char=".">91</td><td class="colsep0 rowsep0" align="left">KDR</td><td class="colsep0 rowsep0" align="char" char=".">108</td></tr></tbody></table></div></div></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> <i>In Vivo</i> PD and PK Data of Compound <b>10</b></h3><div class="NLM_p">After a single intravenous administration of compound <b>10</b> at a dose of 2 mg/kg, the mean terminal half-life (<i>t</i><sub>1/2</sub>) was 0.87 h for male rats and 2.21 h for female rats. The exposure area under the curve (AUC<sub>0â<i>t</i></sub>) in female rats was significantly higher (2.5-fold) than that in male rats. After a single intragastric administration of 10 mg/kg, the time to peak (<i>T</i><sub>max</sub>) concentrations was 0.667 h. The AUC<sub>0â<i>t</i></sub> were 11,720 nM*h in male and 31,676 nM*h in female rats, respectively. The bioavailability was 56.0â61.9%.</div><div class="NLM_p">Four engineered BaF3-NTRK xenograft tumor models were used to assess the therapeutic effect of compound <b>10</b> on tumor growth. Mice bearing 100â200 mm<sup>3</sup> tumors were treated orally at doses of 5, 10, or 20 mg/kg, once daily for 21 days. As shown in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>, compound <b>10</b> produced significant inhibition of tumor growth both in wild-type NTRK fusion mutation cells (Ba/F3 LMNA-NTRK1cells and Ba/F3 ETV6-NTRK3 cells) and drug-resistant mutation cells (Ba/F3 ETV6-NTRK3-G623R cells and Ba/F3 LMNA-NTRK1-G595R) at all three doses, and the anti-tumor effect of compound <b>10</b> at 10 mg/kg was similar to that of LOXO-195 at 100 mg/kg. In addition, some side effects were observed in the LOXO-195 group, including unkempt appearance, weight loss, or even death. In contrast, animals that received the highest dose of compound <b>10</b> only showed slight weight loss and all animals survived during the treatment period. In our previous 4 weeks of repeated administration toxicity study in Cynomolgus monkeys, treatment-related changes included gait disturbance, impaired balance, and poor coordination, which could be attributed to excessive on-target Trk receptor inhibition. In addition, no significant changes in food consumption, electrocardiogram, blood pressure, hematological and biochemical parameters, organ weight, or bone marrow parameters were observed.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> All these data suggest that compound <b>10</b> was more efficacious and safer against tumor growth than LOXO-195 (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>).</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00712/20210716/images/medium/jm1c00712_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00712/20210716/images/large/jm1c00712_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. <i>In vivo</i> efficacy of compound <b>10</b> against four engineered BaF3-NTRK tumor models.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00712/20210716/images/large/jm1c00712_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00712&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. PK Data of Compound <b>10</b> in SpragueâDawley Rats</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="rowsep1 colsep0" align="center">LOXO-195</th><th class="rowsep1 colsep0" align="center">TPX-0005</th><th class="rowsep1 colsep0" colspan="2" align="center"><b>10</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dose (mpk)</td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">2 (M)</td><td class="colsep0 rowsep0" align="left">2 (F)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>0</sub> (nM)</td><td class="colsep0 rowsep0" align="left">23,779Â Â±Â 1526</td><td class="colsep0 rowsep0" align="left">12,870Â Â±Â 831</td><td class="colsep0 rowsep0" align="left">4118Â Â±Â 833</td><td class="colsep0 rowsep0" align="left">3509Â Â±Â 719</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="left">1.2Â Â±Â 0.1</td><td class="colsep0 rowsep0" align="left">2.8Â Â±Â 0.1</td><td class="colsep0 rowsep0" align="left">0.872Â Â±Â 0.0156</td><td class="colsep0 rowsep0" align="left">2.21Â Â±Â 0.215</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>V</i><sub>d</sub> (L/kg)</td><td class="colsep0 rowsep0" align="left">0.5Â Â±Â 0.1</td><td class="colsep0 rowsep0" align="left">1.1Â Â±Â 0.2</td><td class="colsep0 rowsep0" align="left">1.39Â Â±Â 0.229</td><td class="colsep0 rowsep0" align="left">1.46Â Â±Â 0.224</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Cl (mL/kg/min)</td><td class="colsep0 rowsep0" align="left">11.8Â Â±Â 0.8</td><td class="colsep0 rowsep0" align="left">9.4Â Â±Â 0.5</td><td class="colsep0 rowsep0" align="left">19.3Â Â±Â 0.624</td><td class="colsep0 rowsep0" align="left">8.19Â Â±Â 1.96</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC<sub>0â<i>t</i></sub> (nM*h)</td><td class="colsep0 rowsep0" align="left">11,146Â Â±Â 656</td><td class="colsep0 rowsep0" align="left">15,002Â Â±Â 859</td><td class="colsep0 rowsep0" align="left">4191Â Â±Â 139</td><td class="colsep0 rowsep0" align="left">10,282Â Â±Â 2298</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dose (mpk)</td><td class="colsep0 rowsep0" align="left">10</td><td class="colsep0 rowsep0" align="left">10</td><td class="colsep0 rowsep0" align="left">10Â (M)</td><td class="colsep0 rowsep0" align="left">10Â (F)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (nM)</td><td class="colsep0 rowsep0" align="left">12,700Â Â±Â 1121</td><td class="colsep0 rowsep0" align="left">16,900Â Â±Â 1173</td><td class="colsep0 rowsep0" align="left">6384Â Â±Â 1525</td><td class="colsep0 rowsep0" align="left">6628Â Â±Â 626</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>max</sub> (h)</td><td class="colsep0 rowsep0" align="left">0.4Â Â±Â 0.0</td><td class="colsep0 rowsep0" align="left">0.8Â Â±Â 0.0</td><td class="colsep0 rowsep0" align="left">0.667Â Â±Â 0.289</td><td class="colsep0 rowsep0" align="left">0.667Â Â±Â 0.289</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC<sub>0â<i>t</i></sub> (nM*h)</td><td class="colsep0 rowsep0" align="left">27,344Â Â±Â 1590</td><td class="colsep0 rowsep0" align="left">59,724Â Â±Â 1434</td><td class="colsep0 rowsep0" align="left">11,720Â Â±Â 1749</td><td class="colsep0 rowsep0" align="left">31,676Â Â±Â 6628</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>F</i>Â %</td><td class="colsep0 rowsep0" align="left">74Â Â±Â 3</td><td class="colsep0 rowsep0" align="left">119Â Â±Â 4</td><td class="colsep0 rowsep0" align="left">56.0Â Â±Â 8.4</td><td class="colsep0 rowsep0" align="left">61.9Â Â±Â 13.0</td></tr></tbody></table></div></div></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Chemistry</h3><div class="NLM_p">A typical synthetic route toward macrocyclic compound <b>10</b> is described in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. Compound <b>10-1</b> was protected by Boc<sub>2</sub>O (Boc, <i>tert</i>-butyloxycarbonyl) with <i>N</i>,<i>N</i>-dimethylpyridin-4-amine in THF to afford <b>10-2</b>. Enol phosphate <b>10-3</b> was synthesized from compound <b>10-2</b> by reaction with diphenyl phosphorochloridate under basic conditions in THF. Subsequent SuzukiâMiyaura coupling was performed with borate <b>10-4</b> to give <b>10-5</b>. Compound <b>10-5</b> was reduced with H<sub>2</sub> and Pd(OH)<sub>2</sub>/C in EtOH to afford <b>10-6</b>. Compound <b>10-7</b> was obtained from <b>10-6</b><i>via</i> deprotection under acid conditions. Compounds <b>10-3</b>, <b>10-5</b>, <b>10-6</b>, and <b>10-7</b> did not need to be purified, and the crude product was directly subjected to the next reaction. Compound <b>10-7</b> was alkylated by ethyl 5-chloropyrazolo[1,5-a]pyrimidine-3-carboxylate <b>10-8</b> with <i>N</i>,<i>N</i>-diisopropylethylamine in NMP to afford <b>10-9</b>. Compound <b>10-9</b> was demethylated with chlorotrimethylsilane to obtain compound <b>10-10</b>, and the hydrolysis was continued to afford compound <b>11-11</b>. Compounds <b>10-11</b> and <b>10-12</b> were condensed with HATU to give compound <b>10-13</b>. After the intramolecular Mitsunobu reaction, compound <b>10-14</b> was obtained. The racemic material was purified by chiral chromatography to give the target compound <b>10</b>. As a result, compound <b>10</b> was found to be an R-isomer by single-crystal X-ray analysis, as shown in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>.</div><figure id="sch1" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00712/20210716/images/medium/jm1c00712_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00712/20210716/images/large/jm1c00712_0008.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthetic Route for Compound <b>10</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00712/20210716/images/large/jm1c00712_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00712&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Boc<sub>2</sub>O, DMAP, THF, RT, 16 h, 93%; (b) ClPO(OPh)<sub>2</sub>, LiHMDS, THF; (c) Pd(PPh<sub>3</sub>)<sub>4</sub>, NaHCO<sub>3</sub>, THF/H<sub>2</sub>O, reflux, 16 h; (d) H<sub>2</sub>, Pd(OH)<sub>2</sub>/C (5% wt), EtOH, 96 h; (e) HCl/EA, the total yield is 44% from step b to e; (f) DIPEA, NMP, 75 Â°C, 16 h, 85.3%; (g) TMSCl, NaI, ACN, 75 Â°C, 2 h; (h) NaOH, H<sub>2</sub>O/MeOH, 60 Â°C, 2 h, total yield of steps g and h is 98.6%; (i) HATU, DIPEA, DMF, RT, 72.4%; (j) PPh<sub>3</sub>, DEAD, THF.</p></p></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_06254" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_06254" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Due to its high clinical efficacy, there is substantial interest in the development of small-molecule inhibitors of TrkA for the treatment of tumors. We have successfully discovered a novel, highly potent, and selective second-generation Trk inhibitor compound <b>10</b> (LPM4870108). Although initial efforts using a structural modification strategy was largely futile, compound <b>10</b> was found <i>via</i> optimization from the aspects of chemistry and pharmacokinetic properties, which had good activity against wild-type and mutant TrkA/TrkC. Moreover, the high potency, high off-target selectivity, good <i>in vivo</i> toxicity profile, as well as good absorption and human CL predictions made compound <b>10</b> an exciting and promising structurally differentiated asset suitable for advancement into a variety of clinical anti-tumor studies (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>).</div><figure id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00712/20210716/images/medium/jm1c00712_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00712/20210716/images/large/jm1c00712_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. ORTEP of <b>10</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00712/20210716/images/large/jm1c00712_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00712&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77622" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77622" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> General</h3><div class="NLM_p">The recorded <sup>1</sup>H nuclear magnetic resonance (NMR) spectra were found to be consistent with the proposed structures. Characteristic chemical shifts (Î´) are given in parts-per-million (ppm) (Î´ relative to the residual solvent peak) using conventional abbreviations for the designation of major peaks: s, singlet; d, doublet; t, triplet; m, multiplet; and br, broad. The mass spectra (<i>m</i>/<i>z</i>) were recorded using the electrospray ionization technique. The following abbreviations were used for common solvents: CDCl<sub>3</sub>, deuterochloroform; DMSO-<i>d</i><sub>6</sub>, deuterodimethyl sulfoxide; and CD<sub>3</sub>OD, deuteromethanol. All solvents were of reagent grade and, when necessary, were purified and dried by standard methods. The concentration of solutions after reactions and extractions involved the use of a rotary evaporator operating at a reduced pressure of <i>ca.</i> 20 Torr. Anhydrous solvents were obtained from commercial sources and used as received. The chemical yields reported below are unoptimized. Purity criteria: final compounds isolated as singletons are >95% based on LCMS and/or HPLC.</div><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> <i>tert</i>-Butyl 3-Oxomorpholine-4-carboxylate (<b>10-2</b>)</h4><div class="NLM_p last">4-Dimethylaminopyridine (12.08 g, 98.91 mmol, 0.1 equiv) was added to the solution of compound <b>10-1</b> (morpholin-3-one) (100 g, 989.08 mmol, 1 equiv) in tetrahydrofuran (1000 mL) and then Boc<sub>2</sub>O (280.62 g, 1.29 mol, 295.39 mL, 1.3 equiv) was dropped. The mixture was stirred at 30 Â°C for 2 min and poured into an aqueous sodium chloride solution (1 L). The reaction was extracted with EtOAc. The combined organic phases were added with 1% HCl to adjust the pH to 5â6 in an ice bath, washed with water, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to obtain compound <b>10-2</b> (185 g, crude product) as a yellow oily compound.</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> <i>tert</i>-Butyl 5-((Diphenoxyphosphoryl)oxy)-2,3-dihydro-4<i>H</i>-1,4-oxazine-4-carboxylate (<b>10-3</b>)</h4><div class="NLM_p last">Under nitrogen, LiHMDS (1 M, 546.67 mL, 1 equiv) was slowly dropped into the solution of compound <b>10-2</b> (110 g, 546.67 mmol, 1 equiv) in tetrahydrofuran (1000 mL) and the temperature of the reaction was controlled between â60 and â30 Â°C. The reaction mixture was stirred for 1 h and then diphenyl chlorophosphate (146.85 g, 546.67 mmol, 112.96 mL, 1 equiv) in tetrahydrofuran (120 mL) was added dropwise. After stirring for 3 h, the reaction mixture was poured into water (1000 mL) and extracted with EtOAc. The organics were washed with water, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The crude material was purified by SiO<sub>2</sub> column chromatography to afford <b>10-3</b> (127 g, 293.3 mmol, yield 52.87%).</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> <i>tert</i>-Butyl 5-(5-Fluoro-2-methoxypyridin-3-yl)-2,3-dihydro-4<i>H</i>-1,4-oxazine-4-carboxylate (<b>10-5</b>)</h4><div class="NLM_p last">Acetonitrile (1000 mL), water (250 mL), compound <b>10-3</b> (70 g, 161.52 mmol, 1 equiv), potassium phosphate (68.57 g, 323.04 mmol, 2 equiv), and compound <b>10-4</b> (81.75 g, 323.04 mmol, 2 equiv) were sequentially added to the flask. After nitrogen replacement, tri-<i>tert</i>-butylphosphine palladium (6 g, 11.74 mmol) was added under a nitrogen flow, and the reaction mixture was heated at 75 Â°C for 10 h. The reaction mixture was poured into water (1000 mL) and extracted with EtOAc. The organics were washed with water, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The crude material was purified by SiO<sub>2</sub> column chromatography to afford <b>10-5</b> (39.6 g, 127.8 mmol, yield 78.9%). LCMS [M + 1] 311.1; <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>): Î´ ppm 7.87 (d, <i>J</i> = 2.8 Hz, 1H), 7.24â7.19 (m, 1H), 6.30â6.22 (m, 1H), 4.26â4.19 (m, 2H), 3.90 (s, 3H), 3.83â3.75 (m, 2H), 1.15 (s, 9H).</div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> <i>tert</i>-Butyl 3-(5-Fluoro-2-methoxypyridin-3-yl)morpholine-4-carboxylate (<b>10-6</b>)</h4><div class="NLM_p last">Compound <b>10-5</b> (30 g, 96.67 mmol, 1 equiv) was dissolved in ethanol (1000 mL) and then dry palladium hydroxide on carbon (9.62 g, 13.69 mmol, 20% purity) was added under an argon atmosphere. Under a hydrogen atmosphere (50 psi), the reaction was heated at 80 Â°C for 24 h. The reaction solution was filtered, and the filter cake was washed with ethanol (50 mL). The filtration was concentrated in vacuo to obtain compound <b>10-6</b> as a white solid (27.8 g, 89.1 mmol, yield 91.95%). LCMS [M + 1] 313.2; <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>): Î´ ppm 7.87 7.83 (d, <i>J</i> = 2.8 Hz, 1H), 7.24 (dd, <i>J</i> = 2.4, 8.7 Hz, 1H), 5.06 (br d, <i>J</i> = 3.8 Hz, 1H), 4.19 (br d, <i>J</i> = 12.0 Hz, 1H), 3.91â3.79 (m, 5H), 3.72 (dd, <i>J</i> = 4.3, 12.0 Hz, 1H), 3.51 (dt, <i>J</i> = 3.4, 11.6 Hz, 1H), 3.36â3.23 (m, 1H), 1.33 (s, 9H).</div></div><div id="sec4_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> 3-(5-Fluoro-2-methoxypyridin-3-yl)morpholine (<b>10-7</b>)</h4><div class="NLM_p last">HCl/ethyl acetate (4 M, 750.69 mL, 10.91 equiv) was added to the solution of compound <b>10-6</b> (86 g, 275.34 mmol, 1 equiv) in ethyl acetate (300 mL), and the reaction mixture was stirred at 25 Â°C for 16 h. A large amount of white solid precipitated. Under a nitrogen atmosphere, the reaction solution was filtered, washed with ethyl acetate (300 mL), and the filter cake was vacuum-dried without further purification to obtain compound <b>10-7</b> as a white solid (57.46 g, 271 mmol, yield 98.33%). LCMS [M + 1] 213.1; <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>): Î´ ppm 7.88 (d, <i>J</i> = 3.0 Hz, 1H), 7.62â7.57 (m, 1H), 4.17 (dd, <i>J</i> = 3.0, 9.2 Hz, 1H), 3.96 (dd, <i>J</i> = 3.2, 10.8 Hz, 1H), 3.92 (s, 3H), 3.89â3.84 (m, 1H), 3.61 (dt, <i>J</i> = 2.6, 11.0 Hz, 1H), 3.24 (dd, <i>J</i> = 9.2, 10.4 Hz, 1H), 3.15â3.06 (m, 1H), 3.03â2.96 (m, 1H).</div></div><div id="sec4_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> Ethyl 5-(3-(5-Fluoro-2-methoxypyridin-3-yl)morpholino)pyrazolo[1,5-a]pyrimidine-3-carboxylate (<b>10-9</b>)</h4><div class="NLM_p last"><i>N</i>,<i>N</i>-Diisopropylethylamine (88.09 g, 681.58 mmol, 118.72 mL, 2.53 equiv) and compound <b>10-8</b> (50.37 g, 223.24 mmol, 0.83 equiv) were added to the mixture of compound <b>10-7</b> (67 g, 269.42 mmol, 1 equiv, HCl) in 1-methyl-2-pyrrolidone (350 mL) and then stirred at 70 Â°C for 16 h. The reaction solution was poured into ice water (1000 mL) and stirred for 30 min. A large number of solids precipitated out, which were then filtered and washed with water (400 mL). The filter cake was dissolved in dichloromethane (1.5 L), dried with anhydrous sodium sulfate, and concentrated in vacuo to obtain compound <b>10-9</b> (92.2 g, crude product, yield 85.33%).</div></div><div id="sec4_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> Ethyl 5-(3-(5-Fluoro-2-hydroxypyridin-3-yl)morpholino)pyrazolo[1,5-a]pyrimidine-3-carboxylate (<b>10-10</b>)</h4><div class="NLM_p last">The crude compound <b>10-9</b> (90 g, 224.77 mmol, 1 equiv) was dissolved in the acetonitrile solvent (900 mL), then sodium iodide (101.08 g, 674.32 mmol, 3 equiv) and trimethylchlorosilane (73.26 g, 674.32) mmol, 85.58 mL, (3 equiv) were added, and the reaction solution was stirred at 25 Â°C for 24 h. The reaction solution was poured into an aqueous sodium bicarbonate solution (prepared with 65 g of sodium bicarbonate and 1.2 L of water), then the pH was adjusted to 7â8, and extracted with dichloromethane (500 mL). The organic phase was washed with saturated sodium chloride (150 mL), dried over anhydrous sodium sulfate, and concentrated in vacuo to obtain a crude product. The crude product was slurried (ethyl acetateâmethyl <i>tert</i>-butyl ether = 1:1, 400 mL) for 1 h, filtered, and the filter cake was dried in vacuo to obtain compound <b>10-10</b> as a pale yellow solid (86 g, crude product).</div></div><div id="sec4_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> 5-(3-(5-Fluoro-2-hydroxypyridin-3-yl)morpholino)pyrazolo[1,5-a]pyrimidine-3-carboxylic Acid (<b>10-11</b>)</h4><div class="NLM_p last">Compound <b>10-10</b> (85 g, 219.43 mmol, 1 equiv) was dissolved in methanol and then sodium hydroxide (3 M, 292.58 mL, 4 equiv), water (292 mL), and methanol (850 mL) were added. The reaction mixture was stirred at 60 Â°C for 2 h. After the reaction mixture was cooled in an ice water bath, 3 mol/L dilute hydrochloric acid was slowly added to adjust the pH to 2. After stirring for 0.5 h, a solid precipitated out. It was filtered and the filter cake was dried in concentrated vacuum to obtain compound <b>10-11</b> as a light brown solid (60.5 g, 168.38 mmol, yield 76.73%). LCMS [M + 1] 360.9; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 11.75 (br s, 1H), 8.74 (d, <i>J</i> = 8.0 Hz, 1H), 8.21 (s, 1H), 7.56 (br s, 1H), 7.44 (br d, <i>J</i> = 8.0 Hz, 1H), 6.72 (br d, <i>J</i> = 8.0 Hz, 1H), 5.31 (br s, 1H), 4.51 (br s, 1H), 4.37 (br d, <i>J</i> = 12.0 Hz, 1H), 4.07 (br d, <i>J</i> = 8.4 Hz, 1H), 3.84 (br dd, <i>J</i> = 4.0, 11.8 Hz, 1H), 3.66â3.45 (m, 3H).</div></div><div id="sec4_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> 5-(3-(5-Fluoro-2-hydroxypyridin-3-yl)morpholino)-<i>N</i>-(1-(hydroxymethyl)cyclopropyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (<b>10-13</b>)</h4><div class="NLM_p last">Compound <b>10-11</b> (53.5 g, 148.90 mmol, 1 equiv) and compound <b>10-12</b> (20.24 g, 163.79 mmol, 1.1 equiv) were dissolved in <i>N</i>,<i>N</i>-dimethylformamide (530 mL) and then 2-(7-benzotriazole oxide)-<i>N</i>,<i>N</i>,<i>N</i>â²,<i>N</i>â²-tetramethylurea hexafluorophosphate (62.28 g, 163.79 mmol, 1.1 equiv) was added. After <i>N</i>,<i>N</i>-diisopropyl ethylamine (67.35 g, 521.14 mmol, 90.77 mL, 3.5 equiv) was added dropwise and the reaction solution was heated at 15 Â°C for 16 h. The reaction was quenched by adding 16 mL of saturated aqueous ammonium chloride solution to the reaction solution and concentrated in vacuo at 60 Â°C. After concentration, acetonitrile (400 mL) was added and it was stirred for 1 h. A large amount of solids precipitated. This solid was filtered to obtain compound <b>10-13</b> (72 g). LCMS [M + 1] 429.1; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 8.80 (d, <i>J</i> = 8.0 Hz, 1H), 8.15 (s, 1H), 7.87 (s, 1H), 7.56 (s, 1H), 7.43 (d, <i>J</i> = 6.4 Hz, 1H), 6.81 (s, 1H), 5.38 (s, 1H), 4.69 (s, 1H), 4.31 (d, <i>J</i> = 19.2 Hz, 1H), 4.22 (s, 1H), 4.08â4.02 (m, 2H), 3.89â3.85 (m, 2H), 3.66 (d, <i>J</i> = 6.8 Hz, 3H), 0.75â0.71 (m, 3H), 0.60 (br s, 1H).</div></div><div id="sec4_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> (3â²<i>E</i>,4â²<i>E</i>)-5â²-Fluorospiro[cyclopropane-1,6â²-4-oxa-7-aza-2(4,3)-morpholina-1(5,3)-pyrazolo[1,5-a]pyrimidina-3(3,2)-pyridinacyclooctaphan]-8â²-one (<b>10-14</b>)</h4><div class="NLM_p last">Compound <b>10-13</b> (25 g, 58.35 mmol, 1 equiv) was dissolved in tetrahydrofuran (250 mL), then tributylphosphorus (17.71 g, 87.53 mmol, 21.60 mL, 1.5 equiv) was added dropwise, followed by azodimethyl bis(piperidine) (22.09 g, 87.53 mmol, 1.5 equiv), and it was stirred at 15 Â°C for 16 h. The reaction solution was directly filtered, and the obtained white filter cake was compound <b>10-14</b> (35 g, crude product). The crude product was dissolved in dichloromethane (1000 mL) and methanol (100 mL), washed twice with 1 M HCl (250 mL), the organic phase was dried and concentrated in vacuo to obtain the crude product. The crude product was slurried with ethanol (500 mL) and stirred for 1 h, filtered, and the filter cake was vacuum-dried to obtain compound <b>10-14</b> (22 g). LCMS [M + 1] 411.1; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): Î´ ppm 8.98 (s, 1H), 8.33 (d, <i>J</i> = 7.6 Hz, 1H), 8.26 (s, 1H), 7.89 (d, <i>J</i> = 2.4 Hz, 1H), 7.77â7.75 (m, 1H), 6.36 (d, <i>J</i> = 7.6 Hz, 1H), 6.15 (s, 1H), 5.07 (d, <i>J</i> = 10.8 Hz, 1H), 4.39 (d, <i>J</i> = 9.6 Hz, 1H), 4.12â3.88 (m, 4H), 3.76 (d, <i>J</i> = 10.0 Hz, 1H), 3.60 (d, <i>J</i> = 10.8 Hz, 1H), 2.27â2.22 (m, 1H), 1.07â0.94 (m, 2H), 0.84â0.79 (m, 1H).</div></div><div id="sec4_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> (S,3â²<i>E</i>,4â²<i>E</i>)-5â²-Fluorospiro[cyclopropane-1,6â²-4-oxa-7-aza-2(4,3)-morpholina-1(5,3)-pyrazolo[1,5-a]pyrimidina-3(3,2)-pyridinacyclooctaphan]-8â²-one (<b>10</b>)</h4><div class="NLM_p last">Column: CHIRALPAK IG-3 (IG30CD-WE016), 0.46 cm ID Ã 15 cm L; mobile phase: MeOH/DCM = 60/40 (V/V); flow rate: 1.0 mL/min; wavelength: UV 220 nm; Temperature: 35 Â°C; HPLC equipment: Shimadzu LC-20AT CP-HPLC-06. LCMS [M + 1] 411.1; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): Î´ ppm 8.98 (s, 1H), 8.33 (d, <i>J</i> = 7.6 Hz, 1H), 8.26 (s, 1H), 7.89 (d, <i>J</i> = 2.4 Hz, 1H), 7.77â7.75 (m, 1H), 6.36 (d, <i>J</i> = 7.6 Hz, 1H), 6.15 (s, 1H), 5.07 (d, <i>J</i> = 10.8 Hz, 1H), 4.39 (d, <i>J</i> = 9.6 Hz, 1H), 4.12â3.88 (m, 4H), 3.76 (d, <i>J</i> = 10.0 Hz, 1H), 3.60 (d, <i>J</i> = 10.8 Hz, 1H), 2.27â2.22 (m, 1H), 1.07â0.94 (m, 2H), 0.84â0.79 (m, 1H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): Î´ ppm 163.47, 157.17, 156.25, 155.36, 146.03, 145.60, 138.58, 132.71, 125.85, 125.06, 103.55, 96.29, 75.25, 70.91, 66.09, 46.33, 42.40, 33.55, 11.91, 8.29. HRMS for C<sub>20</sub>H<sub>20</sub>FN<sub>6</sub>O<sub>3</sub><i>m</i>/<i>z</i>: [M +H]<sup>+</sup> calcd, 411.15754; found, 411.15746. HPLC 99.64%, chiral HPLC 98.84%.</div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> Computational Modeling Methods</h3><div class="NLM_p last">All molecules were prepared for docking simulation using Discovery Studio 2018 to consider proper protonation states and tautomers. The docking simulation was performed with CDOCK (Discovery Studio 2018) using protein models based on X-ray structures (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4YNE">4YNE</a>) downloaded from RCSB PDB (<a href="http://www.rcsb.org/" class="extLink">http://www.rcsb.org/</a>).</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> Permeability Experiment</h3><div class="NLM_p last">A permeability experiment was conducted with the Caco-2 cell model. Caco-2 cells were seeded on 96-well transport inserts and cultured for 28 days before being used for the experiment. The apical-to-basolateral (A to B) transport of the test compound was measured by adding a transport buffer solution (HBSS, 25 mM HEPES, pH 7.4) containing the test compound (or rosuvastatin or propranolol as the control) to the apical and transport buffer solution (HBSS, 25 mM HEPES, pH 7.4) to basolateral. The basolateral-to-apical (B to A) transport of the test compound was measured by adding transport buffer solution (HBSS, 25 mM HEPES, pH 7.4) containing the test compound to the basolateral and transport buffer solution (HBSS, 25 mM HEPES, pH 7.4) to apical. After incubating at 37 Â°C for 2 h, the cell plates were taken out and samples on both sides were obtained. The concentrations of the test compound were determined by LCâMS/MS. According to the concentrations of the substrate at the donor compartment and the receiver compartment, the apparent permeability of substrate transport from the apical to the basolateral and from the basolateral to the apical in the monolayer were calculated, and the efflux ratio was calculated.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> Metabolism Stability in Microsomes</h3><div class="NLM_p last">The test compound was incubated in liver microsomes at a final concentration of 1 Î¼M, and the protein concentration was 0.5 mg mL<sup>â1</sup>. The reactions were terminated at serial time points after initiation of the reaction. The test compound was analyzed using an optimized LCâMS/MS method. The percentages of the remaining test compound were measured and the <i>in vitro</i> intrinsic clearance was calculated accordingly. Hepatic intrinsic clearance (CL<sub>int,Â <i>inÂ vivo</i></sub>) was evaluated based on the <i>in vitro</i> intrinsic clearance.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> Plasma Protein Binding Assay</h3><div class="NLM_p last">Plasma protein binding studies were performed using a 96-well HTDialysis equilibrium dialysis chamber apparatus. Spiked plasma and phosphate buffer were added to the donor side and the receiver side, respectively. The plate was covered with an adhesive sealing film and placed in a water bath at 37 Â°C with shaking. After a certain time, the samples in the donor side and the receiver side were taken out and analyzed using an optimized LCâMS/MS method. The values of unbound fraction (fu) were calculated.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> CYP Isoenzyme Inhibition Experiment</h3><div class="NLM_p last">Serial concentrations of the test compound were incubated with each probe substrate (phenacetin for CYP1A2, diclofenac for CYP2C9, S-mephenytoin for CYP2C19, dextromethorphan for CYP2D6, and midazolam and testosterone for CYP3A4) in pooled human liver microsomes. The reaction was initiated by the addition of the coenzyme NADPH. The reaction was stopped by adding the ice-cold acetonitrile-containing internal standard to the incubation system. The generation amounts of probe drug metabolites (acetaminophen, OH-diclofenac, OH-S-mephenytoin, dextrorphan, OH-midazolam, and 6-OH-testosterone) at different test compound concentrations were measured by the LCâMS/MS method to calculate the remaining activity percentage of liver microsomal enzymes, and finally the IC<sub>50</sub> values of test compounds for the cytochrome P450 (CYP) isoenzyme were obtained using Graphpad Prism 6.02 software. Selective inhibitors (Î±-naphthoflavone for CYP1A2, sulfaphenazole for CYP2C9, nootkatone for CYP2C19, quinidine for CYP2D6, and ketoconazole for CYP3A) were used as the positive controls to validate the incubation system.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> Kinase Assay</h3><div class="NLM_p last">Compound <b>10</b> was tested against each of the selected kinases using Eurofins standard KinaseProfiler assays. The compounds supplied were prepared to a working stock of 50Ã final assay concentration in 100% DMSO. The required volume of the 50Ã stock of the test compound was added to the assay well before a reaction mix containing the enzyme and the substrate was added. The reaction was initiated by the addition of ATP at the selected concentration. Data were handled using custom-built in-house analysis software. The results were expressed as kinase activity remaining, as a percentage of the DMSO control, which were calculated using the following formula (mean of sample counts â mean of blank counts)/mean of control counts.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> <i>In Vitro</i> PD Assay</h3><div class="NLM_p">The indicated kinases (TrkA, TrkA<sup>G595R</sup>, TrkA<sup>G667C</sup>, TrkC, ALK, or Ros1) were delivered into the substrate solution and gently mixed. Then, the compounds in DMSO were delivered to the kinase reaction mixture utilizing the acoustic technology (Echo 550). <sup>33</sup>P-ATP (specific activity, 0.01 Î¼Ci/Î¼L final) was added to the reaction mixture to initiate the reaction. The kinase reaction was incubated for 120 min at room temperature. Reactions were spotted onto P81 ion-exchange paper (Whatman # 3698-915). The filters were washed extensively in 0.75% phosphoric acid. The radioactive phosphorylated substrate remaining on the filter paper was measured. Kinase activity data were expressed as the percent remaining kinase activity in the test samples compared to vehicle (dimethyl sulfoxide) reactions. IC<sub>50</sub> values and curve fits were obtained using GraphPad Prism 5.</div><div class="NLM_p last">The cell viability was evaluated using the cytotoxicity assay, as described previously.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Briefly, cells were plated at 5000 per well into 96-well plates and then incubated with compounds <b>8â10</b> at the desired concentrations. The MTT solution (5 mg/mL) was added to each well and incubated continuously for 4 h. DMSO was added to dissolve the MTT formazan product, and the absorbance was measured at 570 nm using a Molecular Devices SpectraMax M5 (Molecular Devices, USA). IC<sub>50</sub> values were calculated using GraphPad Prism 5.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> <i>In Vivo</i> PD Study</h3><div class="NLM_p">Animals were provided free access to food and water in strict accordance with the National Institute of Health Guide for the Care and Use of Laboratory Animals (NIH Publications no. 80-23). All animal protocols were approved by the Ethics Committee of Yantai University (no. 011 in 2020 for Animal Ethics Approval). All surgeries were performed under anesthesia, and all efforts were made to minimize suffering. Twelve SpragueâDawley rats (six males and six females) were divided into two groups (three males and three females) randomly. Animals in group A were administered with the test compound by single intravenous administration at 2 mg/kg. Animals in group B were administered with the test compound by single oral administration at 10 mg/kg. Blood samples were collected from the jugular vein cannula at a pre-dose, and 0.083, 0.25, 0.5, 1, 2, 4, 6, 8, 12, and 24 h after finishing the dose for group A and collected at pre-dose and 0.25, 0.5, 1, 2, 4, 6, 8, 12, and 24 h after finishing the dose for group B. The concentration of the test compound was analyzed using an optimized LCâMS/MS method. The pharmacokinetic (PK) parameters were calculated using a non-compartmental model of WinNonlin version 8.0 (Pharsight, St. Louis, USA).</div><div class="NLM_p last">Xenograft models (eight animals/group) were established following a subcutaneous injection of 3 Ã 10<sup>6</sup> Ba/F3 LMNA-NTRK1cells, Ba/F3 ETV6-NTRK3 cells, Ba/F3 ETV6-NTRK3-G623R cells, or Ba/F3 LMNA-NTRK1-G595R cells into the right flank of each animal. When tumors in all animals ranged from 100 to 200 mm<sup>3</sup> in size, compound <b>10</b> was administered orally once daily for 11 days at doses of 5, 10, or 20 mg/kg, and LOXO-195 was administered at 100 mg/kg, respectively. Tumor dimensions and body weights were recorded twice weekly starting from the first day of treatment, and tumor volumes were calculated using the formula (<i>l</i> Ã (<i>w</i>)<sup>2</sup>)/2, where <i>l</i> was the longest dimension of the tumor and <i>w</i> was the width, respectively.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i39"><a href="/doi/suppl/10.1021/acs.jmedchem.1c00712" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_36268" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_36268" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.1c00712?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00712</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Crystallographic data of compounds (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00712/suppl_file/jm1c00712_si_001.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline"><sup>1</sup>H NMR, <sup>13</sup>C NMR, COSY, HSQC, HMBC, <sup>19</sup>F NMR, HRMS, and single-crystal X-ray diffraction experiment report of compound <b>10</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00712/suppl_file/jm1c00712_si_002.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Predicted binding mode of LOXO-195 and TPX-0005 binding to the active site of TrkC (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00712/suppl_file/jm1c00712_si_003.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00712/suppl_file/jm1c00712_si_001.csv">jm1c00712_si_001.csv (1.72 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00712/suppl_file/jm1c00712_si_002.pdf">jm1c00712_si_002.pdf (3.31 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00712/suppl_file/jm1c00712_si_003.pdf">jm1c00712_si_003.pdf (355.58 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.1c00712" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_80631" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_80631" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hongbo Wang</span> - <span class="hlFld-Affiliation affiliation">School
of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation
(Yantai University), Ministry of Education, Collaborative Innovation
Center of Advanced Drug Delivery System and Biotech Drugs in Universities
of Shandong, Yantai University, Yantai 264005, China</span>;Â 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0001-5055-4261" title="Orcid link">https://orcid.org/0000-0001-5055-4261</a>;Â 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#f59d9a9b92979a82949b928c81b59298949c99db969a98"><span class="__cf_email__" data-cfemail="b8d0d7d6dfdad7cfd9d6dfc1ccf8dfd5d9d1d496dbd7d5">[emailÂ protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jingwei Tian</span> - <span class="hlFld-Affiliation affiliation">School
of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation
(Yantai University), Ministry of Education, Collaborative Innovation
Center of Advanced Drug Delivery System and Biotech Drugs in Universities
of Shandong, Yantai University, Yantai 264005, China</span>;Â 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#96e2fff7f8fcfff8f1e1f3ffd6fae3eff3b8f5f8"><span class="__cf_email__" data-cfemail="c8bca1a9a6a2a1a6afbfada188a4bdb1ade6aba6">[emailÂ protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zongliang Liu</span> - <span class="hlFld-Affiliation affiliation">School
of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation
(Yantai University), Ministry of Education, Collaborative Innovation
Center of Advanced Drug Delivery System and Biotech Drugs in Universities
of Shandong, Yantai University, Yantai 264005, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Pengfei Yu</span> - <span class="hlFld-Affiliation affiliation">Department
of Clinical Medicine, Binzhou Medical College, Yantai 256603, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lin Dong</span> - <span class="hlFld-Affiliation affiliation">Luye
Pharma Group, Yantai 264005, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wenyan Wang</span> - <span class="hlFld-Affiliation affiliation">School
of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation
(Yantai University), Ministry of Education, Collaborative Innovation
Center of Advanced Drug Delivery System and Biotech Drugs in Universities
of Shandong, Yantai University, Yantai 264005, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sijin Duan</span> - <span class="hlFld-Affiliation affiliation">Luye
Pharma Group, Yantai 264005, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bingsi Wang</span> - <span class="hlFld-Affiliation affiliation">Luye
Pharma Group, Yantai 264005, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiaoyan Gong</span> - <span class="hlFld-Affiliation affiliation">Luye
Pharma Group, Yantai 264005, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Liang Ye</span> - <span class="hlFld-Affiliation affiliation">Department
of Clinical Medicine, Binzhou Medical College, Yantai 256603, China</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>Z.L. and P.Y. contributed equally. H.W. and J.T. designed the research. Z.L., P.Y., L.D., W.W., S.D., B.W., X.G., and L.Y. performed the experiments. H.W., J.T., and L.Y. performed data analyses. H.W. and J.T. wrote the paper.</p></li><li><span class="author-information-subsection-header">Funding</span><p>This work was partially supported by grants from the National Natural Science Foundation of China (82073888), the Science and Technology Support Program for Youth Innovation in Universities of Shandong (2019KJM009 and 2020KJM003), The Medical and Health Science and Technology Development plan project of Shandong (2017WS691), the Top Talents Program for One Case Discussion of Shandong Province, and the Taishan Scholar Project.</p></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">ATP</td><td class="NLM_def"><p class="first last">adenosine triphosphate</p></td></tr><tr><td class="NLM_term">Boc</td><td class="NLM_def"><p class="first last"><i>tert</i>-butyloxycarbonyl</p></td></tr><tr><td class="NLM_term">CYP</td><td class="NLM_def"><p class="first last">cytochrome P450</p></td></tr><tr><td class="NLM_term">ER</td><td class="NLM_def"><p class="first last">efflux ratio</p></td></tr><tr><td class="NLM_term"><i>F</i></td><td class="NLM_def"><p class="first last">oral bioavailability</p></td></tr><tr><td class="NLM_term">hERG</td><td class="NLM_def"><p class="first last">human ether-a-go-go-related gene</p></td></tr><tr><td class="NLM_term">IC<sub>50</sub></td><td class="NLM_def"><p class="first last">half-maximum inhibitory concentration</p></td></tr><tr><td class="NLM_term">MW</td><td class="NLM_def"><p class="first last">molecular weight</p></td></tr><tr><td class="NLM_term">PDB</td><td class="NLM_def"><p class="first last">Protein Data Bank</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetics</p></td></tr><tr><td class="NLM_term"><i>T</i><sub>1/2</sub></td><td class="NLM_def"><p class="first last">half-life</p></td></tr><tr><td class="NLM_term">Trk</td><td class="NLM_def"><p class="first last">tropomyosin-related kinase</p></td></tr><tr><td class="NLM_term"><i>V</i><sub>d</sub></td><td class="NLM_def"><p class="first last">volume of distribution at steady state</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i42">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_46310" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_46310" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 17 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mitelman, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johansson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mertens, F.</span></span> <span> </span><span class="NLM_article-title">The impact of translocations and gene fusions on cancer causation</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">233</span>â <span class="NLM_lpage">245</span>, <span class="refDoi">Â DOI: 10.1038/nrc2091</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=10.1038%2Fnrc2091" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=17361217" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjtlyhtL0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=233-245&author=F.+Mitelmanauthor=B.+Johanssonauthor=F.+Mertens&title=The+impact+of+translocations+and+gene+fusions+on+cancer+causation&doi=10.1038%2Fnrc2091"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The impact of translocations and gene fusions on cancer causation</span></div><div class="casAuthors">Mitelman, Felix; Johansson, Bertil; Mertens, Fredrik</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">233-245</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Chromosome aberrations, in particular translocations and their corresponding gene fusions, have an important role in the initial steps of tumorigenesis; at present, 358 gene fusions involving 337 different genes have been identified.  An increasing no. of gene fusions are being recognized as important diagnostic and prognostic parameters in malignant hematol. disorders and childhood sarcomas.  The biol. and clin. impact of gene fusions in the more common solid tumor types has been less appreciated.  However, an anal. of available data shows that gene fusions occur in all malignancies, and that they account for 20% of human cancer morbidity.  With the advent of new and powerful investigative tools that enable the detection of cytogenetically cryptic rearrangements, this proportion is likely to increase substantially.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkiYHGC0ahy7Vg90H21EOLACvtfcHk0lgYLHk48tTTOw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjtlyhtL0%253D&md5=8ce22e508cd79b28599b724f6f0a8155</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrc2091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2091%26sid%3Dliteratum%253Aachs%26aulast%3DMitelman%26aufirst%3DF.%26aulast%3DJohansson%26aufirst%3DB.%26aulast%3DMertens%26aufirst%3DF.%26atitle%3DThe%2520impact%2520of%2520translocations%2520and%2520gene%2520fusions%2520on%2520cancer%2520causation%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2007%26volume%3D7%26spage%3D233%26epage%3D245%26doi%3D10.1038%2Fnrc2091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Drilon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laetsch, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kummar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DuBois, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lassen, U. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demetri, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nathenson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doebele, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farago, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pappo, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turpin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowlati, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brose, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mascarenhas, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Federman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berlin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Deiry, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baik, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deeken, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boni, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagasubramanian, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudzinski, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meric-Bernstam, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sohal, D. P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raez, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hechtman, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benayed, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladanyi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuch, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruickshank, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ku, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyman, D. M.</span></span> <span> </span><span class="NLM_article-title">Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>378</i></span>,  <span class="NLM_fpage">731</span>â <span class="NLM_lpage">739</span>, <span class="refDoi">Â DOI: 10.1056/nejmoa1714448</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=10.1056%2FNEJMoa1714448" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=29466156" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=1%3ACAS%3A528%3ADC%252BC1cXkvFalsLY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=378&publication_year=2018&pages=731-739&author=A.+Drilonauthor=T.+W.+Laetschauthor=S.+Kummarauthor=S.+G.+DuBoisauthor=U.+N.+Lassenauthor=G.+D.+Demetriauthor=M.+Nathensonauthor=R.+C.+Doebeleauthor=A.+F.+Faragoauthor=A.+S.+Pappoauthor=B.+Turpinauthor=A.+Dowlatiauthor=M.+S.+Broseauthor=L.+Mascarenhasauthor=N.+Federmanauthor=J.+Berlinauthor=W.+S.+El-Deiryauthor=C.+Baikauthor=J.+Deekenauthor=V.+Boniauthor=R.+Nagasubramanianauthor=M.+Taylorauthor=E.+R.+Rudzinskiauthor=F.+Meric-Bernstamauthor=D.+P.+S.+Sohalauthor=P.+C.+Maauthor=L.+E.+Raezauthor=J.+F.+Hechtmanauthor=R.+Benayedauthor=M.+Ladanyiauthor=B.+B.+Tuchauthor=K.+Ebataauthor=S.+Cruickshankauthor=N.+C.+Kuauthor=M.+C.+Coxauthor=D.+S.+Hawkinsauthor=D.+S.+Hongauthor=D.+M.+Hyman&title=Efficacy+of+Larotrectinib+in+TRK+Fusion-Positive+Cancers+in+Adults+and+Children&doi=10.1056%2Fnejmoa1714448"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children</span></div><div class="casAuthors">Drilon, A.; Laetsch, T. W.; Kummar, S.; DuBois, S. G.; Lassen, U. N.; Demetri, G. D.; Nathenson, M.; Doebele, R. C.; Farago, A. F.; Pappo, A. S.; Turpin, B.; Dowlati, A.; Brose, M. S.; Mascarenhas, L.; Federman, N.; Berlin, J.; El-Deiry, W. S.; Baik, C.; Deeken, J.; Boni, V.; Nagasubramanian, R.; Taylor, M.; Rudzinski, E. R.; Meric-Bernstam, F.; Sohal, D. P. S.; Ma, P. C.; Raez, L. E.; Hechtman, J. F.; Benayed, R.; Ladanyi, M.; Tuch, B. B.; Ebata, K.; Cruickshank, S.; Ku, N. C.; Cox, M. C.; Hawkins, D. S.; Hong, D. S.; Hyman, D. M.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">378</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">731-739</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Fusions involving one of three tropomyosin receptor kinases (TRK) occur in diverse cancers in children and adults.  We evaluated the efficacy and safety of larotrectinib, a highly selective TRK inhibitor, in adults and children who had tumors with these fusions.  METHODS: We enrolled patients with consecutively and prospectively identified TRK fusion-pos. cancers, detected by mol. profiling as routinely performed at each site, into one of three protocols: a phase 1 study involving adults, a phase 1-2 study involving children, or a phase 2 study involving adolescents and adults.  The primary end point for the combined anal. was the overall response rate according to independent review.  Secondary end points included duration of response, progression free survival, and safety.  RESULTS: A total of 55 patients, ranging in age from 4 mo to 76 years, were enrolled and treated.  Patients had 17 unique TRK fusion-pos. tumor types.  The overall response rate was 75% (95% confidence interval [CI], 61 to 85) according to independent review and 80% (95% CI, 67 to 90) according to investigator assessment.  At 1 yr, 71% of the responses were ongoing and 55% of the patients remained progression-free.  The median duration of response and progression-free survival had not been reached.  At a median follow-up of 9.4 mo, 86% of the patients with a response (38 of 44 patients) were continuing treatment or had undergone surgery that was intended to be curative.  Adverse events were predominantly of grade 1, and no adverse event of grade 3 or 4 that was considered by the investigators to be related to larotrectinib occurred in more than 5% of patients.  No patient discontinued larotrectinib owing to drug-related adverse events.  CONCLUSIONS: Larotrectinib had marked and durable antitumor activity in patients with TRK fusion-pos. cancer, regardless of the age of the patient or of the tumor type.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwp_pcLYdv5bVg90H21EOLACvtfcHk0lhkGXR-gQVJqA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXkvFalsLY%253D&md5=b636d83c2cd61b4b35c36e36c950196c</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1714448&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1714448%26sid%3Dliteratum%253Aachs%26aulast%3DDrilon%26aufirst%3DA.%26aulast%3DLaetsch%26aufirst%3DT.%2BW.%26aulast%3DKummar%26aufirst%3DS.%26aulast%3DDuBois%26aufirst%3DS.%2BG.%26aulast%3DLassen%26aufirst%3DU.%2BN.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3DNathenson%26aufirst%3DM.%26aulast%3DDoebele%26aufirst%3DR.%2BC.%26aulast%3DFarago%26aufirst%3DA.%2BF.%26aulast%3DPappo%26aufirst%3DA.%2BS.%26aulast%3DTurpin%26aufirst%3DB.%26aulast%3DDowlati%26aufirst%3DA.%26aulast%3DBrose%26aufirst%3DM.%2BS.%26aulast%3DMascarenhas%26aufirst%3DL.%26aulast%3DFederman%26aufirst%3DN.%26aulast%3DBerlin%26aufirst%3DJ.%26aulast%3DEl-Deiry%26aufirst%3DW.%2BS.%26aulast%3DBaik%26aufirst%3DC.%26aulast%3DDeeken%26aufirst%3DJ.%26aulast%3DBoni%26aufirst%3DV.%26aulast%3DNagasubramanian%26aufirst%3DR.%26aulast%3DTaylor%26aufirst%3DM.%26aulast%3DRudzinski%26aufirst%3DE.%2BR.%26aulast%3DMeric-Bernstam%26aufirst%3DF.%26aulast%3DSohal%26aufirst%3DD.%2BP.%2BS.%26aulast%3DMa%26aufirst%3DP.%2BC.%26aulast%3DRaez%26aufirst%3DL.%2BE.%26aulast%3DHechtman%26aufirst%3DJ.%2BF.%26aulast%3DBenayed%26aufirst%3DR.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DTuch%26aufirst%3DB.%2BB.%26aulast%3DEbata%26aufirst%3DK.%26aulast%3DCruickshank%26aufirst%3DS.%26aulast%3DKu%26aufirst%3DN.%2BC.%26aulast%3DCox%26aufirst%3DM.%2BC.%26aulast%3DHawkins%26aufirst%3DD.%2BS.%26aulast%3DHong%26aufirst%3DD.%2BS.%26aulast%3DHyman%26aufirst%3DD.%2BM.%26atitle%3DEfficacy%2520of%2520Larotrectinib%2520in%2520TRK%2520Fusion-Positive%2520Cancers%2520in%2520Adults%2520and%2520Children%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2018%26volume%3D378%26spage%3D731%26epage%3D739%26doi%3D10.1056%2Fnejmoa1714448" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Amatu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sartore-Bianchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siena, S.</span></span> <span> </span><span class="NLM_article-title">NTRK gene fusions as novel targets of cancer therapy across multiple tumour types</span>. <i>ESMO Open</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>1</i></span>, <span class="NLM_elocation-id">e000023</span> <span class="refDoi">Â DOI: 10.1136/esmoopen-2015-000023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=10.1136%2Fesmoopen-2015-000023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=27843590" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2016&author=A.+Amatuauthor=A.+Sartore-Bianchiauthor=S.+Siena&title=NTRK+gene+fusions+as+novel+targets+of+cancer+therapy+across+multiple+tumour+types&doi=10.1136%2Fesmoopen-2015-000023"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1136%2Fesmoopen-2015-000023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fesmoopen-2015-000023%26sid%3Dliteratum%253Aachs%26aulast%3DAmatu%26aufirst%3DA.%26aulast%3DSartore-Bianchi%26aufirst%3DA.%26aulast%3DSiena%26aufirst%3DS.%26atitle%3DNTRK%2520gene%2520fusions%2520as%2520novel%2520targets%2520of%2520cancer%2520therapy%2520across%2520multiple%2520tumour%2520types%26jtitle%3DESMO%2520Open%26date%3D2016%26volume%3D1%26doi%3D10.1136%2Fesmoopen-2015-000023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shah, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lankerovich, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, J.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroeder, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foltz, G.</span></span> <span> </span><span class="NLM_article-title">Exploration of the gene fusion landscape of glioblastoma using transcriptome sequencing and copy number data</span>. <i>BMC Genom.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">818</span>, <span class="refDoi">Â DOI: 10.1186/1471-2164-14-818</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=10.1186%2F1471-2164-14-818" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=24261984" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=818&author=N.+Shahauthor=M.+Lankerovichauthor=H.+Leeauthor=J.-G.+Yoonauthor=B.+Schroederauthor=G.+Foltz&title=Exploration+of+the+gene+fusion+landscape+of+glioblastoma+using+transcriptome+sequencing+and+copy+number+data&doi=10.1186%2F1471-2164-14-818"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1186%2F1471-2164-14-818&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2164-14-818%26sid%3Dliteratum%253Aachs%26aulast%3DShah%26aufirst%3DN.%26aulast%3DLankerovich%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DH.%26aulast%3DYoon%26aufirst%3DJ.-G.%26aulast%3DSchroeder%26aufirst%3DB.%26aulast%3DFoltz%26aufirst%3DG.%26atitle%3DExploration%2520of%2520the%2520gene%2520fusion%2520landscape%2520of%2520glioblastoma%2520using%2520transcriptome%2520sequencing%2520and%2520copy%2520number%2520data%26jtitle%3DBMC%2520Genom.%26date%3D2013%26volume%3D14%26spage%3D818%26doi%3D10.1186%2F1471-2164-14-818" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Greco, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miranda, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierotti, M. A.</span></span> <span> </span><span class="NLM_article-title">Rearrangements of NTRK1 gene in papillary thyroid carcinoma</span>. <i>Mol. Cell. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>321</i></span>,  <span class="NLM_fpage">44</span>â <span class="NLM_lpage">49</span>, <span class="refDoi">Â DOI: 10.1016/j.mce.2009.10.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=10.1016%2Fj.mce.2009.10.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=19883730" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksVamu7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=321&publication_year=2010&pages=44-49&author=A.+Grecoauthor=C.+Mirandaauthor=M.+A.+Pierotti&title=Rearrangements+of+NTRK1+gene+in+papillary+thyroid+carcinoma&doi=10.1016%2Fj.mce.2009.10.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Rearrangements of NTRK1 gene in papillary thyroid carcinoma</span></div><div class="casAuthors">Greco, A.; Miranda, C.; Pierotti, M. A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Endocrinology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">321</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">44-49</span>CODEN:
                <span class="NLM_cas:coden">MCEND6</span>;
        ISSN:<span class="NLM_cas:issn">0303-7207</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">A review.  TRK oncogenes are obsd. in a consistent fraction of papillary thyroid carcinoma (PTC); they arise from the fusion of the 3' terminal sequences of the NTRK1/NGF receptor gene with 5' terminal sequences of various activating genes, such as TPM3, TPR and TFG.  TRK oncoproteins display constitutive tyrosine-kinase activity, leading to in vitro and in vivo transformation.  In this review studies performed during the last 20 years will be summarized.  The following topics will be illustrated: (a) frequency of TRK oncogenes and correlation with radiation and tumor histopathol. features; (b) mol. mechanisms underlying NTRK1 oncogenic rearrangements; (c) mol. and biochem. characterization of TRK oncoproteins, and their mechanism of action; (d) role of activating sequences in the activation of TRK oncoproteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnGkkW9wYpTLVg90H21EOLACvtfcHk0lhkGXR-gQVJqA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksVamu7g%253D&md5=ea9abddd4191599672958ac3875bf9ae</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.mce.2009.10.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mce.2009.10.009%26sid%3Dliteratum%253Aachs%26aulast%3DGreco%26aufirst%3DA.%26aulast%3DMiranda%26aufirst%3DC.%26aulast%3DPierotti%26aufirst%3DM.%2BA.%26atitle%3DRearrangements%2520of%2520NTRK1%2520gene%2520in%2520papillary%2520thyroid%2520carcinoma%26jtitle%3DMol.%2520Cell.%2520Endocrinol.%26date%3D2010%26volume%3D321%26spage%3D44%26epage%3D49%26doi%3D10.1016%2Fj.mce.2009.10.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vaishnavi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doebele, R. C.</span></span> <span> </span><span class="NLM_article-title">TRKing down an old oncogene in a new era of targeted therapy</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">25</span>â <span class="NLM_lpage">34</span>, <span class="refDoi">Â DOI: 10.1158/2159-8290.cd-14-0765</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=10.1158%2F2159-8290.CD-14-0765" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=25527197" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFCntbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=25-34&author=A.+Vaishnaviauthor=A.+T.+Leauthor=R.+C.+Doebele&title=TRKing+down+an+old+oncogene+in+a+new+era+of+targeted+therapy&doi=10.1158%2F2159-8290.cd-14-0765"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">TRKing Down an Old Oncogene in a New Era of Targeted Therapy</span></div><div class="casAuthors">Vaishnavi, Aria; Le, Anh T.; Doebele, Robert C.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">25-34</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The use of high-throughput next-generation sequencing techniques in multiple tumor types during the last few years has identified NTRK1, 2, and 3 gene rearrangements encoding novel oncogenic fusions in 19 different tumor types to date.  These recent developments have led us to revisit an old oncogene, Trk (originally identified as OncD), which encodes the TPM3-NTRK1 gene fusion and was one of the first transforming chromosomal rearrangements identified 32 years ago.  However, no drug has yet been approved by the FDA for cancers harboring this oncogene.  This review will discuss the biol. of the TRK family of receptors, their role in human cancer, the types of oncogenic alterations, and drugs that are currently in development for this family of oncogene targets.  Significance: Precision oncol. approaches have accelerated recently due to advancements in our ability to detect oncogenic mutations in tumor samples.  Oncogenic alterations, most commonly gene fusions, have now been detected for the genes encoding the TRKA, TRKB, and TRKC receptor tyrosine kinases across multiple tumor types.  The scientific rationale for the targeting of the TRK oncogene family will be discussed here.  Cancer Discov; 5(1); 25-34. Â©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKUH4ooHY0TbVg90H21EOLACvtfcHk0ljXrbP-Jq1C-A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFCntbw%253D&md5=02103d46d85b6dc948dba58d32ffba9f</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-14-0765&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-14-0765%26sid%3Dliteratum%253Aachs%26aulast%3DVaishnavi%26aufirst%3DA.%26aulast%3DLe%26aufirst%3DA.%2BT.%26aulast%3DDoebele%26aufirst%3DR.%2BC.%26atitle%3DTRKing%2520down%2520an%2520old%2520oncogene%2520in%2520a%2520new%2520era%2520of%2520targeted%2520therapy%26jtitle%3DCancer%2520Discovery%26date%3D2015%26volume%3D5%26spage%3D25%26epage%3D34%26doi%3D10.1158%2F2159-8290.cd-14-0765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vaishnavi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capelletti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kako, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butaney, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ercan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahale, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aisner, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilling, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berge, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, S.-i.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kryukov, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garraway, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammerman, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varella-Garcia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">JÃ¤nne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doebele, R. C.</span></span> <span> </span><span class="NLM_article-title">Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1469</span>â <span class="NLM_lpage">1472</span>, <span class="refDoi">Â DOI: 10.1038/nm.3352</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=10.1038%2Fnm.3352" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=24162815" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1yiurrI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=1469-1472&author=A.+Vaishnaviauthor=M.+Capellettiauthor=A.+T.+Leauthor=S.+Kakoauthor=M.+Butaneyauthor=D.+Ercanauthor=S.+Mahaleauthor=K.+D.+Daviesauthor=D.+L.+Aisnerauthor=A.+B.+Pillingauthor=E.+M.+Bergeauthor=J.+Kimauthor=H.+Sasakiauthor=S.-i.+Parkauthor=G.+Kryukovauthor=L.+A.+Garrawayauthor=P.+S.+Hammermanauthor=J.+Haasauthor=S.+W.+Andrewsauthor=D.+Lipsonauthor=P.+J.+Stephensauthor=V.+A.+Millerauthor=M.+Varella-Garciaauthor=P.+A.+J%C3%A4nneauthor=R.+C.+Doebele&title=Oncogenic+and+drug-sensitive+NTRK1+rearrangements+in+lung+cancer&doi=10.1038%2Fnm.3352"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer</span></div><div class="casAuthors">Vaishnavi, Aria; Capelletti, Marzia; Le, Anh T.; Kako, Severine; Butaney, Mohit; Ercan, Dalia; Mahale, Sakshi; Davies, Kurtis D.; Aisner, Dara L.; Pilling, Amanda B.; Berge, Eamon M.; Kim, Jhingook; Sasaki, Hidefumi; Park, Seung-il; Kryukov, Gregory; Garraway, Levi A.; Hammerman, Peter S.; Haas, Julia; Andrews, Steven W.; Lipson, Doron; Stephens, Philip J.; Miller, Vince A.; Varella-Garcia, Marileila; Jaenne, Pasi A.; Doebele, Robert C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1469-1472</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We identified new gene fusions in patients with lung cancer harboring the kinase domain of the NTRK1 gene that encodes the high-affinity nerve growth factor receptor (TRKA protein).  Both the MPRIP-NTRK1 and CD74-NTRK1 fusions lead to constitutive TRKA kinase activity and are oncogenic.  Treatment of cells expressing NTRK1 fusions with inhibitors of TRKA kinase activity inhibited autophosphorylation of TRKA and cell growth.  Tumor samples from 3 of 91 patients with lung cancer (3.3%) without known oncogenic alterations assayed by next-generation sequencing or fluorescence in situ hybridization demonstrated evidence of NTRK1 gene fusions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBHNoZGMQLMrVg90H21EOLACvtfcHk0ljXrbP-Jq1C-A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1yiurrI&md5=23b413826ea700bd831eadbfde270615</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnm.3352&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3352%26sid%3Dliteratum%253Aachs%26aulast%3DVaishnavi%26aufirst%3DA.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DLe%26aufirst%3DA.%2BT.%26aulast%3DKako%26aufirst%3DS.%26aulast%3DButaney%26aufirst%3DM.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DMahale%26aufirst%3DS.%26aulast%3DDavies%26aufirst%3DK.%2BD.%26aulast%3DAisner%26aufirst%3DD.%2BL.%26aulast%3DPilling%26aufirst%3DA.%2BB.%26aulast%3DBerge%26aufirst%3DE.%2BM.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DSasaki%26aufirst%3DH.%26aulast%3DPark%26aufirst%3DS.-i.%26aulast%3DKryukov%26aufirst%3DG.%26aulast%3DGarraway%26aufirst%3DL.%2BA.%26aulast%3DHammerman%26aufirst%3DP.%2BS.%26aulast%3DHaas%26aufirst%3DJ.%26aulast%3DAndrews%26aufirst%3DS.%2BW.%26aulast%3DLipson%26aufirst%3DD.%26aulast%3DStephens%26aufirst%3DP.%2BJ.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DVarella-Garcia%26aufirst%3DM.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DDoebele%26aufirst%3DR.%2BC.%26atitle%3DOncogenic%2520and%2520drug-sensitive%2520NTRK1%2520rearrangements%2520in%2520lung%2520cancer%26jtitle%3DNat.%2520Med.%26date%3D2013%26volume%3D19%26spage%3D1469%26epage%3D1472%26doi%3D10.1038%2Fnm.3352" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ardini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosotti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borgia, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Ponti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somaschini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cammarota, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amboldi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raddrizzani, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnaghi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballinari, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casero, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasparri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banfi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avanzi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saccardo, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alzani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandiera, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felder, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donati, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pesenti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sartore-Bianchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gambacorta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierotti, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siena, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veronese, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galvani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isacchi, A.</span></span> <span> </span><span class="NLM_article-title">The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition</span>. <i>Mol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1495</span>â <span class="NLM_lpage">1507</span>, <span class="refDoi">Â DOI: 10.1016/j.molonc.2014.06.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=10.1016%2Fj.molonc.2014.06.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=24962792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVaktb%252FI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2014&pages=1495-1507&author=E.+Ardiniauthor=R.+Bosottiauthor=A.+L.+Borgiaauthor=C.+De+Pontiauthor=A.+Somaschiniauthor=R.+Cammarotaauthor=N.+Amboldiauthor=L.+Raddrizzaniauthor=A.+Milaniauthor=P.+Magnaghiauthor=D.+Ballinariauthor=D.+Caseroauthor=F.+Gasparriauthor=P.+Banfiauthor=N.+Avanziauthor=M.+B.+Saccardoauthor=R.+Alzaniauthor=T.+Bandieraauthor=E.+Felderauthor=D.+Donatiauthor=E.+Pesentiauthor=A.+Sartore-Bianchiauthor=M.+Gambacortaauthor=M.+A.+Pierottiauthor=S.+Sienaauthor=S.+Veroneseauthor=A.+Galvaniauthor=A.+Isacchi&title=The+TPM3-NTRK1+rearrangement+is+a+recurring+event+in+colorectal+carcinoma+and+is+associated+with+tumor+sensitivity+to+TRKA+kinase+inhibition&doi=10.1016%2Fj.molonc.2014.06.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition</span></div><div class="casAuthors">Ardini, Elena; Bosotti, Roberta; Borgia, Andrea Lombardi; De Ponti, Cristina; Somaschini, Alessio; Cammarota, Rosaria; Amboldi, Nadia; Raddrizzani, Laura; Milani, Andrea; Magnaghi, Paola; Ballinari, Dario; Casero, Daniele; Gasparri, Fabio; Banfi, Patrizia; Avanzi, Nilla; Saccardo, Maria B.; Alzani, Rachele; Bandiera, Tiziano; Felder, Eduard; Donati, Daniele; Pesenti, Enrico; Sartore-Bianchi, Andrea; Gambacorta, Marcello; Pierotti, Marco A.; Siena, Salvatore; Veronese, Silvio; Galvani, Arturo; Isacchi, Antonella</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1495-1507</span>CODEN:
                <span class="NLM_cas:coden">MOONC3</span>;
        ISSN:<span class="NLM_cas:issn">1574-7891</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The NTRK1 gene encodes Tropomyosin-related kinase A (TRKA), the high-affinity Nerve Growth Factor Receptor.  NTRK1 was originally isolated from a colorectal carcinoma (CRC) sample as component of a somatic rearrangement (TPM3-NTRK1) resulting in expression of the oncogenic chimeric protein TPM3-TRKA, but there has been no subsequent report regarding the relevance of this oncogene in CRC.  The KM12 human CRC cell line expresses the chimeric TPM3-TRKA protein and is hypersensitive to TRKA kinase inhibition.  We report the detailed characterization of the TPM3-NTRK1 genomic rearrangement in KM12 cells and through a cellular screening approach, the identification of NMS-P626, a novel highly potent and selective TRKA inhibitor.  NMS-P626 suppressed TPM3-TRKA phosphorylation and downstream signaling in KM12 cells and showed remarkable antitumor activity in mice bearing KM12 tumors.  Finally, using quant. reverse transcriptase PCR and immunohistochem. (IHC) we identified the TPM3-NTRK1 rearrangement in a CRC clin. sample, therefore suggesting that this chromosomal translocation is indeed a low frequency recurring event in CRC and that such patients might benefit from therapy with TRKA kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-EhukkQ24OrVg90H21EOLACvtfcHk0ljzPZQkY-XRsA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVaktb%252FI&md5=2a9de2410f69e2eb8ff84c9516828984</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.molonc.2014.06.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molonc.2014.06.001%26sid%3Dliteratum%253Aachs%26aulast%3DArdini%26aufirst%3DE.%26aulast%3DBosotti%26aufirst%3DR.%26aulast%3DBorgia%26aufirst%3DA.%2BL.%26aulast%3DDe%2BPonti%26aufirst%3DC.%26aulast%3DSomaschini%26aufirst%3DA.%26aulast%3DCammarota%26aufirst%3DR.%26aulast%3DAmboldi%26aufirst%3DN.%26aulast%3DRaddrizzani%26aufirst%3DL.%26aulast%3DMilani%26aufirst%3DA.%26aulast%3DMagnaghi%26aufirst%3DP.%26aulast%3DBallinari%26aufirst%3DD.%26aulast%3DCasero%26aufirst%3DD.%26aulast%3DGasparri%26aufirst%3DF.%26aulast%3DBanfi%26aufirst%3DP.%26aulast%3DAvanzi%26aufirst%3DN.%26aulast%3DSaccardo%26aufirst%3DM.%2BB.%26aulast%3DAlzani%26aufirst%3DR.%26aulast%3DBandiera%26aufirst%3DT.%26aulast%3DFelder%26aufirst%3DE.%26aulast%3DDonati%26aufirst%3DD.%26aulast%3DPesenti%26aufirst%3DE.%26aulast%3DSartore-Bianchi%26aufirst%3DA.%26aulast%3DGambacorta%26aufirst%3DM.%26aulast%3DPierotti%26aufirst%3DM.%2BA.%26aulast%3DSiena%26aufirst%3DS.%26aulast%3DVeronese%26aufirst%3DS.%26aulast%3DGalvani%26aufirst%3DA.%26aulast%3DIsacchi%26aufirst%3DA.%26atitle%3DThe%2520TPM3-NTRK1%2520rearrangement%2520is%2520a%2520recurring%2520event%2520in%2520colorectal%2520carcinoma%2520and%2520is%2520associated%2520with%2520tumor%2520sensitivity%2520to%2520TRKA%2520kinase%2520inhibition%26jtitle%3DMol.%2520Oncol.%26date%3D2014%26volume%3D8%26spage%3D1495%26epage%3D1507%26doi%3D10.1016%2Fj.molonc.2014.06.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ardini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menichincheri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banfi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosotti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Ponti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulci, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballinari, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciomei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Texido, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degrassi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avanzi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amboldi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saccardo, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casero, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orsini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandiera, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mologni, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vernier, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felder, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donati, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isacchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pesenti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnaghi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galvani, A.</span></span> <span> </span><span class="NLM_article-title">Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">628</span>â <span class="NLM_lpage">639</span>, <span class="refDoi">Â DOI: 10.1158/1535-7163.mct-15-0758</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=10.1158%2F1535-7163.MCT-15-0758" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=26939704" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=1%3ACAS%3A528%3ADC%252BC28XlsVSqtL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=628-639&author=E.+Ardiniauthor=M.+Menichincheriauthor=P.+Banfiauthor=R.+Bosottiauthor=C.+De+Pontiauthor=R.+Pulciauthor=D.+Ballinariauthor=M.+Ciomeiauthor=G.+Texidoauthor=A.+Degrassiauthor=N.+Avanziauthor=N.+Amboldiauthor=M.+B.+Saccardoauthor=D.+Caseroauthor=P.+Orsiniauthor=T.+Bandieraauthor=L.+Mologniauthor=D.+Andersonauthor=G.+Weiauthor=J.+Harrisauthor=J.-M.+Vernierauthor=G.+Liauthor=E.+Felderauthor=D.+Donatiauthor=A.+Isacchiauthor=E.+Pesentiauthor=P.+Magnaghiauthor=A.+Galvani&title=Entrectinib%2C+a+Pan-TRK%2C+ROS1%2C+and+ALK+Inhibitor+with+Activity+in+Multiple+Molecularly+Defined+Cancer+Indications&doi=10.1158%2F1535-7163.mct-15-0758"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications</span></div><div class="casAuthors">Ardini, Elena; Menichincheri, Maria; Banfi, Patrizia; Bosotti, Roberta; De Ponti, Cristina; Pulci, Romana; Ballinari, Dario; Ciomei, Marina; Texido, Gemma; Degrassi, Anna; Avanzi, Nilla; Amboldi, Nadia; Saccardo, Maria Beatrice; Casero, Daniele; Orsini, Paolo; Bandiera, Tiziano; Mologni, Luca; Anderson, David; Wei, Ge; Harris, Jason; Vernier, Jean-Michel; Li, Gang; Felder, Eduard; Donati, Daniele; Isacchi, Antonella; Pesenti, Enrico; Magnaghi, Paola; Galvani, Arturo</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">628-639</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Activated ALK and ROS1 tyrosine kinases, resulting from chromosomal rearrangements, occur in a subset of non-small cell lung cancers (NSCLC) as well as other tumor types and their oncogenic relevance as actionable targets has been demonstrated by the efficacy of selective kinase inhibitors such as crizotinib, ceritinib, and alectinib.  More recently, low-frequency rearrangements of TRK kinases have been described in NSCLC, colorectal carcinoma, glioblastoma, and Spitzoid melanoma.  Entrectinib, whose discovery and preclin. characterization are reported herein, is a novel, potent inhibitor of ALK, ROS1, and, importantly, of TRK family kinases, which shows promise for therapy of tumors bearing oncogenic forms of these proteins.  Proliferation profiling against over 200 human tumor cell lines revealed that entrectinib is exquisitely potent in vitro against lines that are dependent on the drug's pharmacol. targets.  Oral administration of entrectinib to tumor-bearing mice induced regression in relevant human xenograft tumors, including the TRKA-dependent colorectal carcinoma KM12, ROS1-driven tumors, and several ALK-dependent models of different tissue origins, including a model of brain-localized lung cancer metastasis.  Entrectinib is currently showing great promise in phase I/II clin. trials, including the first documented objective responses to a TRK inhibitor in colorectal carcinoma and in NSCLC.  The drug is, thus, potentially suited to the therapy of several molecularly defined cancer settings, esp. that of TRK-dependent tumors, for which no approved drugs are currently available.  Mol Cancer Ther; 15(4); 628-39. Â©2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOaNX-kFz2qbVg90H21EOLACvtfcHk0ljzPZQkY-XRsA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlsVSqtL4%253D&md5=dd75115cb344f0e3a6d299781043d7d6</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-15-0758&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-15-0758%26sid%3Dliteratum%253Aachs%26aulast%3DArdini%26aufirst%3DE.%26aulast%3DMenichincheri%26aufirst%3DM.%26aulast%3DBanfi%26aufirst%3DP.%26aulast%3DBosotti%26aufirst%3DR.%26aulast%3DDe%2BPonti%26aufirst%3DC.%26aulast%3DPulci%26aufirst%3DR.%26aulast%3DBallinari%26aufirst%3DD.%26aulast%3DCiomei%26aufirst%3DM.%26aulast%3DTexido%26aufirst%3DG.%26aulast%3DDegrassi%26aufirst%3DA.%26aulast%3DAvanzi%26aufirst%3DN.%26aulast%3DAmboldi%26aufirst%3DN.%26aulast%3DSaccardo%26aufirst%3DM.%2BB.%26aulast%3DCasero%26aufirst%3DD.%26aulast%3DOrsini%26aufirst%3DP.%26aulast%3DBandiera%26aufirst%3DT.%26aulast%3DMologni%26aufirst%3DL.%26aulast%3DAnderson%26aufirst%3DD.%26aulast%3DWei%26aufirst%3DG.%26aulast%3DHarris%26aufirst%3DJ.%26aulast%3DVernier%26aufirst%3DJ.-M.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DFelder%26aufirst%3DE.%26aulast%3DDonati%26aufirst%3DD.%26aulast%3DIsacchi%26aufirst%3DA.%26aulast%3DPesenti%26aufirst%3DE.%26aulast%3DMagnaghi%26aufirst%3DP.%26aulast%3DGalvani%26aufirst%3DA.%26atitle%3DEntrectinib%252C%2520a%2520Pan-TRK%252C%2520ROS1%252C%2520and%2520ALK%2520Inhibitor%2520with%2520Activity%2520in%2520Multiple%2520Molecularly%2520Defined%2520Cancer%2520Indications%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2016%26volume%3D15%26spage%3D628%26epage%3D639%26doi%3D10.1158%2F1535-7163.mct-15-0758" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martens, U. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bochum, S.</span></span> <span> </span><span class="NLM_article-title">Bochum, S. Larotrectinib (LOXO-101)</span>. <i>Recent Results Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>211</i></span>,  <span class="NLM_fpage">141</span>â <span class="NLM_lpage">151</span>, <span class="refDoi">Â DOI: 10.1007/978-3-319-91442-8_10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=10.1007%2F978-3-319-91442-8_10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=30069765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVShu7nI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=211&publication_year=2018&pages=141-151&author=S.+Bergerauthor=U.+M.+Martensauthor=S.+Bochum&title=Bochum%2C+S.+Larotrectinib+%28LOXO-101%29&doi=10.1007%2F978-3-319-91442-8_10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Larotrectinib (LOXO-101)</span></div><div class="casAuthors">Berger, Stephanie; Martens, Uwe M.; Bochum, Sylvia</div><div class="citationInfo"><span class="NLM_cas:title">Recent Results in Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">211</span>
        (<span class="NLM_cas:issue">Small Molecules in Oncology</span>),
    <span class="NLM_cas:pages">141-151</span>CODEN:
                <span class="NLM_cas:coden">RRCRBU</span>;
        ISSN:<span class="NLM_cas:issn">2197-6767</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">A review.  One of the most challenging issues in oncol. research and treatment is identifying oncogenic drivers within an individual patient's tumor which can be directly targeted by a clin. available therapeutic drug.  In this context, gene fusions as one important example of genetic aberrations leading to carcinogen-esis follow the widely accepted concept that cell growth and proliferation are driven by the accomplished fusion (usually involving former proto-oncogenes) and may therefore be successfully inhibited by substances directed against the fusion.  This concept has already been established with oncogenic gene fusions like BCR-ABL in chronic myelogenous leukemia (CML) or anaplastic lymphoma kinase (ALK) in lung cancer, including special tyrosine kinase inhibitors (TKIs) which are able to block the activation of the depending downstream proliferation pathways and, consequently, tumor growth.  During the last decade, the NTRK1, 2, and 3 genes, encoding the TRKA, B, and C proteins, have attracted increasing attention as another significant and targetable gene fusion in a variety of cancers.  Several TRK inhibitors have been developed, and one of them, Larotrectinib (formerly known as LOXO-101), represents an orally available, selective inhibitor of the TRK receptor family that has already shown substantial clin. benefit in both pediatric and adult patients harboring an NTRK gene fusion over the last few years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-6RXwWHZbSbVg90H21EOLACvtfcHk0ljzPZQkY-XRsA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVShu7nI&md5=0b066eef6e07f7ad41cf0a53a1e2fdcc</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1007%2F978-3-319-91442-8_10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-3-319-91442-8_10%26sid%3Dliteratum%253Aachs%26aulast%3DBerger%26aufirst%3DS.%26aulast%3DMartens%26aufirst%3DU.%2BM.%26aulast%3DBochum%26aufirst%3DS.%26atitle%3DBochum%252C%2520S.%2520Larotrectinib%2520%2528LOXO-101%2529%26jtitle%3DRecent%2520Results%2520Cancer%2520Res.%26date%3D2018%26volume%3D211%26spage%3D141%26epage%3D151%26doi%3D10.1007%2F978-3-319-91442-8_10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Drilon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagasubramanian, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blake, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ku, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuch, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lauriault, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolakowski, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandhuber, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsen, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouhana, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winski, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamor, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, W.-I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morales, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, F. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeWolf, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wollenberg, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douglas-Lindsay, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scaltriti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benayed, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raj, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanusch, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schram, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonsson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hechtman, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothenberg, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyman, D. M.</span></span> <span> </span><span class="NLM_article-title">A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">963</span>â <span class="NLM_lpage">972</span>, <span class="refDoi">Â DOI: 10.1158/2159-8290.cd-17-0507</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=10.1158%2F2159-8290.CD-17-0507" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=28578312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVyis7fE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=963-972&author=A.+Drilonauthor=R.+Nagasubramanianauthor=J.+F.+Blakeauthor=N.+Kuauthor=B.+B.+Tuchauthor=K.+Ebataauthor=S.+Smithauthor=V.+Lauriaultauthor=G.+R.+Kolakowskiauthor=B.+J.+Brandhuberauthor=P.+D.+Larsenauthor=K.+S.+Bouhanaauthor=S.+L.+Winskiauthor=R.+Hamorauthor=W.-I.+Wuauthor=A.+Parkerauthor=T.+H.+Moralesauthor=F.+X.+Sullivanauthor=W.+E.+DeWolfauthor=L.+A.+Wollenbergauthor=P.+R.+Gordonauthor=D.+N.+Douglas-Lindsayauthor=M.+Scaltritiauthor=R.+Benayedauthor=S.+Rajauthor=B.+Hanuschauthor=A.+M.+Schramauthor=P.+Jonssonauthor=M.+F.+Bergerauthor=J.+F.+Hechtmanauthor=B.+S.+Taylorauthor=S.+Andrewsauthor=S.+M.+Rothenbergauthor=D.+M.+Hyman&title=A+Next-Generation+TRK+Kinase+Inhibitor+Overcomes+Acquired+Resistance+to+Prior+TRK+Kinase+Inhibition+in+Patients+with+TRK+Fusion-Positive+Solid+Tumors&doi=10.1158%2F2159-8290.cd-17-0507"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors</span></div><div class="casAuthors">Drilon, Alexander; Nagasubramanian, Ramamoorthy; Blake, James F.; Ku, Nora; Tuch, Brian B.; Ebata, Kevin; Smith, Steve; Lauriault, Veronique; Kolakowski, Gabrielle R.; Brandhuber, Barbara J.; Larsen, Paul D.; Bouhana, Karyn S.; Winski, Shannon L.; Hamor, Robyn; Wu, Wen-I.; Parker, Andrew; Morales, Tony H.; Sullivan, Francis X.; DeWolf, Walter E.; Wollenberg, Lance A.; Gordon, Paul R.; Douglas-Lindsay, Dorothea N.; Scaltriti, Maurizio; Benayed, Ryma; Raj, Sandeep; Hanusch, Bethany; Schram, Alison M.; Jonsson, Philip; Berger, Michael F.; Hechtman, Jaclyn F.; Taylor, Barry S.; Andrews, Steve; Rothenberg, S. Michael; Hyman, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">963-972</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Larotrectinib, a selective TRK tyrosine kinase inhibitor (TKI), has demonstrated histol.-agnostic efficacy in patients with TRK fusion-pos. cancers.  Although responses to TRK inhibition can be dramatic and durable, duration of response may eventually be limited by acquired resistance.  LOXO-195 is a selective TRK TKI designed to overcome acquired resistance mediated by recurrent kinase domain (solvent front and xDFG) mutations identified in multiple patients who have developed resistance to TRK TKIs.  Activity against these acquired mutations was confirmed in enzyme and cell-based assays and in vivo tumor models.  As clin. proof of concept, the first 2 patients with TRK fusion-pos. cancers who developed acquired resistance mutations on larotrectinib were treated with LOXO-195 on a first-in-human basis, utilizing rapid dose titrn. guided by pharmacokinetic assessments.  This approach led to rapid tumor responses and extended the overall duration of disease control achieved with TRK inhibition in both patients.  Significance: LOXO-195 abrogated resistance in TRK fusion-pos. cancers that acquired kinase domain mutations, a shared liability with all existing TRK TKIs.  This establishes a role for sequential treatment by demonstrating continued TRK dependence and validates a paradigm for the accelerated development of next-generation inhibitors against validated oncogenic targets.  Cancer Discov; 7(9); 963-72. Â©2017 AACR.  See related commentary by Parikh and Corcoran, p. 934.  This article is highlighted in the In This Issue feature, p.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpG4KsnHeEsHLVg90H21EOLACvtfcHk0lhTVoeMWXnHoQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVyis7fE&md5=aac35c31a9645a16a61deaafba5f106e</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-17-0507&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-17-0507%26sid%3Dliteratum%253Aachs%26aulast%3DDrilon%26aufirst%3DA.%26aulast%3DNagasubramanian%26aufirst%3DR.%26aulast%3DBlake%26aufirst%3DJ.%2BF.%26aulast%3DKu%26aufirst%3DN.%26aulast%3DTuch%26aufirst%3DB.%2BB.%26aulast%3DEbata%26aufirst%3DK.%26aulast%3DSmith%26aufirst%3DS.%26aulast%3DLauriault%26aufirst%3DV.%26aulast%3DKolakowski%26aufirst%3DG.%2BR.%26aulast%3DBrandhuber%26aufirst%3DB.%2BJ.%26aulast%3DLarsen%26aufirst%3DP.%2BD.%26aulast%3DBouhana%26aufirst%3DK.%2BS.%26aulast%3DWinski%26aufirst%3DS.%2BL.%26aulast%3DHamor%26aufirst%3DR.%26aulast%3DWu%26aufirst%3DW.-I.%26aulast%3DParker%26aufirst%3DA.%26aulast%3DMorales%26aufirst%3DT.%2BH.%26aulast%3DSullivan%26aufirst%3DF.%2BX.%26aulast%3DDeWolf%26aufirst%3DW.%2BE.%26aulast%3DWollenberg%26aufirst%3DL.%2BA.%26aulast%3DGordon%26aufirst%3DP.%2BR.%26aulast%3DDouglas-Lindsay%26aufirst%3DD.%2BN.%26aulast%3DScaltriti%26aufirst%3DM.%26aulast%3DBenayed%26aufirst%3DR.%26aulast%3DRaj%26aufirst%3DS.%26aulast%3DHanusch%26aufirst%3DB.%26aulast%3DSchram%26aufirst%3DA.%2BM.%26aulast%3DJonsson%26aufirst%3DP.%26aulast%3DBerger%26aufirst%3DM.%2BF.%26aulast%3DHechtman%26aufirst%3DJ.%2BF.%26aulast%3DTaylor%26aufirst%3DB.%2BS.%26aulast%3DAndrews%26aufirst%3DS.%26aulast%3DRothenberg%26aufirst%3DS.%2BM.%26aulast%3DHyman%26aufirst%3DD.%2BM.%26atitle%3DA%2520Next-Generation%2520TRK%2520Kinase%2520Inhibitor%2520Overcomes%2520Acquired%2520Resistance%2520to%2520Prior%2520TRK%2520Kinase%2520Inhibition%2520in%2520Patients%2520with%2520TRK%2520Fusion-Positive%2520Solid%2520Tumors%26jtitle%3DCancer%2520Discovery%26date%3D2017%26volume%3D7%26spage%3D963%26epage%3D972%26doi%3D10.1158%2F2159-8290.cd-17-0507" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Drilon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S.-H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, V. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, M.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camidge, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitten, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stopatschinskaja, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyman, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doebele, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span> <span> </span><span class="NLM_article-title">Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1227</span>â <span class="NLM_lpage">1236</span>, <span class="refDoi">Â DOI: 10.1158/2159-8290.cd-18-0484</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=10.1158%2F2159-8290.CD-18-0484" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=30093503" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmt1ehtLs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=1227-1236&author=A.+Drilonauthor=S.-H.+I.+Ouauthor=B.+C.+Choauthor=D.-W.+Kimauthor=J.+Leeauthor=J.+J.+Linauthor=V.+W.+Zhuauthor=M.-J.+Ahnauthor=D.+R.+Camidgeauthor=J.+Nguyenauthor=D.+Zhaiauthor=W.+Dengauthor=Z.+Huangauthor=E.+Rogersauthor=J.+Liuauthor=J.+Whittenauthor=J.+K.+Limauthor=S.+Stopatschinskajaauthor=D.+M.+Hymanauthor=R.+C.+Doebeleauthor=J.+J.+Cuiauthor=A.+T.+Shaw&title=Repotrectinib+%28TPX-0005%29+Is+a+Next-Generation+ROS1%2FTRK%2FALK+Inhibitor+That+Potently+Inhibits+ROS1%2FTRK%2FALK+Solvent-+Front+Mutations&doi=10.1158%2F2159-8290.cd-18-0484"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Repotrectinib (TPX-0005) is a next-generation ROS1/TRK/ALK inhibitor that potently inhibits ROS1/TRK/ALK solvent-front mutations</span></div><div class="casAuthors">Drilon, Alexander; Ou, Sai-Hong Ignatius; Cho, Byoung Chul; Kim, Dong-Wan; Lee, Jeeyun; Lin, Jessica J.; Zhu, Viola W.; Ahn, Myung-Ju; Camidge, D. Ross; Nguyen, Judy; Zhai, Dayong; Deng, Wei; Huang, Zhongdong; Rogers, Evan; Liu, Juliet; Whitten, Jeff; Lim, John K.; Stopatschinskaja, Shanna; Hyman, David M.; Doebele, Robert C.; Cui, J. Jean; Shaw, Alice T.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1227-1236</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The use of tyrosine kinase inhibitors (TKI) with activity against ALK, ROS1, or TRKA-C can result in signifi cant clin. benefit in patients with diverse tumors harboring ALK, ROS1, or NTRK1-3 rearrangements; however, resistance invariably develops.  The emergence of on-target kinase domain mutations represents a major mechanism of acquired resistance.  Solvent-front substitutions such as ALKG1202R, ROS1G2032R or ROS1D2033N, TRKAG595R, and TRKCG623R are among the most recalcitrant of these mechanisms.  Repotrectinib (TPX-0005) is a rationally designed, low-mol.-wt., macrocyclic TKI that is selective and highly potent against ROS1, TRKA-C, and ALK.  Importantly, repotrectinib exhibits activity against a variety of solventfront substitutions in vitro and in vivo.  As clin. proof of concept, in an ongoing first-in-human phase I/II trial, repotrectinib achieved confirmed responses in patients with ROS1 or NTRK3 fusion- pos. cancers who had relapsed on earlier-generation TKIs due to ROS1 or TRKC solvent-front substitution-mediated resistance.  SIGNIFICANCE: Repotrectinib (TPX-0005), a next-generation ROS1, pan-TRK, and ALK TKI, overcomes resistance due to acquired solvent-front mutations involving ROS1, NTRK1-3, and ALK.  Repotrectinib may represent an effective therapeutic option for patients with ROS1-, NTRK1-3-, or ALK-rearranged malignancies who have progressed on earlier-generation TKIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNmuKNmAgWKLVg90H21EOLACvtfcHk0lhTVoeMWXnHoQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmt1ehtLs%253D&md5=b5408bf045e049629557cb347ab61980</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-18-0484&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-18-0484%26sid%3Dliteratum%253Aachs%26aulast%3DDrilon%26aufirst%3DA.%26aulast%3DOu%26aufirst%3DS.-H.%2BI.%26aulast%3DCho%26aufirst%3DB.%2BC.%26aulast%3DKim%26aufirst%3DD.-W.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DJ.%2BJ.%26aulast%3DZhu%26aufirst%3DV.%2BW.%26aulast%3DAhn%26aufirst%3DM.-J.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26aulast%3DNguyen%26aufirst%3DJ.%26aulast%3DZhai%26aufirst%3DD.%26aulast%3DDeng%26aufirst%3DW.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DRogers%26aufirst%3DE.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DWhitten%26aufirst%3DJ.%26aulast%3DLim%26aufirst%3DJ.%2BK.%26aulast%3DStopatschinskaja%26aufirst%3DS.%26aulast%3DHyman%26aufirst%3DD.%2BM.%26aulast%3DDoebele%26aufirst%3DR.%2BC.%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26atitle%3DRepotrectinib%2520%2528TPX-0005%2529%2520Is%2520a%2520Next-Generation%2520ROS1%252FTRK%252FALK%2520Inhibitor%2520That%2520Potently%2520Inhibits%2520ROS1%252FTRK%252FALK%2520Solvent-%2520Front%2520Mutations%26jtitle%3DCancer%2520Discovery%26date%3D2018%26volume%3D8%26spage%3D1227%26epage%3D1236%26doi%3D10.1158%2F2159-8290.cd-18-0484" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, L. A.</span>; <span class="NLM_string-name">Platz, E. A.</span>; <span class="NLM_string-name">Teicher, B.</span></span> <span> </span><span class="NLM_article-title">Combating Acquired TRK Inhibitor Resistance</span>.  <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume">9</span>,  <span class="NLM_fpage">684</span>- <span class="NLM_lpage">685</span>.<span class="refDoi">Â DOI: 10.1158/2159-8290.CD-NB2019-047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=10.1158%2F2159-8290.CD-NB2019-047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=30936083" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=684-685&author=L.+A.+Diaz&author=E.+A.+Platz&author=B.+Teicher&title=Combating+Acquired+TRK+Inhibitor+Resistance&doi=10.1158%2F2159-8290.CD-NB2019-047"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-NB2019-047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-NB2019-047%26sid%3Dliteratum%253Aachs%26aulast%3DDiaz%26aufirst%3DL.%2BA.%26atitle%3DCombating%2520Acquired%2520TRK%2520Inhibitor%2520Resistance%26jtitle%3DCancer%2520Discovery%26date%3D2019%26volume%3D9%26spage%3D684%26epage%3D685%26doi%3D10.1158%2F2159-8290.CD-NB2019-047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbst, R. S.</span></span> <span> </span><span class="NLM_article-title">Larotrectinib in NTRK-Rearranged Solid TumorsPublished as part of the Biochemistry series â³Biochemistry to Bedside</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">1555</span>â <span class="NLM_lpage">1557</span>, <span class="refDoi">Â DOI: 10.1021/acs.biochem.9b00126</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.biochem.9b00126" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=1%3ACAS%3A528%3ADC%252BC1MXks1Chsb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2019&pages=1555-1557&author=F.+H.+Wilsonauthor=R.+S.+Herbst&title=Larotrectinib+in+NTRK-Rearranged+Solid+TumorsPublished+as+part+of+the+Biochemistry+series+%E2%80%B3Biochemistry+to+Bedside&doi=10.1021%2Facs.biochem.9b00126"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Larotrectinib in NTRK-Rearranged Solid Tumors</span></div><div class="casAuthors">Wilson, Frederick H.; Herbst, Roy S.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1555-1557</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Larotrectinib (LOXO-101 and ARRY470) is an orally available, potent, and selective ATP-competitive pan-tropomyosin receptor tyrosine kinase (TRK) inhibitor with low nanomolar 50% inhibitory concns.  Early phase clin. trials for safety and efficacy of larotrectinib in adult and pediatric patients with diverse TRK fusion-pos. malignancies were recently reported.  Responses were obsd. in 75% of patients regardless of patient age, tumor type, TRK family member, or identity of the TRK fusion partner.  On the basis of these findings, the Food and Drug Administration granted accelerated approval to larotrectinib in Nov. 2018 for the treatment of adult and pediatric patients with advanced solid tumors harboring an NTRK gene fusion.  Using structural insights derived from X-ray crystallog. of TRK proteins and in silico modeling of addnl. structurally distinct TRK inhibitors, a second TRK inhibitor called LOXO195 was identified as a candidate compd. with potential activity against secondary mutations conferring resistance to larotrectinib.  On the basis of prior experience with acquired resistance to other kinase-directed therapies, LOXO-195 was developed nearly in parallel with larotrectinib in anticipation of acquired resistance to larotrectinib in treated patients.  A phase 1/2 clin. trial evaluating the safety and preliminary efficacy of LOXO-195 in adults and children with TRK-driven solid tumors refractory to a prior TRK inhibitor is currently underway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7SElFd-Ty17Vg90H21EOLACvtfcHk0lj2al7GPewPVA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXks1Chsb0%253D&md5=d92f8170ae3bd22f4c5e76bf058d8edc</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Facs.biochem.9b00126&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.biochem.9b00126%26sid%3Dliteratum%253Aachs%26aulast%3DWilson%26aufirst%3DF.%2BH.%26aulast%3DHerbst%26aufirst%3DR.%2BS.%26atitle%3DLarotrectinib%2520in%2520NTRK-Rearranged%2520Solid%2520TumorsPublished%2520as%2520part%2520of%2520the%2520Biochemistry%2520series%2520%25E2%2580%25B3Biochemistry%2520to%2520Bedside%26jtitle%3DBiochemistry%26date%3D2019%26volume%3D58%26spage%3D1555%26epage%3D1557%26doi%3D10.1021%2Facs.biochem.9b00126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Choi, H.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rucker, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albaugh, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chopiuk, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gessier, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adrian, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hood, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Che, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCormack, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steffy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Culazzo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tompkins, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phung, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreusch, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhary, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prashad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuntland, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seidel, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loren, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molteni, V.</span></span> <span> </span><span class="NLM_article-title">(R)-2-Phenylpyrrolidine Substituted Imidazopyridazines: A New Class of Potent and Selective Pan-TRK Inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">562</span>â <span class="NLM_lpage">567</span>, <span class="refDoi">Â DOI: 10.1021/acsmedchemlett.5b00050</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00050" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=1%3ACAS%3A528%3ADC%252BC2MXksVOrsbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=562-567&author=H.-S.+Choiauthor=P.+V.+Ruckerauthor=Z.+Wangauthor=Y.+Fanauthor=P.+Albaughauthor=G.+Chopiukauthor=F.+Gessierauthor=F.+Sunauthor=F.+Adrianauthor=G.+Liuauthor=T.+Hoodauthor=N.+Liauthor=Y.+Jiaauthor=J.+Cheauthor=S.+McCormackauthor=A.+Liauthor=J.+Liauthor=A.+Steffyauthor=A.+Culazzoauthor=C.+Tompkinsauthor=V.+Phungauthor=A.+Kreuschauthor=M.+Luauthor=B.+Huauthor=A.+Chaudharyauthor=M.+Prashadauthor=T.+Tuntlandauthor=B.+Liuauthor=J.+Harrisauthor=H.+M.+Seidelauthor=J.+Lorenauthor=V.+Molteni&title=%28R%29-2-Phenylpyrrolidine+Substituted+Imidazopyridazines%3A+A+New+Class+of+Potent+and+Selective+Pan-TRK+Inhibitors&doi=10.1021%2Facsmedchemlett.5b00050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">(R)-2-Phenylpyrrolidine Substituted Imidazopyridazines: A New Class of Potent and Selective Pan-TRK Inhibitors</span></div><div class="casAuthors">Choi, Ha-Soon; Rucker, Paul V.; Wang, Zhicheng; Fan, Yi; Albaugh, Pamela; Chopiuk, Greg; Gessier, Francois; Sun, Fangxian; Adrian, Francisco; Liu, Guoxun; Hood, Tami; Li, Nanxin; Jia, Yong; Che, Jianwei; McCormack, Susan; Li, Allen; Li, Jie; Steffy, Auzon; Culazzo, AnneMarie; Tompkins, Celine; Phung, Van; Kreusch, Andreas; Lu, Min; Hu, Bin; Chaudhary, Apurva; Prashad, Mahavir; Tuntland, Tove; Liu, Bo; Harris, Jennifer; Seidel, H. Martin; Loren, Jon; Molteni, Valentina</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">562-567</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Deregulated kinase activities of tropomyosin receptor kinase (TRK) family members have been shown to be assocd. with tumorigenesis and poor prognosis in a variety of cancer types.  In particular, several chromosomal rearrangements involving TRKA have been reported in colorectal, papillary thyroid, glioblastoma, melanoma, and lung tissue that are believed to be the key oncogenic driver in these tumors.  By screening the Novartis compd. collection, a novel imidazopyridazine TRK inhibitor was identified that served as a launching point for drug optimization.  Structure guided drug design led to the identification of (R)-2-phenylpyrrolidine substituted imidazopyridazines, e.g., I, as a series of potent, selective, orally bioavailable pan-TRK inhibitors achieving tumor regression in rats bearing KM12 xenografts.  From this work the (R)-2-phenylpyrrolidine has emerged as an ideal moiety to incorporate in bicyclic TRK inhibitors by virtue of its shape complementarity to the hydrophobic pocket of TRKs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBOGdLZcZ2HbVg90H21EOLACvtfcHk0liImjHrigG6Mw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXksVOrsbo%253D&md5=e2eacf85a3e762e8f2474a568e6d1b39</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00050%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DH.-S.%26aulast%3DRucker%26aufirst%3DP.%2BV.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DFan%26aufirst%3DY.%26aulast%3DAlbaugh%26aufirst%3DP.%26aulast%3DChopiuk%26aufirst%3DG.%26aulast%3DGessier%26aufirst%3DF.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DAdrian%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DHood%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DJia%26aufirst%3DY.%26aulast%3DChe%26aufirst%3DJ.%26aulast%3DMcCormack%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DSteffy%26aufirst%3DA.%26aulast%3DCulazzo%26aufirst%3DA.%26aulast%3DTompkins%26aufirst%3DC.%26aulast%3DPhung%26aufirst%3DV.%26aulast%3DKreusch%26aufirst%3DA.%26aulast%3DLu%26aufirst%3DM.%26aulast%3DHu%26aufirst%3DB.%26aulast%3DChaudhary%26aufirst%3DA.%26aulast%3DPrashad%26aufirst%3DM.%26aulast%3DTuntland%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DHarris%26aufirst%3DJ.%26aulast%3DSeidel%26aufirst%3DH.%2BM.%26aulast%3DLoren%26aufirst%3DJ.%26aulast%3DMolteni%26aufirst%3DV.%26atitle%3D%2528R%2529-2-Phenylpyrrolidine%2520Substituted%2520Imidazopyridazines%253A%2520A%2520New%2520Class%2520of%2520Potent%2520and%2520Selective%2520Pan-TRK%2520Inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26spage%3D562%26epage%3D567%26doi%3D10.1021%2Facsmedchemlett.5b00050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, J.</span></span> <span> </span><span class="NLM_article-title">Assessment of the toxicity and toxicokinetics of the novel potent tropomyosin receptor kinase (Trk) inhibitor LPM4870108 in rhesus monkeys</span>. <i>Regul. Toxicol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>122</i></span>,  <span class="NLM_fpage">104886</span>, <span class="refDoi">Â DOI: 10.1016/j.yrtph.2021.104886</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=10.1016%2Fj.yrtph.2021.104886" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=33556418" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=1%3ACAS%3A528%3ADC%252BB3MXksl2qtbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2021&pages=104886&author=S.+Duanauthor=L.+Dongauthor=B.+Wangauthor=S.+Weiauthor=X.+Gongauthor=P.+Yuauthor=C.+Liauthor=Y.+Gaoauthor=L.+Yeauthor=H.+Wangauthor=J.+Tian&title=Assessment+of+the+toxicity+and+toxicokinetics+of+the+novel+potent+tropomyosin+receptor+kinase+%28Trk%29+inhibitor+LPM4870108+in+rhesus+monkeys&doi=10.1016%2Fj.yrtph.2021.104886"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Assessment of the toxicity and toxicokinetics of the novel potent tropomyosin receptor kinase (Trk) inhibitor LPM4870108 in rhesus monkeys</span></div><div class="casAuthors">Duan, Sijin; Dong, Lin; Wang, Bingsi; Wei, Shujuan; Gong, Xiaoyan; Yu, Pengfei; Li, Chunmei; Gao, Yonglin; Ye, Liang; Wang, Hongbo; Tian, Jingwei</div><div class="citationInfo"><span class="NLM_cas:title">Regulatory Toxicology and Pharmacology</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">104886</span>CODEN:
                <span class="NLM_cas:coden">RTOPDW</span>;
        ISSN:<span class="NLM_cas:issn">0273-2300</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">LPM4870108 is a tropomyosin receptor kinase (Trk) inhibitor that is currently under consideration for human clin. trials.  We characterized the toxicity and toxicokinetic properties of LPM4870108 following its oral administration to rhesus monkeys (5, 10, or 20 mg/kg/day for 4 wk with a 4-wk recovery period).  No evidence of LPM4870108 toxicity was obsd. over this study as reflected by an absence of difference in body wt., ophthalmoscopy, urinalysis, gross, or histopathol. findings.  No significant differences in toxicity-related outcomes were detected when comparing LPM4870108 and control groups, and no significant treatment-related changes in food consumption, ECG results, blood pressure, hematol. parameters, biochem. values, organ wt., or bone marrow parameters were obsd.  Treatment caused dose-dependent effects of gait disturbance, impaired balance, poor coordination, and decreased grip strength in all LPM4870108-treated animals, with these effects being attributable to excessive on-target Trk receptor inhibition.  After the 4-wk recovery period, all these abnormal treatment-related findings had fully or partially resolved.  The toxicokinetic study of monkeys revealed that the LPM4870108 exposure increased with dose.  Overall, LPM4870108 exhibited a safety profile in treated monkeys, indicating that the Highest Non-Severely Toxic Dose (HNSTD) for LPM4870108 in monkeys was 20 mg/kg/day.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_h0UffODCgLVg90H21EOLACvtfcHk0liImjHrigG6Mw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXksl2qtbc%253D&md5=2be164d3485b107672973aef3e479491</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.yrtph.2021.104886&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.yrtph.2021.104886%26sid%3Dliteratum%253Aachs%26aulast%3DDuan%26aufirst%3DS.%26aulast%3DDong%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DWei%26aufirst%3DS.%26aulast%3DGong%26aufirst%3DX.%26aulast%3DYu%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DYe%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DTian%26aufirst%3DJ.%26atitle%3DAssessment%2520of%2520the%2520toxicity%2520and%2520toxicokinetics%2520of%2520the%2520novel%2520potent%2520tropomyosin%2520receptor%2520kinase%2520%2528Trk%2529%2520inhibitor%2520LPM4870108%2520in%2520rhesus%2520monkeys%26jtitle%3DRegul.%2520Toxicol.%2520Pharmacol.%26date%3D2021%26volume%3D122%26spage%3D104886%26doi%3D10.1016%2Fj.yrtph.2021.104886" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span> <span> </span><span class="NLM_article-title">PCC0208017 a novel small-molecule inhibitor of MARK3/MARK4, suppresses glioma progression in vitro and in vivo</span>. <i>Acta Pharm. Sin. B</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">289</span>â <span class="NLM_lpage">300</span>, <span class="refDoi">Â DOI: 10.1016/j.apsb.2019.09.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=10.1016%2Fj.apsb.2019.09.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=32082974" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=1%3ACAS%3A528%3ADC%252BB3MXnslWitg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2020&pages=289-300&author=F.+Liauthor=Z.+Liuauthor=H.+Sunauthor=C.+Liauthor=W.+Wangauthor=L.+Yeauthor=C.+Yanauthor=J.+Tianauthor=H.+Wang&title=PCC0208017+a+novel+small-molecule+inhibitor+of+MARK3%2FMARK4%2C+suppresses+glioma+progression+in+vitro+and+in+vivo&doi=10.1016%2Fj.apsb.2019.09.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">PCC0208017, a novel small-molecule inhibitor of MARK3/MARK4, suppresses glioma progression in vitro and in vivo</span></div><div class="casAuthors">Li, Fangfang; Liu, Zongliang; Sun, Heyuan; Li, Chunmei; Wang, Wenyan; Ye, Liang; Yan, Chunhong; Tian, Jingwei; Wang, Hongbo</div><div class="citationInfo"><span class="NLM_cas:title">Acta Pharmaceutica Sinica B</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">289-300</span>CODEN:
                <span class="NLM_cas:coden">APSBCW</span>;
        ISSN:<span class="NLM_cas:issn">2211-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Gliomas are the most common primary intracranial neoplasms among all brain malignancies, and the microtubule affinity regulating kinases (MARKs) have become potential drug targets for glioma.  Here, we report a novel dual small-mol. inhibitor of MARK3 and MARK4, designated as PCC0208017.  In vitro, PCC0208017 strongly inhibited kinase activity against MARK3 and MARK4, and strongly reduced proliferation in three glioma cell lines.  This compd. attenuated glioma cell migration, glioma cell invasion, and angiogenesis.  Mol. mechanism studies revealed that PCC0208017 decreased the phosphorylation of Tau, disrupted microtubule dynamics, and induced a G2/M phase cell cycle arrest.  In an in vivo glioma model, PCC0208017 showed robust anti-tumor activity, blood-brain barrier permeability, and a good oral pharmacokinetic profile.  Mol. docking studies showed that PCC0208017 exhibited high binding affinity to MARK3 and MARK4.  Taken together, our study describes for the first time that PCC0208017, a novel MARK3/MARK4 inhibitor, might be a promising lead compd. for treatment of glioma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEiB0tMNKC9rVg90H21EOLACvtfcHk0liImjHrigG6Mw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXnslWitg%253D%253D&md5=3af5bf801677d2f616db37763a0f1e3c</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.apsb.2019.09.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.apsb.2019.09.004%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DYe%26aufirst%3DL.%26aulast%3DYan%26aufirst%3DC.%26aulast%3DTian%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DH.%26atitle%3DPCC0208017%2520a%2520novel%2520small-molecule%2520inhibitor%2520of%2520MARK3%252FMARK4%252C%2520suppresses%2520glioma%2520progression%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DActa%2520Pharm.%2520Sin.%2520B%26date%3D2020%26volume%3D10%26spage%3D289%26epage%3D300%26doi%3D10.1016%2Fj.apsb.2019.09.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article has not yet been cited by other publications.</p></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00712/20210716/images/medium/jm1c00712_0009.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00712/20210716/images/large/jm1c00712_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00712&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00712/20210716/images/medium/jm1c00712_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00712/20210716/images/large/jm1c00712_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Trk inhibitors approved and in clinical trials.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00712/20210716/images/large/jm1c00712_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00712&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00712/20210716/images/medium/jm1c00712_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00712/20210716/images/large/jm1c00712_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Docking of LOXO-195 and TPX-0005 with TrkA.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00712/20210716/images/large/jm1c00712_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00712&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00712/20210716/images/medium/jm1c00712_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00712/20210716/images/large/jm1c00712_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Structureâactivity relationship of TPX-0005.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00712/20210716/images/large/jm1c00712_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00712&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00712/20210716/images/medium/jm1c00712_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00712/20210716/images/large/jm1c00712_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Design of compounds with one-chiral atom.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00712/20210716/images/large/jm1c00712_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00712&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00712/20210716/images/medium/jm1c00712_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00712/20210716/images/large/jm1c00712_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. <i>In vivo</i> efficacy of compound <b>10</b> against four engineered BaF3-NTRK tumor models.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00712/20210716/images/large/jm1c00712_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00712&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00712/20210716/images/medium/jm1c00712_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00712/20210716/images/large/jm1c00712_0008.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthetic Route for Compound <b>10</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00712/20210716/images/large/jm1c00712_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00712&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Boc<sub>2</sub>O, DMAP, THF, RT, 16 h, 93%; (b) ClPO(OPh)<sub>2</sub>, LiHMDS, THF; (c) Pd(PPh<sub>3</sub>)<sub>4</sub>, NaHCO<sub>3</sub>, THF/H<sub>2</sub>O, reflux, 16 h; (d) H<sub>2</sub>, Pd(OH)<sub>2</sub>/C (5% wt), EtOH, 96 h; (e) HCl/EA, the total yield is 44% from step b to e; (f) DIPEA, NMP, 75 Â°C, 16 h, 85.3%; (g) TMSCl, NaI, ACN, 75 Â°C, 2 h; (h) NaOH, H<sub>2</sub>O/MeOH, 60 Â°C, 2 h, total yield of steps g and h is 98.6%; (i) HATU, DIPEA, DMF, RT, 72.4%; (j) PPh<sub>3</sub>, DEAD, THF.</p></p></figure><figure data-id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00712/20210716/images/medium/jm1c00712_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00712/20210716/images/large/jm1c00712_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. ORTEP of <b>10</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00712/20210716/images/large/jm1c00712_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00712&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i42">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_40602" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_40602" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 17 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mitelman, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johansson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mertens, F.</span></span> <span> </span><span class="NLM_article-title">The impact of translocations and gene fusions on cancer causation</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">233</span>â <span class="NLM_lpage">245</span>, <span class="refDoi">Â DOI: 10.1038/nrc2091</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=10.1038%2Fnrc2091" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=17361217" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjtlyhtL0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=233-245&author=F.+Mitelmanauthor=B.+Johanssonauthor=F.+Mertens&title=The+impact+of+translocations+and+gene+fusions+on+cancer+causation&doi=10.1038%2Fnrc2091"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The impact of translocations and gene fusions on cancer causation</span></div><div class="casAuthors">Mitelman, Felix; Johansson, Bertil; Mertens, Fredrik</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">233-245</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Chromosome aberrations, in particular translocations and their corresponding gene fusions, have an important role in the initial steps of tumorigenesis; at present, 358 gene fusions involving 337 different genes have been identified.  An increasing no. of gene fusions are being recognized as important diagnostic and prognostic parameters in malignant hematol. disorders and childhood sarcomas.  The biol. and clin. impact of gene fusions in the more common solid tumor types has been less appreciated.  However, an anal. of available data shows that gene fusions occur in all malignancies, and that they account for 20% of human cancer morbidity.  With the advent of new and powerful investigative tools that enable the detection of cytogenetically cryptic rearrangements, this proportion is likely to increase substantially.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkiYHGC0ahy7Vg90H21EOLACvtfcHk0liRr9pJeoLnaA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjtlyhtL0%253D&md5=8ce22e508cd79b28599b724f6f0a8155</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrc2091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2091%26sid%3Dliteratum%253Aachs%26aulast%3DMitelman%26aufirst%3DF.%26aulast%3DJohansson%26aufirst%3DB.%26aulast%3DMertens%26aufirst%3DF.%26atitle%3DThe%2520impact%2520of%2520translocations%2520and%2520gene%2520fusions%2520on%2520cancer%2520causation%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2007%26volume%3D7%26spage%3D233%26epage%3D245%26doi%3D10.1038%2Fnrc2091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Drilon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laetsch, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kummar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DuBois, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lassen, U. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demetri, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nathenson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doebele, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farago, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pappo, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turpin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowlati, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brose, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mascarenhas, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Federman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berlin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Deiry, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baik, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deeken, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boni, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagasubramanian, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudzinski, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meric-Bernstam, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sohal, D. P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raez, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hechtman, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benayed, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladanyi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuch, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruickshank, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ku, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyman, D. M.</span></span> <span> </span><span class="NLM_article-title">Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>378</i></span>,  <span class="NLM_fpage">731</span>â <span class="NLM_lpage">739</span>, <span class="refDoi">Â DOI: 10.1056/nejmoa1714448</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=10.1056%2FNEJMoa1714448" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=29466156" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=1%3ACAS%3A528%3ADC%252BC1cXkvFalsLY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=378&publication_year=2018&pages=731-739&author=A.+Drilonauthor=T.+W.+Laetschauthor=S.+Kummarauthor=S.+G.+DuBoisauthor=U.+N.+Lassenauthor=G.+D.+Demetriauthor=M.+Nathensonauthor=R.+C.+Doebeleauthor=A.+F.+Faragoauthor=A.+S.+Pappoauthor=B.+Turpinauthor=A.+Dowlatiauthor=M.+S.+Broseauthor=L.+Mascarenhasauthor=N.+Federmanauthor=J.+Berlinauthor=W.+S.+El-Deiryauthor=C.+Baikauthor=J.+Deekenauthor=V.+Boniauthor=R.+Nagasubramanianauthor=M.+Taylorauthor=E.+R.+Rudzinskiauthor=F.+Meric-Bernstamauthor=D.+P.+S.+Sohalauthor=P.+C.+Maauthor=L.+E.+Raezauthor=J.+F.+Hechtmanauthor=R.+Benayedauthor=M.+Ladanyiauthor=B.+B.+Tuchauthor=K.+Ebataauthor=S.+Cruickshankauthor=N.+C.+Kuauthor=M.+C.+Coxauthor=D.+S.+Hawkinsauthor=D.+S.+Hongauthor=D.+M.+Hyman&title=Efficacy+of+Larotrectinib+in+TRK+Fusion-Positive+Cancers+in+Adults+and+Children&doi=10.1056%2Fnejmoa1714448"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children</span></div><div class="casAuthors">Drilon, A.; Laetsch, T. W.; Kummar, S.; DuBois, S. G.; Lassen, U. N.; Demetri, G. D.; Nathenson, M.; Doebele, R. C.; Farago, A. F.; Pappo, A. S.; Turpin, B.; Dowlati, A.; Brose, M. S.; Mascarenhas, L.; Federman, N.; Berlin, J.; El-Deiry, W. S.; Baik, C.; Deeken, J.; Boni, V.; Nagasubramanian, R.; Taylor, M.; Rudzinski, E. R.; Meric-Bernstam, F.; Sohal, D. P. S.; Ma, P. C.; Raez, L. E.; Hechtman, J. F.; Benayed, R.; Ladanyi, M.; Tuch, B. B.; Ebata, K.; Cruickshank, S.; Ku, N. C.; Cox, M. C.; Hawkins, D. S.; Hong, D. S.; Hyman, D. M.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">378</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">731-739</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Fusions involving one of three tropomyosin receptor kinases (TRK) occur in diverse cancers in children and adults.  We evaluated the efficacy and safety of larotrectinib, a highly selective TRK inhibitor, in adults and children who had tumors with these fusions.  METHODS: We enrolled patients with consecutively and prospectively identified TRK fusion-pos. cancers, detected by mol. profiling as routinely performed at each site, into one of three protocols: a phase 1 study involving adults, a phase 1-2 study involving children, or a phase 2 study involving adolescents and adults.  The primary end point for the combined anal. was the overall response rate according to independent review.  Secondary end points included duration of response, progression free survival, and safety.  RESULTS: A total of 55 patients, ranging in age from 4 mo to 76 years, were enrolled and treated.  Patients had 17 unique TRK fusion-pos. tumor types.  The overall response rate was 75% (95% confidence interval [CI], 61 to 85) according to independent review and 80% (95% CI, 67 to 90) according to investigator assessment.  At 1 yr, 71% of the responses were ongoing and 55% of the patients remained progression-free.  The median duration of response and progression-free survival had not been reached.  At a median follow-up of 9.4 mo, 86% of the patients with a response (38 of 44 patients) were continuing treatment or had undergone surgery that was intended to be curative.  Adverse events were predominantly of grade 1, and no adverse event of grade 3 or 4 that was considered by the investigators to be related to larotrectinib occurred in more than 5% of patients.  No patient discontinued larotrectinib owing to drug-related adverse events.  CONCLUSIONS: Larotrectinib had marked and durable antitumor activity in patients with TRK fusion-pos. cancer, regardless of the age of the patient or of the tumor type.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwp_pcLYdv5bVg90H21EOLACvtfcHk0liRr9pJeoLnaA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXkvFalsLY%253D&md5=b636d83c2cd61b4b35c36e36c950196c</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1714448&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1714448%26sid%3Dliteratum%253Aachs%26aulast%3DDrilon%26aufirst%3DA.%26aulast%3DLaetsch%26aufirst%3DT.%2BW.%26aulast%3DKummar%26aufirst%3DS.%26aulast%3DDuBois%26aufirst%3DS.%2BG.%26aulast%3DLassen%26aufirst%3DU.%2BN.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3DNathenson%26aufirst%3DM.%26aulast%3DDoebele%26aufirst%3DR.%2BC.%26aulast%3DFarago%26aufirst%3DA.%2BF.%26aulast%3DPappo%26aufirst%3DA.%2BS.%26aulast%3DTurpin%26aufirst%3DB.%26aulast%3DDowlati%26aufirst%3DA.%26aulast%3DBrose%26aufirst%3DM.%2BS.%26aulast%3DMascarenhas%26aufirst%3DL.%26aulast%3DFederman%26aufirst%3DN.%26aulast%3DBerlin%26aufirst%3DJ.%26aulast%3DEl-Deiry%26aufirst%3DW.%2BS.%26aulast%3DBaik%26aufirst%3DC.%26aulast%3DDeeken%26aufirst%3DJ.%26aulast%3DBoni%26aufirst%3DV.%26aulast%3DNagasubramanian%26aufirst%3DR.%26aulast%3DTaylor%26aufirst%3DM.%26aulast%3DRudzinski%26aufirst%3DE.%2BR.%26aulast%3DMeric-Bernstam%26aufirst%3DF.%26aulast%3DSohal%26aufirst%3DD.%2BP.%2BS.%26aulast%3DMa%26aufirst%3DP.%2BC.%26aulast%3DRaez%26aufirst%3DL.%2BE.%26aulast%3DHechtman%26aufirst%3DJ.%2BF.%26aulast%3DBenayed%26aufirst%3DR.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DTuch%26aufirst%3DB.%2BB.%26aulast%3DEbata%26aufirst%3DK.%26aulast%3DCruickshank%26aufirst%3DS.%26aulast%3DKu%26aufirst%3DN.%2BC.%26aulast%3DCox%26aufirst%3DM.%2BC.%26aulast%3DHawkins%26aufirst%3DD.%2BS.%26aulast%3DHong%26aufirst%3DD.%2BS.%26aulast%3DHyman%26aufirst%3DD.%2BM.%26atitle%3DEfficacy%2520of%2520Larotrectinib%2520in%2520TRK%2520Fusion-Positive%2520Cancers%2520in%2520Adults%2520and%2520Children%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2018%26volume%3D378%26spage%3D731%26epage%3D739%26doi%3D10.1056%2Fnejmoa1714448" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Amatu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sartore-Bianchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siena, S.</span></span> <span> </span><span class="NLM_article-title">NTRK gene fusions as novel targets of cancer therapy across multiple tumour types</span>. <i>ESMO Open</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>1</i></span>, <span class="NLM_elocation-id">e000023</span> <span class="refDoi">Â DOI: 10.1136/esmoopen-2015-000023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=10.1136%2Fesmoopen-2015-000023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=27843590" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2016&author=A.+Amatuauthor=A.+Sartore-Bianchiauthor=S.+Siena&title=NTRK+gene+fusions+as+novel+targets+of+cancer+therapy+across+multiple+tumour+types&doi=10.1136%2Fesmoopen-2015-000023"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1136%2Fesmoopen-2015-000023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fesmoopen-2015-000023%26sid%3Dliteratum%253Aachs%26aulast%3DAmatu%26aufirst%3DA.%26aulast%3DSartore-Bianchi%26aufirst%3DA.%26aulast%3DSiena%26aufirst%3DS.%26atitle%3DNTRK%2520gene%2520fusions%2520as%2520novel%2520targets%2520of%2520cancer%2520therapy%2520across%2520multiple%2520tumour%2520types%26jtitle%3DESMO%2520Open%26date%3D2016%26volume%3D1%26doi%3D10.1136%2Fesmoopen-2015-000023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shah, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lankerovich, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, J.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroeder, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foltz, G.</span></span> <span> </span><span class="NLM_article-title">Exploration of the gene fusion landscape of glioblastoma using transcriptome sequencing and copy number data</span>. <i>BMC Genom.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">818</span>, <span class="refDoi">Â DOI: 10.1186/1471-2164-14-818</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=10.1186%2F1471-2164-14-818" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=24261984" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=818&author=N.+Shahauthor=M.+Lankerovichauthor=H.+Leeauthor=J.-G.+Yoonauthor=B.+Schroederauthor=G.+Foltz&title=Exploration+of+the+gene+fusion+landscape+of+glioblastoma+using+transcriptome+sequencing+and+copy+number+data&doi=10.1186%2F1471-2164-14-818"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1186%2F1471-2164-14-818&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2164-14-818%26sid%3Dliteratum%253Aachs%26aulast%3DShah%26aufirst%3DN.%26aulast%3DLankerovich%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DH.%26aulast%3DYoon%26aufirst%3DJ.-G.%26aulast%3DSchroeder%26aufirst%3DB.%26aulast%3DFoltz%26aufirst%3DG.%26atitle%3DExploration%2520of%2520the%2520gene%2520fusion%2520landscape%2520of%2520glioblastoma%2520using%2520transcriptome%2520sequencing%2520and%2520copy%2520number%2520data%26jtitle%3DBMC%2520Genom.%26date%3D2013%26volume%3D14%26spage%3D818%26doi%3D10.1186%2F1471-2164-14-818" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Greco, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miranda, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierotti, M. A.</span></span> <span> </span><span class="NLM_article-title">Rearrangements of NTRK1 gene in papillary thyroid carcinoma</span>. <i>Mol. Cell. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>321</i></span>,  <span class="NLM_fpage">44</span>â <span class="NLM_lpage">49</span>, <span class="refDoi">Â DOI: 10.1016/j.mce.2009.10.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=10.1016%2Fj.mce.2009.10.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=19883730" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksVamu7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=321&publication_year=2010&pages=44-49&author=A.+Grecoauthor=C.+Mirandaauthor=M.+A.+Pierotti&title=Rearrangements+of+NTRK1+gene+in+papillary+thyroid+carcinoma&doi=10.1016%2Fj.mce.2009.10.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Rearrangements of NTRK1 gene in papillary thyroid carcinoma</span></div><div class="casAuthors">Greco, A.; Miranda, C.; Pierotti, M. A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Endocrinology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">321</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">44-49</span>CODEN:
                <span class="NLM_cas:coden">MCEND6</span>;
        ISSN:<span class="NLM_cas:issn">0303-7207</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">A review.  TRK oncogenes are obsd. in a consistent fraction of papillary thyroid carcinoma (PTC); they arise from the fusion of the 3' terminal sequences of the NTRK1/NGF receptor gene with 5' terminal sequences of various activating genes, such as TPM3, TPR and TFG.  TRK oncoproteins display constitutive tyrosine-kinase activity, leading to in vitro and in vivo transformation.  In this review studies performed during the last 20 years will be summarized.  The following topics will be illustrated: (a) frequency of TRK oncogenes and correlation with radiation and tumor histopathol. features; (b) mol. mechanisms underlying NTRK1 oncogenic rearrangements; (c) mol. and biochem. characterization of TRK oncoproteins, and their mechanism of action; (d) role of activating sequences in the activation of TRK oncoproteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnGkkW9wYpTLVg90H21EOLACvtfcHk0lhF6Zrn5l3abw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksVamu7g%253D&md5=ea9abddd4191599672958ac3875bf9ae</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.mce.2009.10.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mce.2009.10.009%26sid%3Dliteratum%253Aachs%26aulast%3DGreco%26aufirst%3DA.%26aulast%3DMiranda%26aufirst%3DC.%26aulast%3DPierotti%26aufirst%3DM.%2BA.%26atitle%3DRearrangements%2520of%2520NTRK1%2520gene%2520in%2520papillary%2520thyroid%2520carcinoma%26jtitle%3DMol.%2520Cell.%2520Endocrinol.%26date%3D2010%26volume%3D321%26spage%3D44%26epage%3D49%26doi%3D10.1016%2Fj.mce.2009.10.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vaishnavi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doebele, R. C.</span></span> <span> </span><span class="NLM_article-title">TRKing down an old oncogene in a new era of targeted therapy</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">25</span>â <span class="NLM_lpage">34</span>, <span class="refDoi">Â DOI: 10.1158/2159-8290.cd-14-0765</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=10.1158%2F2159-8290.CD-14-0765" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=25527197" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFCntbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=25-34&author=A.+Vaishnaviauthor=A.+T.+Leauthor=R.+C.+Doebele&title=TRKing+down+an+old+oncogene+in+a+new+era+of+targeted+therapy&doi=10.1158%2F2159-8290.cd-14-0765"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">TRKing Down an Old Oncogene in a New Era of Targeted Therapy</span></div><div class="casAuthors">Vaishnavi, Aria; Le, Anh T.; Doebele, Robert C.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">25-34</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The use of high-throughput next-generation sequencing techniques in multiple tumor types during the last few years has identified NTRK1, 2, and 3 gene rearrangements encoding novel oncogenic fusions in 19 different tumor types to date.  These recent developments have led us to revisit an old oncogene, Trk (originally identified as OncD), which encodes the TPM3-NTRK1 gene fusion and was one of the first transforming chromosomal rearrangements identified 32 years ago.  However, no drug has yet been approved by the FDA for cancers harboring this oncogene.  This review will discuss the biol. of the TRK family of receptors, their role in human cancer, the types of oncogenic alterations, and drugs that are currently in development for this family of oncogene targets.  Significance: Precision oncol. approaches have accelerated recently due to advancements in our ability to detect oncogenic mutations in tumor samples.  Oncogenic alterations, most commonly gene fusions, have now been detected for the genes encoding the TRKA, TRKB, and TRKC receptor tyrosine kinases across multiple tumor types.  The scientific rationale for the targeting of the TRK oncogene family will be discussed here.  Cancer Discov; 5(1); 25-34. Â©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKUH4ooHY0TbVg90H21EOLACvtfcHk0lhF6Zrn5l3abw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFCntbw%253D&md5=02103d46d85b6dc948dba58d32ffba9f</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-14-0765&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-14-0765%26sid%3Dliteratum%253Aachs%26aulast%3DVaishnavi%26aufirst%3DA.%26aulast%3DLe%26aufirst%3DA.%2BT.%26aulast%3DDoebele%26aufirst%3DR.%2BC.%26atitle%3DTRKing%2520down%2520an%2520old%2520oncogene%2520in%2520a%2520new%2520era%2520of%2520targeted%2520therapy%26jtitle%3DCancer%2520Discovery%26date%3D2015%26volume%3D5%26spage%3D25%26epage%3D34%26doi%3D10.1158%2F2159-8290.cd-14-0765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vaishnavi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capelletti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kako, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butaney, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ercan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahale, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aisner, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilling, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berge, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, S.-i.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kryukov, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garraway, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammerman, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varella-Garcia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">JÃ¤nne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doebele, R. C.</span></span> <span> </span><span class="NLM_article-title">Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1469</span>â <span class="NLM_lpage">1472</span>, <span class="refDoi">Â DOI: 10.1038/nm.3352</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=10.1038%2Fnm.3352" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=24162815" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1yiurrI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=1469-1472&author=A.+Vaishnaviauthor=M.+Capellettiauthor=A.+T.+Leauthor=S.+Kakoauthor=M.+Butaneyauthor=D.+Ercanauthor=S.+Mahaleauthor=K.+D.+Daviesauthor=D.+L.+Aisnerauthor=A.+B.+Pillingauthor=E.+M.+Bergeauthor=J.+Kimauthor=H.+Sasakiauthor=S.-i.+Parkauthor=G.+Kryukovauthor=L.+A.+Garrawayauthor=P.+S.+Hammermanauthor=J.+Haasauthor=S.+W.+Andrewsauthor=D.+Lipsonauthor=P.+J.+Stephensauthor=V.+A.+Millerauthor=M.+Varella-Garciaauthor=P.+A.+J%C3%A4nneauthor=R.+C.+Doebele&title=Oncogenic+and+drug-sensitive+NTRK1+rearrangements+in+lung+cancer&doi=10.1038%2Fnm.3352"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer</span></div><div class="casAuthors">Vaishnavi, Aria; Capelletti, Marzia; Le, Anh T.; Kako, Severine; Butaney, Mohit; Ercan, Dalia; Mahale, Sakshi; Davies, Kurtis D.; Aisner, Dara L.; Pilling, Amanda B.; Berge, Eamon M.; Kim, Jhingook; Sasaki, Hidefumi; Park, Seung-il; Kryukov, Gregory; Garraway, Levi A.; Hammerman, Peter S.; Haas, Julia; Andrews, Steven W.; Lipson, Doron; Stephens, Philip J.; Miller, Vince A.; Varella-Garcia, Marileila; Jaenne, Pasi A.; Doebele, Robert C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1469-1472</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We identified new gene fusions in patients with lung cancer harboring the kinase domain of the NTRK1 gene that encodes the high-affinity nerve growth factor receptor (TRKA protein).  Both the MPRIP-NTRK1 and CD74-NTRK1 fusions lead to constitutive TRKA kinase activity and are oncogenic.  Treatment of cells expressing NTRK1 fusions with inhibitors of TRKA kinase activity inhibited autophosphorylation of TRKA and cell growth.  Tumor samples from 3 of 91 patients with lung cancer (3.3%) without known oncogenic alterations assayed by next-generation sequencing or fluorescence in situ hybridization demonstrated evidence of NTRK1 gene fusions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBHNoZGMQLMrVg90H21EOLACvtfcHk0lg30bVoCCf39Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1yiurrI&md5=23b413826ea700bd831eadbfde270615</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnm.3352&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3352%26sid%3Dliteratum%253Aachs%26aulast%3DVaishnavi%26aufirst%3DA.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DLe%26aufirst%3DA.%2BT.%26aulast%3DKako%26aufirst%3DS.%26aulast%3DButaney%26aufirst%3DM.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DMahale%26aufirst%3DS.%26aulast%3DDavies%26aufirst%3DK.%2BD.%26aulast%3DAisner%26aufirst%3DD.%2BL.%26aulast%3DPilling%26aufirst%3DA.%2BB.%26aulast%3DBerge%26aufirst%3DE.%2BM.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DSasaki%26aufirst%3DH.%26aulast%3DPark%26aufirst%3DS.-i.%26aulast%3DKryukov%26aufirst%3DG.%26aulast%3DGarraway%26aufirst%3DL.%2BA.%26aulast%3DHammerman%26aufirst%3DP.%2BS.%26aulast%3DHaas%26aufirst%3DJ.%26aulast%3DAndrews%26aufirst%3DS.%2BW.%26aulast%3DLipson%26aufirst%3DD.%26aulast%3DStephens%26aufirst%3DP.%2BJ.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DVarella-Garcia%26aufirst%3DM.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DDoebele%26aufirst%3DR.%2BC.%26atitle%3DOncogenic%2520and%2520drug-sensitive%2520NTRK1%2520rearrangements%2520in%2520lung%2520cancer%26jtitle%3DNat.%2520Med.%26date%3D2013%26volume%3D19%26spage%3D1469%26epage%3D1472%26doi%3D10.1038%2Fnm.3352" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ardini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosotti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borgia, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Ponti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somaschini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cammarota, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amboldi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raddrizzani, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnaghi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballinari, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casero, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasparri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banfi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avanzi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saccardo, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alzani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandiera, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felder, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donati, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pesenti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sartore-Bianchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gambacorta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierotti, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siena, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veronese, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galvani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isacchi, A.</span></span> <span> </span><span class="NLM_article-title">The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition</span>. <i>Mol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1495</span>â <span class="NLM_lpage">1507</span>, <span class="refDoi">Â DOI: 10.1016/j.molonc.2014.06.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=10.1016%2Fj.molonc.2014.06.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=24962792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVaktb%252FI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2014&pages=1495-1507&author=E.+Ardiniauthor=R.+Bosottiauthor=A.+L.+Borgiaauthor=C.+De+Pontiauthor=A.+Somaschiniauthor=R.+Cammarotaauthor=N.+Amboldiauthor=L.+Raddrizzaniauthor=A.+Milaniauthor=P.+Magnaghiauthor=D.+Ballinariauthor=D.+Caseroauthor=F.+Gasparriauthor=P.+Banfiauthor=N.+Avanziauthor=M.+B.+Saccardoauthor=R.+Alzaniauthor=T.+Bandieraauthor=E.+Felderauthor=D.+Donatiauthor=E.+Pesentiauthor=A.+Sartore-Bianchiauthor=M.+Gambacortaauthor=M.+A.+Pierottiauthor=S.+Sienaauthor=S.+Veroneseauthor=A.+Galvaniauthor=A.+Isacchi&title=The+TPM3-NTRK1+rearrangement+is+a+recurring+event+in+colorectal+carcinoma+and+is+associated+with+tumor+sensitivity+to+TRKA+kinase+inhibition&doi=10.1016%2Fj.molonc.2014.06.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition</span></div><div class="casAuthors">Ardini, Elena; Bosotti, Roberta; Borgia, Andrea Lombardi; De Ponti, Cristina; Somaschini, Alessio; Cammarota, Rosaria; Amboldi, Nadia; Raddrizzani, Laura; Milani, Andrea; Magnaghi, Paola; Ballinari, Dario; Casero, Daniele; Gasparri, Fabio; Banfi, Patrizia; Avanzi, Nilla; Saccardo, Maria B.; Alzani, Rachele; Bandiera, Tiziano; Felder, Eduard; Donati, Daniele; Pesenti, Enrico; Sartore-Bianchi, Andrea; Gambacorta, Marcello; Pierotti, Marco A.; Siena, Salvatore; Veronese, Silvio; Galvani, Arturo; Isacchi, Antonella</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1495-1507</span>CODEN:
                <span class="NLM_cas:coden">MOONC3</span>;
        ISSN:<span class="NLM_cas:issn">1574-7891</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The NTRK1 gene encodes Tropomyosin-related kinase A (TRKA), the high-affinity Nerve Growth Factor Receptor.  NTRK1 was originally isolated from a colorectal carcinoma (CRC) sample as component of a somatic rearrangement (TPM3-NTRK1) resulting in expression of the oncogenic chimeric protein TPM3-TRKA, but there has been no subsequent report regarding the relevance of this oncogene in CRC.  The KM12 human CRC cell line expresses the chimeric TPM3-TRKA protein and is hypersensitive to TRKA kinase inhibition.  We report the detailed characterization of the TPM3-NTRK1 genomic rearrangement in KM12 cells and through a cellular screening approach, the identification of NMS-P626, a novel highly potent and selective TRKA inhibitor.  NMS-P626 suppressed TPM3-TRKA phosphorylation and downstream signaling in KM12 cells and showed remarkable antitumor activity in mice bearing KM12 tumors.  Finally, using quant. reverse transcriptase PCR and immunohistochem. (IHC) we identified the TPM3-NTRK1 rearrangement in a CRC clin. sample, therefore suggesting that this chromosomal translocation is indeed a low frequency recurring event in CRC and that such patients might benefit from therapy with TRKA kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-EhukkQ24OrVg90H21EOLACvtfcHk0lg30bVoCCf39Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVaktb%252FI&md5=2a9de2410f69e2eb8ff84c9516828984</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.molonc.2014.06.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molonc.2014.06.001%26sid%3Dliteratum%253Aachs%26aulast%3DArdini%26aufirst%3DE.%26aulast%3DBosotti%26aufirst%3DR.%26aulast%3DBorgia%26aufirst%3DA.%2BL.%26aulast%3DDe%2BPonti%26aufirst%3DC.%26aulast%3DSomaschini%26aufirst%3DA.%26aulast%3DCammarota%26aufirst%3DR.%26aulast%3DAmboldi%26aufirst%3DN.%26aulast%3DRaddrizzani%26aufirst%3DL.%26aulast%3DMilani%26aufirst%3DA.%26aulast%3DMagnaghi%26aufirst%3DP.%26aulast%3DBallinari%26aufirst%3DD.%26aulast%3DCasero%26aufirst%3DD.%26aulast%3DGasparri%26aufirst%3DF.%26aulast%3DBanfi%26aufirst%3DP.%26aulast%3DAvanzi%26aufirst%3DN.%26aulast%3DSaccardo%26aufirst%3DM.%2BB.%26aulast%3DAlzani%26aufirst%3DR.%26aulast%3DBandiera%26aufirst%3DT.%26aulast%3DFelder%26aufirst%3DE.%26aulast%3DDonati%26aufirst%3DD.%26aulast%3DPesenti%26aufirst%3DE.%26aulast%3DSartore-Bianchi%26aufirst%3DA.%26aulast%3DGambacorta%26aufirst%3DM.%26aulast%3DPierotti%26aufirst%3DM.%2BA.%26aulast%3DSiena%26aufirst%3DS.%26aulast%3DVeronese%26aufirst%3DS.%26aulast%3DGalvani%26aufirst%3DA.%26aulast%3DIsacchi%26aufirst%3DA.%26atitle%3DThe%2520TPM3-NTRK1%2520rearrangement%2520is%2520a%2520recurring%2520event%2520in%2520colorectal%2520carcinoma%2520and%2520is%2520associated%2520with%2520tumor%2520sensitivity%2520to%2520TRKA%2520kinase%2520inhibition%26jtitle%3DMol.%2520Oncol.%26date%3D2014%26volume%3D8%26spage%3D1495%26epage%3D1507%26doi%3D10.1016%2Fj.molonc.2014.06.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ardini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menichincheri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banfi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosotti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Ponti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulci, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballinari, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciomei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Texido, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degrassi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avanzi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amboldi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saccardo, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casero, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orsini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandiera, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mologni, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vernier, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felder, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donati, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isacchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pesenti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnaghi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galvani, A.</span></span> <span> </span><span class="NLM_article-title">Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">628</span>â <span class="NLM_lpage">639</span>, <span class="refDoi">Â DOI: 10.1158/1535-7163.mct-15-0758</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=10.1158%2F1535-7163.MCT-15-0758" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=26939704" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=1%3ACAS%3A528%3ADC%252BC28XlsVSqtL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=628-639&author=E.+Ardiniauthor=M.+Menichincheriauthor=P.+Banfiauthor=R.+Bosottiauthor=C.+De+Pontiauthor=R.+Pulciauthor=D.+Ballinariauthor=M.+Ciomeiauthor=G.+Texidoauthor=A.+Degrassiauthor=N.+Avanziauthor=N.+Amboldiauthor=M.+B.+Saccardoauthor=D.+Caseroauthor=P.+Orsiniauthor=T.+Bandieraauthor=L.+Mologniauthor=D.+Andersonauthor=G.+Weiauthor=J.+Harrisauthor=J.-M.+Vernierauthor=G.+Liauthor=E.+Felderauthor=D.+Donatiauthor=A.+Isacchiauthor=E.+Pesentiauthor=P.+Magnaghiauthor=A.+Galvani&title=Entrectinib%2C+a+Pan-TRK%2C+ROS1%2C+and+ALK+Inhibitor+with+Activity+in+Multiple+Molecularly+Defined+Cancer+Indications&doi=10.1158%2F1535-7163.mct-15-0758"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications</span></div><div class="casAuthors">Ardini, Elena; Menichincheri, Maria; Banfi, Patrizia; Bosotti, Roberta; De Ponti, Cristina; Pulci, Romana; Ballinari, Dario; Ciomei, Marina; Texido, Gemma; Degrassi, Anna; Avanzi, Nilla; Amboldi, Nadia; Saccardo, Maria Beatrice; Casero, Daniele; Orsini, Paolo; Bandiera, Tiziano; Mologni, Luca; Anderson, David; Wei, Ge; Harris, Jason; Vernier, Jean-Michel; Li, Gang; Felder, Eduard; Donati, Daniele; Isacchi, Antonella; Pesenti, Enrico; Magnaghi, Paola; Galvani, Arturo</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">628-639</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Activated ALK and ROS1 tyrosine kinases, resulting from chromosomal rearrangements, occur in a subset of non-small cell lung cancers (NSCLC) as well as other tumor types and their oncogenic relevance as actionable targets has been demonstrated by the efficacy of selective kinase inhibitors such as crizotinib, ceritinib, and alectinib.  More recently, low-frequency rearrangements of TRK kinases have been described in NSCLC, colorectal carcinoma, glioblastoma, and Spitzoid melanoma.  Entrectinib, whose discovery and preclin. characterization are reported herein, is a novel, potent inhibitor of ALK, ROS1, and, importantly, of TRK family kinases, which shows promise for therapy of tumors bearing oncogenic forms of these proteins.  Proliferation profiling against over 200 human tumor cell lines revealed that entrectinib is exquisitely potent in vitro against lines that are dependent on the drug's pharmacol. targets.  Oral administration of entrectinib to tumor-bearing mice induced regression in relevant human xenograft tumors, including the TRKA-dependent colorectal carcinoma KM12, ROS1-driven tumors, and several ALK-dependent models of different tissue origins, including a model of brain-localized lung cancer metastasis.  Entrectinib is currently showing great promise in phase I/II clin. trials, including the first documented objective responses to a TRK inhibitor in colorectal carcinoma and in NSCLC.  The drug is, thus, potentially suited to the therapy of several molecularly defined cancer settings, esp. that of TRK-dependent tumors, for which no approved drugs are currently available.  Mol Cancer Ther; 15(4); 628-39. Â©2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOaNX-kFz2qbVg90H21EOLACvtfcHk0lg419iuZgIoWA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlsVSqtL4%253D&md5=dd75115cb344f0e3a6d299781043d7d6</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-15-0758&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-15-0758%26sid%3Dliteratum%253Aachs%26aulast%3DArdini%26aufirst%3DE.%26aulast%3DMenichincheri%26aufirst%3DM.%26aulast%3DBanfi%26aufirst%3DP.%26aulast%3DBosotti%26aufirst%3DR.%26aulast%3DDe%2BPonti%26aufirst%3DC.%26aulast%3DPulci%26aufirst%3DR.%26aulast%3DBallinari%26aufirst%3DD.%26aulast%3DCiomei%26aufirst%3DM.%26aulast%3DTexido%26aufirst%3DG.%26aulast%3DDegrassi%26aufirst%3DA.%26aulast%3DAvanzi%26aufirst%3DN.%26aulast%3DAmboldi%26aufirst%3DN.%26aulast%3DSaccardo%26aufirst%3DM.%2BB.%26aulast%3DCasero%26aufirst%3DD.%26aulast%3DOrsini%26aufirst%3DP.%26aulast%3DBandiera%26aufirst%3DT.%26aulast%3DMologni%26aufirst%3DL.%26aulast%3DAnderson%26aufirst%3DD.%26aulast%3DWei%26aufirst%3DG.%26aulast%3DHarris%26aufirst%3DJ.%26aulast%3DVernier%26aufirst%3DJ.-M.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DFelder%26aufirst%3DE.%26aulast%3DDonati%26aufirst%3DD.%26aulast%3DIsacchi%26aufirst%3DA.%26aulast%3DPesenti%26aufirst%3DE.%26aulast%3DMagnaghi%26aufirst%3DP.%26aulast%3DGalvani%26aufirst%3DA.%26atitle%3DEntrectinib%252C%2520a%2520Pan-TRK%252C%2520ROS1%252C%2520and%2520ALK%2520Inhibitor%2520with%2520Activity%2520in%2520Multiple%2520Molecularly%2520Defined%2520Cancer%2520Indications%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2016%26volume%3D15%26spage%3D628%26epage%3D639%26doi%3D10.1158%2F1535-7163.mct-15-0758" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martens, U. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bochum, S.</span></span> <span> </span><span class="NLM_article-title">Bochum, S. Larotrectinib (LOXO-101)</span>. <i>Recent Results Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>211</i></span>,  <span class="NLM_fpage">141</span>â <span class="NLM_lpage">151</span>, <span class="refDoi">Â DOI: 10.1007/978-3-319-91442-8_10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=10.1007%2F978-3-319-91442-8_10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=30069765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVShu7nI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=211&publication_year=2018&pages=141-151&author=S.+Bergerauthor=U.+M.+Martensauthor=S.+Bochum&title=Bochum%2C+S.+Larotrectinib+%28LOXO-101%29&doi=10.1007%2F978-3-319-91442-8_10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Larotrectinib (LOXO-101)</span></div><div class="casAuthors">Berger, Stephanie; Martens, Uwe M.; Bochum, Sylvia</div><div class="citationInfo"><span class="NLM_cas:title">Recent Results in Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">211</span>
        (<span class="NLM_cas:issue">Small Molecules in Oncology</span>),
    <span class="NLM_cas:pages">141-151</span>CODEN:
                <span class="NLM_cas:coden">RRCRBU</span>;
        ISSN:<span class="NLM_cas:issn">2197-6767</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">A review.  One of the most challenging issues in oncol. research and treatment is identifying oncogenic drivers within an individual patient's tumor which can be directly targeted by a clin. available therapeutic drug.  In this context, gene fusions as one important example of genetic aberrations leading to carcinogen-esis follow the widely accepted concept that cell growth and proliferation are driven by the accomplished fusion (usually involving former proto-oncogenes) and may therefore be successfully inhibited by substances directed against the fusion.  This concept has already been established with oncogenic gene fusions like BCR-ABL in chronic myelogenous leukemia (CML) or anaplastic lymphoma kinase (ALK) in lung cancer, including special tyrosine kinase inhibitors (TKIs) which are able to block the activation of the depending downstream proliferation pathways and, consequently, tumor growth.  During the last decade, the NTRK1, 2, and 3 genes, encoding the TRKA, B, and C proteins, have attracted increasing attention as another significant and targetable gene fusion in a variety of cancers.  Several TRK inhibitors have been developed, and one of them, Larotrectinib (formerly known as LOXO-101), represents an orally available, selective inhibitor of the TRK receptor family that has already shown substantial clin. benefit in both pediatric and adult patients harboring an NTRK gene fusion over the last few years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-6RXwWHZbSbVg90H21EOLACvtfcHk0lg419iuZgIoWA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVShu7nI&md5=0b066eef6e07f7ad41cf0a53a1e2fdcc</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1007%2F978-3-319-91442-8_10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-3-319-91442-8_10%26sid%3Dliteratum%253Aachs%26aulast%3DBerger%26aufirst%3DS.%26aulast%3DMartens%26aufirst%3DU.%2BM.%26aulast%3DBochum%26aufirst%3DS.%26atitle%3DBochum%252C%2520S.%2520Larotrectinib%2520%2528LOXO-101%2529%26jtitle%3DRecent%2520Results%2520Cancer%2520Res.%26date%3D2018%26volume%3D211%26spage%3D141%26epage%3D151%26doi%3D10.1007%2F978-3-319-91442-8_10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Drilon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagasubramanian, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blake, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ku, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuch, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lauriault, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolakowski, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandhuber, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsen, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouhana, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winski, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamor, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, W.-I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morales, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, F. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeWolf, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wollenberg, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douglas-Lindsay, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scaltriti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benayed, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raj, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanusch, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schram, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonsson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hechtman, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothenberg, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyman, D. M.</span></span> <span> </span><span class="NLM_article-title">A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">963</span>â <span class="NLM_lpage">972</span>, <span class="refDoi">Â DOI: 10.1158/2159-8290.cd-17-0507</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=10.1158%2F2159-8290.CD-17-0507" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=28578312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVyis7fE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=963-972&author=A.+Drilonauthor=R.+Nagasubramanianauthor=J.+F.+Blakeauthor=N.+Kuauthor=B.+B.+Tuchauthor=K.+Ebataauthor=S.+Smithauthor=V.+Lauriaultauthor=G.+R.+Kolakowskiauthor=B.+J.+Brandhuberauthor=P.+D.+Larsenauthor=K.+S.+Bouhanaauthor=S.+L.+Winskiauthor=R.+Hamorauthor=W.-I.+Wuauthor=A.+Parkerauthor=T.+H.+Moralesauthor=F.+X.+Sullivanauthor=W.+E.+DeWolfauthor=L.+A.+Wollenbergauthor=P.+R.+Gordonauthor=D.+N.+Douglas-Lindsayauthor=M.+Scaltritiauthor=R.+Benayedauthor=S.+Rajauthor=B.+Hanuschauthor=A.+M.+Schramauthor=P.+Jonssonauthor=M.+F.+Bergerauthor=J.+F.+Hechtmanauthor=B.+S.+Taylorauthor=S.+Andrewsauthor=S.+M.+Rothenbergauthor=D.+M.+Hyman&title=A+Next-Generation+TRK+Kinase+Inhibitor+Overcomes+Acquired+Resistance+to+Prior+TRK+Kinase+Inhibition+in+Patients+with+TRK+Fusion-Positive+Solid+Tumors&doi=10.1158%2F2159-8290.cd-17-0507"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors</span></div><div class="casAuthors">Drilon, Alexander; Nagasubramanian, Ramamoorthy; Blake, James F.; Ku, Nora; Tuch, Brian B.; Ebata, Kevin; Smith, Steve; Lauriault, Veronique; Kolakowski, Gabrielle R.; Brandhuber, Barbara J.; Larsen, Paul D.; Bouhana, Karyn S.; Winski, Shannon L.; Hamor, Robyn; Wu, Wen-I.; Parker, Andrew; Morales, Tony H.; Sullivan, Francis X.; DeWolf, Walter E.; Wollenberg, Lance A.; Gordon, Paul R.; Douglas-Lindsay, Dorothea N.; Scaltriti, Maurizio; Benayed, Ryma; Raj, Sandeep; Hanusch, Bethany; Schram, Alison M.; Jonsson, Philip; Berger, Michael F.; Hechtman, Jaclyn F.; Taylor, Barry S.; Andrews, Steve; Rothenberg, S. Michael; Hyman, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">963-972</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Larotrectinib, a selective TRK tyrosine kinase inhibitor (TKI), has demonstrated histol.-agnostic efficacy in patients with TRK fusion-pos. cancers.  Although responses to TRK inhibition can be dramatic and durable, duration of response may eventually be limited by acquired resistance.  LOXO-195 is a selective TRK TKI designed to overcome acquired resistance mediated by recurrent kinase domain (solvent front and xDFG) mutations identified in multiple patients who have developed resistance to TRK TKIs.  Activity against these acquired mutations was confirmed in enzyme and cell-based assays and in vivo tumor models.  As clin. proof of concept, the first 2 patients with TRK fusion-pos. cancers who developed acquired resistance mutations on larotrectinib were treated with LOXO-195 on a first-in-human basis, utilizing rapid dose titrn. guided by pharmacokinetic assessments.  This approach led to rapid tumor responses and extended the overall duration of disease control achieved with TRK inhibition in both patients.  Significance: LOXO-195 abrogated resistance in TRK fusion-pos. cancers that acquired kinase domain mutations, a shared liability with all existing TRK TKIs.  This establishes a role for sequential treatment by demonstrating continued TRK dependence and validates a paradigm for the accelerated development of next-generation inhibitors against validated oncogenic targets.  Cancer Discov; 7(9); 963-72. Â©2017 AACR.  See related commentary by Parikh and Corcoran, p. 934.  This article is highlighted in the In This Issue feature, p.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpG4KsnHeEsHLVg90H21EOLACvtfcHk0lgG055WSUYqYQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVyis7fE&md5=aac35c31a9645a16a61deaafba5f106e</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-17-0507&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-17-0507%26sid%3Dliteratum%253Aachs%26aulast%3DDrilon%26aufirst%3DA.%26aulast%3DNagasubramanian%26aufirst%3DR.%26aulast%3DBlake%26aufirst%3DJ.%2BF.%26aulast%3DKu%26aufirst%3DN.%26aulast%3DTuch%26aufirst%3DB.%2BB.%26aulast%3DEbata%26aufirst%3DK.%26aulast%3DSmith%26aufirst%3DS.%26aulast%3DLauriault%26aufirst%3DV.%26aulast%3DKolakowski%26aufirst%3DG.%2BR.%26aulast%3DBrandhuber%26aufirst%3DB.%2BJ.%26aulast%3DLarsen%26aufirst%3DP.%2BD.%26aulast%3DBouhana%26aufirst%3DK.%2BS.%26aulast%3DWinski%26aufirst%3DS.%2BL.%26aulast%3DHamor%26aufirst%3DR.%26aulast%3DWu%26aufirst%3DW.-I.%26aulast%3DParker%26aufirst%3DA.%26aulast%3DMorales%26aufirst%3DT.%2BH.%26aulast%3DSullivan%26aufirst%3DF.%2BX.%26aulast%3DDeWolf%26aufirst%3DW.%2BE.%26aulast%3DWollenberg%26aufirst%3DL.%2BA.%26aulast%3DGordon%26aufirst%3DP.%2BR.%26aulast%3DDouglas-Lindsay%26aufirst%3DD.%2BN.%26aulast%3DScaltriti%26aufirst%3DM.%26aulast%3DBenayed%26aufirst%3DR.%26aulast%3DRaj%26aufirst%3DS.%26aulast%3DHanusch%26aufirst%3DB.%26aulast%3DSchram%26aufirst%3DA.%2BM.%26aulast%3DJonsson%26aufirst%3DP.%26aulast%3DBerger%26aufirst%3DM.%2BF.%26aulast%3DHechtman%26aufirst%3DJ.%2BF.%26aulast%3DTaylor%26aufirst%3DB.%2BS.%26aulast%3DAndrews%26aufirst%3DS.%26aulast%3DRothenberg%26aufirst%3DS.%2BM.%26aulast%3DHyman%26aufirst%3DD.%2BM.%26atitle%3DA%2520Next-Generation%2520TRK%2520Kinase%2520Inhibitor%2520Overcomes%2520Acquired%2520Resistance%2520to%2520Prior%2520TRK%2520Kinase%2520Inhibition%2520in%2520Patients%2520with%2520TRK%2520Fusion-Positive%2520Solid%2520Tumors%26jtitle%3DCancer%2520Discovery%26date%3D2017%26volume%3D7%26spage%3D963%26epage%3D972%26doi%3D10.1158%2F2159-8290.cd-17-0507" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Drilon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S.-H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, V. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, M.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camidge, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitten, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stopatschinskaja, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyman, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doebele, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span> <span> </span><span class="NLM_article-title">Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1227</span>â <span class="NLM_lpage">1236</span>, <span class="refDoi">Â DOI: 10.1158/2159-8290.cd-18-0484</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=10.1158%2F2159-8290.CD-18-0484" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=30093503" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmt1ehtLs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=1227-1236&author=A.+Drilonauthor=S.-H.+I.+Ouauthor=B.+C.+Choauthor=D.-W.+Kimauthor=J.+Leeauthor=J.+J.+Linauthor=V.+W.+Zhuauthor=M.-J.+Ahnauthor=D.+R.+Camidgeauthor=J.+Nguyenauthor=D.+Zhaiauthor=W.+Dengauthor=Z.+Huangauthor=E.+Rogersauthor=J.+Liuauthor=J.+Whittenauthor=J.+K.+Limauthor=S.+Stopatschinskajaauthor=D.+M.+Hymanauthor=R.+C.+Doebeleauthor=J.+J.+Cuiauthor=A.+T.+Shaw&title=Repotrectinib+%28TPX-0005%29+Is+a+Next-Generation+ROS1%2FTRK%2FALK+Inhibitor+That+Potently+Inhibits+ROS1%2FTRK%2FALK+Solvent-+Front+Mutations&doi=10.1158%2F2159-8290.cd-18-0484"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Repotrectinib (TPX-0005) is a next-generation ROS1/TRK/ALK inhibitor that potently inhibits ROS1/TRK/ALK solvent-front mutations</span></div><div class="casAuthors">Drilon, Alexander; Ou, Sai-Hong Ignatius; Cho, Byoung Chul; Kim, Dong-Wan; Lee, Jeeyun; Lin, Jessica J.; Zhu, Viola W.; Ahn, Myung-Ju; Camidge, D. Ross; Nguyen, Judy; Zhai, Dayong; Deng, Wei; Huang, Zhongdong; Rogers, Evan; Liu, Juliet; Whitten, Jeff; Lim, John K.; Stopatschinskaja, Shanna; Hyman, David M.; Doebele, Robert C.; Cui, J. Jean; Shaw, Alice T.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1227-1236</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The use of tyrosine kinase inhibitors (TKI) with activity against ALK, ROS1, or TRKA-C can result in signifi cant clin. benefit in patients with diverse tumors harboring ALK, ROS1, or NTRK1-3 rearrangements; however, resistance invariably develops.  The emergence of on-target kinase domain mutations represents a major mechanism of acquired resistance.  Solvent-front substitutions such as ALKG1202R, ROS1G2032R or ROS1D2033N, TRKAG595R, and TRKCG623R are among the most recalcitrant of these mechanisms.  Repotrectinib (TPX-0005) is a rationally designed, low-mol.-wt., macrocyclic TKI that is selective and highly potent against ROS1, TRKA-C, and ALK.  Importantly, repotrectinib exhibits activity against a variety of solventfront substitutions in vitro and in vivo.  As clin. proof of concept, in an ongoing first-in-human phase I/II trial, repotrectinib achieved confirmed responses in patients with ROS1 or NTRK3 fusion- pos. cancers who had relapsed on earlier-generation TKIs due to ROS1 or TRKC solvent-front substitution-mediated resistance.  SIGNIFICANCE: Repotrectinib (TPX-0005), a next-generation ROS1, pan-TRK, and ALK TKI, overcomes resistance due to acquired solvent-front mutations involving ROS1, NTRK1-3, and ALK.  Repotrectinib may represent an effective therapeutic option for patients with ROS1-, NTRK1-3-, or ALK-rearranged malignancies who have progressed on earlier-generation TKIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNmuKNmAgWKLVg90H21EOLACvtfcHk0lgG055WSUYqYQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmt1ehtLs%253D&md5=b5408bf045e049629557cb347ab61980</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-18-0484&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-18-0484%26sid%3Dliteratum%253Aachs%26aulast%3DDrilon%26aufirst%3DA.%26aulast%3DOu%26aufirst%3DS.-H.%2BI.%26aulast%3DCho%26aufirst%3DB.%2BC.%26aulast%3DKim%26aufirst%3DD.-W.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DJ.%2BJ.%26aulast%3DZhu%26aufirst%3DV.%2BW.%26aulast%3DAhn%26aufirst%3DM.-J.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26aulast%3DNguyen%26aufirst%3DJ.%26aulast%3DZhai%26aufirst%3DD.%26aulast%3DDeng%26aufirst%3DW.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DRogers%26aufirst%3DE.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DWhitten%26aufirst%3DJ.%26aulast%3DLim%26aufirst%3DJ.%2BK.%26aulast%3DStopatschinskaja%26aufirst%3DS.%26aulast%3DHyman%26aufirst%3DD.%2BM.%26aulast%3DDoebele%26aufirst%3DR.%2BC.%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26atitle%3DRepotrectinib%2520%2528TPX-0005%2529%2520Is%2520a%2520Next-Generation%2520ROS1%252FTRK%252FALK%2520Inhibitor%2520That%2520Potently%2520Inhibits%2520ROS1%252FTRK%252FALK%2520Solvent-%2520Front%2520Mutations%26jtitle%3DCancer%2520Discovery%26date%3D2018%26volume%3D8%26spage%3D1227%26epage%3D1236%26doi%3D10.1158%2F2159-8290.cd-18-0484" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, L. A.</span>; <span class="NLM_string-name">Platz, E. A.</span>; <span class="NLM_string-name">Teicher, B.</span></span> <span> </span><span class="NLM_article-title">Combating Acquired TRK Inhibitor Resistance</span>.  <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume">9</span>,  <span class="NLM_fpage">684</span>- <span class="NLM_lpage">685</span>.<span class="refDoi">Â DOI: 10.1158/2159-8290.CD-NB2019-047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=10.1158%2F2159-8290.CD-NB2019-047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=30936083" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=684-685&author=L.+A.+Diaz&author=E.+A.+Platz&author=B.+Teicher&title=Combating+Acquired+TRK+Inhibitor+Resistance&doi=10.1158%2F2159-8290.CD-NB2019-047"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-NB2019-047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-NB2019-047%26sid%3Dliteratum%253Aachs%26aulast%3DDiaz%26aufirst%3DL.%2BA.%26atitle%3DCombating%2520Acquired%2520TRK%2520Inhibitor%2520Resistance%26jtitle%3DCancer%2520Discovery%26date%3D2019%26volume%3D9%26spage%3D684%26epage%3D685%26doi%3D10.1158%2F2159-8290.CD-NB2019-047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbst, R. S.</span></span> <span> </span><span class="NLM_article-title">Larotrectinib in NTRK-Rearranged Solid TumorsPublished as part of the Biochemistry series â³Biochemistry to Bedside</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">1555</span>â <span class="NLM_lpage">1557</span>, <span class="refDoi">Â DOI: 10.1021/acs.biochem.9b00126</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.biochem.9b00126" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=1%3ACAS%3A528%3ADC%252BC1MXks1Chsb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2019&pages=1555-1557&author=F.+H.+Wilsonauthor=R.+S.+Herbst&title=Larotrectinib+in+NTRK-Rearranged+Solid+TumorsPublished+as+part+of+the+Biochemistry+series+%E2%80%B3Biochemistry+to+Bedside&doi=10.1021%2Facs.biochem.9b00126"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Larotrectinib in NTRK-Rearranged Solid Tumors</span></div><div class="casAuthors">Wilson, Frederick H.; Herbst, Roy S.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1555-1557</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Larotrectinib (LOXO-101 and ARRY470) is an orally available, potent, and selective ATP-competitive pan-tropomyosin receptor tyrosine kinase (TRK) inhibitor with low nanomolar 50% inhibitory concns.  Early phase clin. trials for safety and efficacy of larotrectinib in adult and pediatric patients with diverse TRK fusion-pos. malignancies were recently reported.  Responses were obsd. in 75% of patients regardless of patient age, tumor type, TRK family member, or identity of the TRK fusion partner.  On the basis of these findings, the Food and Drug Administration granted accelerated approval to larotrectinib in Nov. 2018 for the treatment of adult and pediatric patients with advanced solid tumors harboring an NTRK gene fusion.  Using structural insights derived from X-ray crystallog. of TRK proteins and in silico modeling of addnl. structurally distinct TRK inhibitors, a second TRK inhibitor called LOXO195 was identified as a candidate compd. with potential activity against secondary mutations conferring resistance to larotrectinib.  On the basis of prior experience with acquired resistance to other kinase-directed therapies, LOXO-195 was developed nearly in parallel with larotrectinib in anticipation of acquired resistance to larotrectinib in treated patients.  A phase 1/2 clin. trial evaluating the safety and preliminary efficacy of LOXO-195 in adults and children with TRK-driven solid tumors refractory to a prior TRK inhibitor is currently underway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7SElFd-Ty17Vg90H21EOLACvtfcHk0lj_-wLEOGmrgA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXks1Chsb0%253D&md5=d92f8170ae3bd22f4c5e76bf058d8edc</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Facs.biochem.9b00126&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.biochem.9b00126%26sid%3Dliteratum%253Aachs%26aulast%3DWilson%26aufirst%3DF.%2BH.%26aulast%3DHerbst%26aufirst%3DR.%2BS.%26atitle%3DLarotrectinib%2520in%2520NTRK-Rearranged%2520Solid%2520TumorsPublished%2520as%2520part%2520of%2520the%2520Biochemistry%2520series%2520%25E2%2580%25B3Biochemistry%2520to%2520Bedside%26jtitle%3DBiochemistry%26date%3D2019%26volume%3D58%26spage%3D1555%26epage%3D1557%26doi%3D10.1021%2Facs.biochem.9b00126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Choi, H.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rucker, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albaugh, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chopiuk, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gessier, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adrian, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hood, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Che, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCormack, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steffy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Culazzo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tompkins, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phung, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreusch, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhary, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prashad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuntland, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seidel, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loren, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molteni, V.</span></span> <span> </span><span class="NLM_article-title">(R)-2-Phenylpyrrolidine Substituted Imidazopyridazines: A New Class of Potent and Selective Pan-TRK Inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">562</span>â <span class="NLM_lpage">567</span>, <span class="refDoi">Â DOI: 10.1021/acsmedchemlett.5b00050</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00050" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=1%3ACAS%3A528%3ADC%252BC2MXksVOrsbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=562-567&author=H.-S.+Choiauthor=P.+V.+Ruckerauthor=Z.+Wangauthor=Y.+Fanauthor=P.+Albaughauthor=G.+Chopiukauthor=F.+Gessierauthor=F.+Sunauthor=F.+Adrianauthor=G.+Liuauthor=T.+Hoodauthor=N.+Liauthor=Y.+Jiaauthor=J.+Cheauthor=S.+McCormackauthor=A.+Liauthor=J.+Liauthor=A.+Steffyauthor=A.+Culazzoauthor=C.+Tompkinsauthor=V.+Phungauthor=A.+Kreuschauthor=M.+Luauthor=B.+Huauthor=A.+Chaudharyauthor=M.+Prashadauthor=T.+Tuntlandauthor=B.+Liuauthor=J.+Harrisauthor=H.+M.+Seidelauthor=J.+Lorenauthor=V.+Molteni&title=%28R%29-2-Phenylpyrrolidine+Substituted+Imidazopyridazines%3A+A+New+Class+of+Potent+and+Selective+Pan-TRK+Inhibitors&doi=10.1021%2Facsmedchemlett.5b00050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">(R)-2-Phenylpyrrolidine Substituted Imidazopyridazines: A New Class of Potent and Selective Pan-TRK Inhibitors</span></div><div class="casAuthors">Choi, Ha-Soon; Rucker, Paul V.; Wang, Zhicheng; Fan, Yi; Albaugh, Pamela; Chopiuk, Greg; Gessier, Francois; Sun, Fangxian; Adrian, Francisco; Liu, Guoxun; Hood, Tami; Li, Nanxin; Jia, Yong; Che, Jianwei; McCormack, Susan; Li, Allen; Li, Jie; Steffy, Auzon; Culazzo, AnneMarie; Tompkins, Celine; Phung, Van; Kreusch, Andreas; Lu, Min; Hu, Bin; Chaudhary, Apurva; Prashad, Mahavir; Tuntland, Tove; Liu, Bo; Harris, Jennifer; Seidel, H. Martin; Loren, Jon; Molteni, Valentina</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">562-567</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Deregulated kinase activities of tropomyosin receptor kinase (TRK) family members have been shown to be assocd. with tumorigenesis and poor prognosis in a variety of cancer types.  In particular, several chromosomal rearrangements involving TRKA have been reported in colorectal, papillary thyroid, glioblastoma, melanoma, and lung tissue that are believed to be the key oncogenic driver in these tumors.  By screening the Novartis compd. collection, a novel imidazopyridazine TRK inhibitor was identified that served as a launching point for drug optimization.  Structure guided drug design led to the identification of (R)-2-phenylpyrrolidine substituted imidazopyridazines, e.g., I, as a series of potent, selective, orally bioavailable pan-TRK inhibitors achieving tumor regression in rats bearing KM12 xenografts.  From this work the (R)-2-phenylpyrrolidine has emerged as an ideal moiety to incorporate in bicyclic TRK inhibitors by virtue of its shape complementarity to the hydrophobic pocket of TRKs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBOGdLZcZ2HbVg90H21EOLACvtfcHk0lj_-wLEOGmrgA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXksVOrsbo%253D&md5=e2eacf85a3e762e8f2474a568e6d1b39</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00050%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DH.-S.%26aulast%3DRucker%26aufirst%3DP.%2BV.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DFan%26aufirst%3DY.%26aulast%3DAlbaugh%26aufirst%3DP.%26aulast%3DChopiuk%26aufirst%3DG.%26aulast%3DGessier%26aufirst%3DF.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DAdrian%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DHood%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DJia%26aufirst%3DY.%26aulast%3DChe%26aufirst%3DJ.%26aulast%3DMcCormack%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DSteffy%26aufirst%3DA.%26aulast%3DCulazzo%26aufirst%3DA.%26aulast%3DTompkins%26aufirst%3DC.%26aulast%3DPhung%26aufirst%3DV.%26aulast%3DKreusch%26aufirst%3DA.%26aulast%3DLu%26aufirst%3DM.%26aulast%3DHu%26aufirst%3DB.%26aulast%3DChaudhary%26aufirst%3DA.%26aulast%3DPrashad%26aufirst%3DM.%26aulast%3DTuntland%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DHarris%26aufirst%3DJ.%26aulast%3DSeidel%26aufirst%3DH.%2BM.%26aulast%3DLoren%26aufirst%3DJ.%26aulast%3DMolteni%26aufirst%3DV.%26atitle%3D%2528R%2529-2-Phenylpyrrolidine%2520Substituted%2520Imidazopyridazines%253A%2520A%2520New%2520Class%2520of%2520Potent%2520and%2520Selective%2520Pan-TRK%2520Inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26spage%3D562%26epage%3D567%26doi%3D10.1021%2Facsmedchemlett.5b00050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, J.</span></span> <span> </span><span class="NLM_article-title">Assessment of the toxicity and toxicokinetics of the novel potent tropomyosin receptor kinase (Trk) inhibitor LPM4870108 in rhesus monkeys</span>. <i>Regul. Toxicol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>122</i></span>,  <span class="NLM_fpage">104886</span>, <span class="refDoi">Â DOI: 10.1016/j.yrtph.2021.104886</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=10.1016%2Fj.yrtph.2021.104886" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=33556418" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=1%3ACAS%3A528%3ADC%252BB3MXksl2qtbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2021&pages=104886&author=S.+Duanauthor=L.+Dongauthor=B.+Wangauthor=S.+Weiauthor=X.+Gongauthor=P.+Yuauthor=C.+Liauthor=Y.+Gaoauthor=L.+Yeauthor=H.+Wangauthor=J.+Tian&title=Assessment+of+the+toxicity+and+toxicokinetics+of+the+novel+potent+tropomyosin+receptor+kinase+%28Trk%29+inhibitor+LPM4870108+in+rhesus+monkeys&doi=10.1016%2Fj.yrtph.2021.104886"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Assessment of the toxicity and toxicokinetics of the novel potent tropomyosin receptor kinase (Trk) inhibitor LPM4870108 in rhesus monkeys</span></div><div class="casAuthors">Duan, Sijin; Dong, Lin; Wang, Bingsi; Wei, Shujuan; Gong, Xiaoyan; Yu, Pengfei; Li, Chunmei; Gao, Yonglin; Ye, Liang; Wang, Hongbo; Tian, Jingwei</div><div class="citationInfo"><span class="NLM_cas:title">Regulatory Toxicology and Pharmacology</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">104886</span>CODEN:
                <span class="NLM_cas:coden">RTOPDW</span>;
        ISSN:<span class="NLM_cas:issn">0273-2300</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">LPM4870108 is a tropomyosin receptor kinase (Trk) inhibitor that is currently under consideration for human clin. trials.  We characterized the toxicity and toxicokinetic properties of LPM4870108 following its oral administration to rhesus monkeys (5, 10, or 20 mg/kg/day for 4 wk with a 4-wk recovery period).  No evidence of LPM4870108 toxicity was obsd. over this study as reflected by an absence of difference in body wt., ophthalmoscopy, urinalysis, gross, or histopathol. findings.  No significant differences in toxicity-related outcomes were detected when comparing LPM4870108 and control groups, and no significant treatment-related changes in food consumption, ECG results, blood pressure, hematol. parameters, biochem. values, organ wt., or bone marrow parameters were obsd.  Treatment caused dose-dependent effects of gait disturbance, impaired balance, poor coordination, and decreased grip strength in all LPM4870108-treated animals, with these effects being attributable to excessive on-target Trk receptor inhibition.  After the 4-wk recovery period, all these abnormal treatment-related findings had fully or partially resolved.  The toxicokinetic study of monkeys revealed that the LPM4870108 exposure increased with dose.  Overall, LPM4870108 exhibited a safety profile in treated monkeys, indicating that the Highest Non-Severely Toxic Dose (HNSTD) for LPM4870108 in monkeys was 20 mg/kg/day.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_h0UffODCgLVg90H21EOLACvtfcHk0ljqg1Cevkz5IQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXksl2qtbc%253D&md5=2be164d3485b107672973aef3e479491</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.yrtph.2021.104886&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.yrtph.2021.104886%26sid%3Dliteratum%253Aachs%26aulast%3DDuan%26aufirst%3DS.%26aulast%3DDong%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DWei%26aufirst%3DS.%26aulast%3DGong%26aufirst%3DX.%26aulast%3DYu%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DYe%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DTian%26aufirst%3DJ.%26atitle%3DAssessment%2520of%2520the%2520toxicity%2520and%2520toxicokinetics%2520of%2520the%2520novel%2520potent%2520tropomyosin%2520receptor%2520kinase%2520%2528Trk%2529%2520inhibitor%2520LPM4870108%2520in%2520rhesus%2520monkeys%26jtitle%3DRegul.%2520Toxicol.%2520Pharmacol.%26date%3D2021%26volume%3D122%26spage%3D104886%26doi%3D10.1016%2Fj.yrtph.2021.104886" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span> <span> </span><span class="NLM_article-title">PCC0208017 a novel small-molecule inhibitor of MARK3/MARK4, suppresses glioma progression in vitro and in vivo</span>. <i>Acta Pharm. Sin. B</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">289</span>â <span class="NLM_lpage">300</span>, <span class="refDoi">Â DOI: 10.1016/j.apsb.2019.09.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=10.1016%2Fj.apsb.2019.09.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=32082974" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;key=1%3ACAS%3A528%3ADC%252BB3MXnslWitg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2020&pages=289-300&author=F.+Liauthor=Z.+Liuauthor=H.+Sunauthor=C.+Liauthor=W.+Wangauthor=L.+Yeauthor=C.+Yanauthor=J.+Tianauthor=H.+Wang&title=PCC0208017+a+novel+small-molecule+inhibitor+of+MARK3%2FMARK4%2C+suppresses+glioma+progression+in+vitro+and+in+vivo&doi=10.1016%2Fj.apsb.2019.09.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">PCC0208017, a novel small-molecule inhibitor of MARK3/MARK4, suppresses glioma progression in vitro and in vivo</span></div><div class="casAuthors">Li, Fangfang; Liu, Zongliang; Sun, Heyuan; Li, Chunmei; Wang, Wenyan; Ye, Liang; Yan, Chunhong; Tian, Jingwei; Wang, Hongbo</div><div class="citationInfo"><span class="NLM_cas:title">Acta Pharmaceutica Sinica B</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">289-300</span>CODEN:
                <span class="NLM_cas:coden">APSBCW</span>;
        ISSN:<span class="NLM_cas:issn">2211-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Gliomas are the most common primary intracranial neoplasms among all brain malignancies, and the microtubule affinity regulating kinases (MARKs) have become potential drug targets for glioma.  Here, we report a novel dual small-mol. inhibitor of MARK3 and MARK4, designated as PCC0208017.  In vitro, PCC0208017 strongly inhibited kinase activity against MARK3 and MARK4, and strongly reduced proliferation in three glioma cell lines.  This compd. attenuated glioma cell migration, glioma cell invasion, and angiogenesis.  Mol. mechanism studies revealed that PCC0208017 decreased the phosphorylation of Tau, disrupted microtubule dynamics, and induced a G2/M phase cell cycle arrest.  In an in vivo glioma model, PCC0208017 showed robust anti-tumor activity, blood-brain barrier permeability, and a good oral pharmacokinetic profile.  Mol. docking studies showed that PCC0208017 exhibited high binding affinity to MARK3 and MARK4.  Taken together, our study describes for the first time that PCC0208017, a novel MARK3/MARK4 inhibitor, might be a promising lead compd. for treatment of glioma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEiB0tMNKC9rVg90H21EOLACvtfcHk0ljqg1Cevkz5IQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXnslWitg%253D%253D&md5=3af5bf801677d2f616db37763a0f1e3c</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.apsb.2019.09.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.apsb.2019.09.004%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DYe%26aufirst%3DL.%26aulast%3DYan%26aufirst%3DC.%26aulast%3DTian%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DH.%26atitle%3DPCC0208017%2520a%2520novel%2520small-molecule%2520inhibitor%2520of%2520MARK3%252FMARK4%252C%2520suppresses%2520glioma%2520progression%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DActa%2520Pharm.%2520Sin.%2520B%26date%3D2020%26volume%3D10%26spage%3D289%26epage%3D300%26doi%3D10.1016%2Fj.apsb.2019.09.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4YNE" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4YNE','PDB','4YNE'); return false;">PDB: 4YNE</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i39"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00712">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_34106"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00712?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00712</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Crystallographic data of compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00712/suppl_file/jm1c00712_si_001.csv">CSV</a>)</p></li><li><p class="inline"><sup>1</sup>H NMR, <sup>13</sup>C NMR, COSY, HSQC, HMBC, <sup>19</sup>F NMR, HRMS, and single-crystal X-ray diffraction experiment report of compound <b>10</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00712/suppl_file/jm1c00712_si_002.pdf">PDF</a>)</p></li><li><p class="inline">Predicted binding mode of LOXO-195 and TPX-0005 binding to the active site of TrkC (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00712/suppl_file/jm1c00712_si_003.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00712/suppl_file/jm1c00712_si_001.csv">jm1c00712_si_001.csv (1.72 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00712/suppl_file/jm1c00712_si_002.pdf">jm1c00712_si_002.pdf (3.31 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00712/suppl_file/jm1c00712_si_003.pdf">jm1c00712_si_003.pdf (355.58 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.1c00712&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.1c00712%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-14" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.1c00712" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright Â© 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">Youâve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677ac84708f03cfa","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
